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ABSTRACT

Spinal cord injuries cost the United States $20 billion per year, with an existing
patient population of 256,000 growing by an estimated 12,000 each year. Current clinical
therapies for spinal cord injury are limited to spinal immobilization and realignment via
traction, surgery, administration of methylprednisolone sodium succinate (MPSS) within
eight hours post-injury, and rehabilitation exercises. While these therapies are important
and may minimize damage and restore limited function, there is a dire clinical need for
treatments to address the growing population of chronically-injured patients.
Varying degrees of axonal regeneration and functional recovery following spinal
cord injury have been achieved in animal models by transplantation of glial cells from the
peripheral nervous system and olfactory region. The recent identification of bioactive
soluble and adhesive molecules produced by glial cells provides the opportunity to
deliver these stimuli through biomaterial-mediated approaches, such as controlled
release, gene therapy, and recombinant protein immobilization. The long-term objective
of this project is a biomimetic, multi-factorial approach utilizing grooved fibers to restore
structure and provide guidance for regenerating axons coupled with bioactive adhesive
molecule delivery via immobilization to a hydrogel within the fiber grooves and
controlled release of neurotrophic factors from the hydrogel. The implant design can
serve as a platform for both in vitro and in vivo analysis of combination therapies for
different injured nerve populations.
The first part of this research focused on cloning and expression of a bioactive
140kDa fragment of L1 neural cell adhesion molecule. L1 is a particularly attractive
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candidate for neural regeneration because it is critical for proper nervous system
development and in vitro studies have demonstrated selectivity of neuron adhesion to L1
in the presence of astrocytes, which play a major role in nervous system inflammation.
The second part of this research focused on the synthesis and purification of acrylated
Tetronic macromers, and the development of Michael addition methods for hydrogel
crosslinking and protein immobilization. In order to establish the feasibility of these
hydrogels for neural regeneration, initial testing was conducted using NIH 3T3
fibroblasts and fibronectin because of the well-known RGD-dependent interaction.
Results demonstrated that fibronectin encapsulation and surface-immobilization through
acrylation of fibronectin positively influenced fibroblast spreading and proliferation. The
last part of this research focused on evaluating neuronal cell line and primary neuron
response to L1, evaluating cytocompatibility of T904-acrylate hydrogels with neural
cells, and developing immobilization methods for L1. Results indicate that surfaceimmobilization of L1 to hydrogels may be the most promising method of bioactive cell
adhesion molecule delivery for neural regeneration.
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CHAPTER ONE
INTRODUCTION

Spinal cord injury requires continuous medical care as a result of the devastating
physical and psychological consequences to the affected individual, including paralysis,
respiratory deficiency, bladder and bowel dysfunction, loss of reproductive and sexual
function, and ultimately, loss of personal independence. According to the National Spinal
Cord Injury Statistical Center (NSCISC, Facts and Figures at a Glance, January 2008),
approximately 12,000 new spinal cord injuries occur in the United States each year, in
addition to an existing patient population of approximately 256,000. The average patient
age at injury is 39.5 years, with life expectancies and lifetime medical costs ranging from
approximately 20-40 years and $494,000 to $3,000,000, respectively.

Spinal cord

injuries typically occur during an individual’s most productive years, resulting in a
substantial economic burden to society, not only because of medical costs but also the
ongoing disability support and lost productivity due to unemployment or reduced
employment. A 1998 analysis estimated that spinal cord injuries cost the United States
over $14.5 billion per year in direct medical costs and disability support, as well as an
additional $5.5 billion per year in lost productivity, for an estimated total $20 billion per
year. [1]
Current clinical therapies for spinal cord injury are limited to spinal
immobilization

and

realignment

via

traction,

surgery,

administration

of

methylprednisolone sodium succinate (MPSS) within eight hours post-injury, and
rehabilitation exercises. MPSS is thought to attenuate the secondary injury cascade and
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improve functional recovery, and has been adopted as the standard of care since 1990 in
most of North America. [2] Other experimental methods for treatment of acute injuries
include decompression surgery and moderate hypothermia. [3] While these therapies are
important and may minimize damage and restore limited function, there is a dire clinical
need for treatments to address the growing population of chronically-injured patients.
Spinal cord injury and paralysis have been considered severe and irreversible
conditions throughout much of scientific history, beginning with an account from an
Egyptian papyrus roll manuscript as early as 1700 B.C. describing spinal cord injury
accompanied by paralysis as "an ailment not to be treated." [4] Evidence of the first
nerve graft in dogs resulting in limited degree of functional restoration was reported in
France in the 1860s [5]; however, pioneering work by Spanish neuroanatomist and
histologist Ramόn y Cajal in the early 1900’s provided evidence that nerve cells from the
peripheral nervous system (PNS) have the capacity to repair themselves, but nerve cells
from the adult central nervous system (CNS) display only an abortive sprouting attempt
in response to injury. [6, 7] Cajal hypothesized that the differences in regenerative
capacity were likely a result of the cellular environment that supports the nerve cells, and
stated, “From this it may be inferred that if experimental neurology is some day to supply
artificially the deficiencies in question it must accomplish these two objects: First, it must
give to the sprouts by means of adequate alimentation a vigorous capacity for growth,
and second, place in front of the disoriented nerve cones and in the thickness of white
matter tracks, specific orienting substances.”
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[8]

Cajal believed the regenerative

capacity of the adult central nervous system could be enhanced through bioengineering
efforts.
A number of mechanisms have been implicated in regenerative failure of the adult
CNS following injury and are broadly classified into two categories: intrinsic barriers, or
an inherent decline in growth capacity that occurs with neuronal cell maturation; and
extrinsic barriers, or the non-permissive regenerative environment in the adult CNS
following injury as compared to the permissive PNS and developing CNS environments.
Proposed mechanisms of intrinsic regenerative failure include a decrease in the rate of
retrograde transport of injury signals with increasing distance between axotomy site and
cell body, delayed synthesis and diminished anterograde transport of cytoskeletal proteins
required for growth cone and axon formation, a developmentally-regulated decrease in
endogenous levels of neuronal cyclic adenosine monophosphate (cAMP) in mature
neurons, and variable ability of different neuronal cell types to sustain expression of
regeneration-associated genes. [9-12] Surviving neurons in the CNS generally do sprout
axons in an attempt at regeneration; however, this attempt is quickly aborted upon
encountering the hostile external environment. [13] Proposed mechanisms of extrinsic
regenerative failure include delayed and incomplete clearance of axon and myelin debris;
exposure to myelin-associated inhibitory glycoproteins that are not present during early
stages of development; exposure to inhibitory chondroitin sulfate proteoglycans (CSPGs)
present in reactive astrocytic glial scar tissue; the formation of cystic cavities; the loss of
the structural organization of the mature CNS; and a lack of supporting neurotrophic
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factors and growth-promoting adhesion ligands that are present during development. [9,
11, 12, 14]
Varying degrees of axonal regeneration and functional recovery following spinal
cord injury have been achieved in animal models by transplantation of glial cells from the
peripheral nervous system and olfactory region; however, major limitations of cell
transplantation approaches include the time required to isolate, purify, genetically
modify, and expand suitable autologous cells for transplantation and immune
complications inherent to allographic or xenographic cell transplantation. Cell therapies
for spinal cord repair do not necessarily address the disorganized structure of the injured
CNS, and are plagued with additional challenges including limited cell survival and
migration out of the lesion area following transplantation. Current approaches seek to
address these challenges by incorporating cells within biomaterial-based scaffolds with
channels to improve cell survival, limit migration, and also provide guidance for
regenerating axons [15-17]; however, the recent identification of bioactive soluble and
adhesive molecules produced by glial cells provides the opportunity to deliver these
stimuli through biomaterial-mediated approaches, such as controlled release, gene
therapy, and recombinant protein immobilization.
Synthetic degradable acellular biomaterial bridges with customizable properties
and combinations of adhesive stimuli and growth factors offer the unique opportunity to
tailor implants to the desired nerve populations that are to be regenerated, and also
potentially open the door to readily available, large-scale production of “off-the-shelf”
implants for patients with both CNS and PNS nerve injuries. [12, 18] The long-term
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objective of this project is a biomimetic, multi-factorial approach utilizing grooved fibers
to restore structure and provide guidance for regenerating axons coupled with bioactive
adhesive molecule delivery via immobilization to a hydrogel within the fiber grooves and
controlled release of neurotrophic factors from the hydrogel (Figure 1.1). The implant
design can serve as a platform for both in vitro and in vivo analysis of combination
therapies for different injured nerve populations.

Degradable
Hydrogel
Coating
Capillary
Channel
Fiber

..
. . . ..
. ... .. .

Neurotrophin
Release

Recombinant CAM
Immobilization

Figure 1.1 Proposed Implant Design

Neurotrophic factors are excellent promoters of neurite outgrowth on permissive
substrates, but they are not sufficient for growth cone or cell adhesion to a biologically
inert material; therefore, this research is focused on covalent immobilization of cell
adhesion proteins to acrylated Tetronic® hydrogels with future plans of neurotrophin

5

incorporation to further enhance neural regeneration rates. The goals of this research
were: (1) cloning and expression of a bioactive 140kDa fragment of L1 neural cell
adhesion molecule, chosen for its critical role in proper nervous system development and
because it has demonstrated selectivity of neuron adhesion in the presence of astrocytes,
which play a major role in nervous system inflammation, (2) synthesis and purification of
acrylated Tetronic macromers and the development of Michael addition methods for
hydrogel crosslinking and protein immobilization, (3) evaluation of hydrogel
cytocompatibility, immobilized protein bioactivity, and immobilization efficiency in
terms of cell spreading and proliferation using NIH 3T3 fibroblasts and fibronectin
because of the well-known RGD-dependent interaction, to demonstrate the feasibility of
this system for neural repair, and (4) assessment of neuronal cell line and primary neuron
response to L1, evaluation of the cytocompatibility of T904-acrylate hydrogels with
neural cells, and development of immobilization methods for L1.
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CHAPTER TWO
LITERATURE REVIEW

INTRODUCTION
This chapter begins by studying the mechanisms of regenerative failure in the
adult CNS and investigating the differences in CNS and PNS anatomy, physiology, and
response to injury in order to gain an understanding of the cues driving regeneration as
well as factors contributing to the inhibition of regeneration. An understanding of these
cues and factors is of crucial importance in developing therapies for functional neural
regeneration (axonal regeneration with restoration of function).

Current reported

experimental approaches to regeneration and those that have made it to human clinical
trials will also be discussed.

THE NERVOUS SYSTEM
General Anatomy/Physiology of Nervous Tissue
The human nervous system is classified into two main categories: the central
nervous system (CNS), consisting of the brain and spinal cord; and the peripheral nervous
system (PNS), consisting of twelve pairs of cranial nerves; thirty-one pairs of spinal
nerves; and dorsal root ganglia, which are bundles of sensory nerve cell bodies with
processes that branch into both the CNS and PNS. Both branches function as one
actively conducting axon, which transmits information from the periphery to the CNS.
Spinal nerves are connected to the spinal cord by two short roots: the dorsal root (toward
the back), where sensory signals from dorsal root ganglia enter the grey matter of the
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CNS; and the ventral root (toward the abdomen), where motor signals are transmitted
from motor neuron cell bodies in the grey matter of the CNS to the periphery. The two
roots join to form the spinal nerve just before the nerve leaves the vertebral column. [19]
Figure 2.1 depicts a cross-section of the spinal cord and the position of the dorsal and
ventral roots as they join to form a spinal nerve.

Figure 2.1 Cross-Section of the Spinal Cord
(http://webanatomy.net/anatomy/spinal_neurons.jpg)
Permission granted by Dr. Jim Swan, University of New Mexico

Cells of the Nervous System
The two main cell types in the human nervous system are neurons and neuroglia.
Neurons are the main functional conducting units of the nervous system and are postmitotic cells.

They typically consist of a cell body, one axon, and one to several

dendrites; however, dorsal root ganglia generally do not exhibit dendrites due to
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bifurcation of their axon. Dendrites appear as branches of a tree or spikes and receive
messages for the cell body. Axons may be long, short, single, or branched, and they
transmit messages from the cell body to other neurons or target cells. Dendrites are most
commonly observed in grey matter, where neural cell bodies are concentrated. The three
classes of neurons include sensory (afferent) neurons, which transmit sensory information
to the brain; motor (efferent) neurons, which have long axons and transmit information to
the muscles and glands of the body; and interneurons, which provide connections
between sensory and motor neurons, have short axons, only communicate within their
immediate region, and are prevalent in grey matter of the spinal cord.
Neuroglia are nonconductive, mitotic cells and serve to support, nourish, and
protect neurons by providing physical structure and insulation, supplying nutrients and
oxygen, and destroying pathogens and removing necrotic neural tissue. Neuroglia in the
CNS consist of oligodendrocytes, which myelinate axons [20]; astrocytes, which are
fibroblast-like cells that secrete neurotrophic factors and are involved in signaling, energy
metabolism, extracellular ion homeostasis, volume regulation, and neuroprotection [21];
and microglia, which are phagocytic, specialized macrophages of the CNS that normally
maintain a resting phenotype.

The brain and spinal cord are considered “immune

privileged” because they are separated from the blood circulation by a series of
endothelial cells known as the blood-brain barrier (BBB). The BBB prevents blood-borne
immune cells such as lymphocytes, monocytes and neutrophils, as well as antibodies,
from entering the CNS; therefore, microglia are thought to enable the CNS to mount a
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prompt immune response to infectious or inflammatory stimuli despite the inability of
blood-borne immune cells to cross the blood-brain barrier. [22]
Oligodendrocyte precursor cells (OPCs) are a newly recognized glial cell type of
unknown function in the normal adult CNS; however, these cells have been shown to
rapidly proliferate following injury in localized areas close to the site of damage, and
their distribution in the developing CNS may point to a function in axonal guidance. [23]
In addition, these cells appear to possess similar characteristics as neuronal and glial stem
cells.
Schwann cells function as neuroglia in the PNS and may be divided into four
classes in the mature nervous system: myelinating Schwann cells (MSCs),
nonmyelinating Schwann cells (NMSCs), perisynaptic Schwann cells (PSCs), and
satellite cells of peripheral dorsal root ganglia (DRG). [24] MSCs are the most wellcharacterized category and function similarly to oligodendrocytes in the CNS in that they
wrap around large-diameter PNS axons to form the myelin sheath. The function of
NMSCs is not as well-characterized but they wrap around several small-diameter
unmyelinated sensory axons to form a Remak bundle, keeping individual axons separated
by thin extensions of the Schwann cell body.

The interaction of NMSCs with

unmyelinated axons may play a key role in sensitivity to pain and other sensory stimuli.
PSCs express similar proteins to MSCs and are important in development and
maintenance of the neuromuscular junction.

Little is known about the function of

satellite cells except that they surround DRG cell bodies to form a discrete anatomical
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unit. [25] Schwann cells appear to be able to switch their function by a change in gene
expression. [26]

Peripheral Nerve Structure
Figure 2.2 depicts a cross-section of a peripheral nerve. Individual myelinated
axons are surrounded by spirally-wrapped myelinating Schwann cells. The myelin sheath
is called the neurilemma. [27] Myelinated nerves and Remak bundles of unmyelinated
axons are individually-encased by endoneurium. The perineurium then binds bundles of
endoneurium-encased axons together to form fascicles. Epineurium, a loose connective
tissue layer, is the collagen-rich outer nerve covering forming a sheath around a bundle of
fascicles.

Fibroblasts secrete the type I collagen fibers and are located in the

endoneurium. [28] Each peripheral nerve typically contains twice as many unmyelinated
axons as myelinated axons. [19]
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Figure 2.2 Peripheral Nerve Structure
(Reprinted from Schmidt and Leach 2003 [28])

The blood supply of peripheral nerves is composed of an intrinsic system of
capillaries ensheathed along with axons within the perineurium, arterioles ensheathed
within the epineurium [9], and an extrinsic system made up of vessels that penetrate the
nerve from surrounding arteries and veins. [28] Figure 2.3 depicts a diagram of potential
patterns of blood supply to the peripheral nerves. [29]
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Figure 2.3 Peripheral Nerve Blood Supply Patterns
(Reprinted from el-Barrany et al. 1999 [29])

Spinal Cord Structure
The human spinal cord is highly organized and is divided into a central canal,
remaining from embryonic development and containing cerebrospinal fluid (CSF); grey
matter, the inner region consisting of unmyelinated cell bodies and short fibers; and white
matter, the outer region consisting of myelinated long fibers in bundles called tracts. The
grey-brown color of the grey matter results from the capillary blood vessels and neuronal
cell bodies. The white matter appears white because of the high concentration of lipids in
the myelin sheath surrounding the axons. Reflexes are also mediated in the spinal cord
without going to the higher brain centers.
White matter axon tracts provide a route for signals to be transmitted up and down
the spinal cord between the brain and spinal nerves. Knowledge of the functions of the
different spinal cord tracts aids a neurologist in determining if an injury is complete or
incomplete based on what type of sensory, motor, and reflex information the injured
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patient has lost, as damage to white matter affects function at all levels below the
neurological injury site.

Complete lesions result in loss of all sensory and motor

functions below the level of injury.

Incomplete lesions result in retention of some

sensory and motor functions, which can be used to diagnose which side of the spinal cord
the injury has occurred.

For example, the dorsal column medial lemniscus system

transmits ipsilateral fine touch, proprioception, and vibration information to the brain.
The lateral spinothalamic tract transmits contralateral pain and temperature sensations.
The corticospinal tract is primarily responsible for skilled motor movements and injury
results in ipsilateral paralysis. [19] One important consideration to take into account
when developing therapies for spinal cord injury is that different axon tracts may respond
differently to injury and therapeutic measures, and may have specific requirements for
regeneration. [12]
Blood supply to the spinal cord is complex. [30] Briefly, arterial supply of the
spinal cord is from the vertebral arteries and radicular arteries originating from the
thoracic and abdominal aortae. Vertebral arteries supply upper cervical levels and branch
into two posterior spinal arteries, which are located along the dorsal roots; and two
anterior spinal arteries which fuse to form a single midline anterior spinal artery that runs
the length of the spinal cord.

Lower cervical levels are supplied by vertebral and

radicular arteries but are generally dependent upon radicular arteries for survival. Figure
2.4 depicts the horizontal view of blood distribution from the posterior (dorsal) and
anterior (ventral) arteries.
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Figure 2.4 Horizontal View of Spinal Cord Blood Supply
(http://www.anaesthesiauk.com/images/spinal-cord4.jpg)
Reprinted with permission

The PNS-CNS Transitional Zone
The transitional zone consists of the thin dorsal and ventral roots that connect
spinal nerves to the spinal cord. It is the location where CNS tissue is separated from
PNS tissue by the glia limitans and the basal lamina of blood vessels. [31] On the CNS
side of the glia limitans, nerves are surrounded mainly by astrocytic processes along with
a small population of oligodendrocytes and microglia. On the PNS side of the glia
limitans, nerves are ensheathed by endoneurial connective tissue consisting of Schwann
cells, fibroblasts, and collagen.

Lesioned dorsal root ganglia (DRG) axons that

successfully regenerate the peripheral segment have been shown to stop upon reaching

15

the transitional zone [9], thus demonstrating the inhibitory nature of the CNS
environment to regeneration.

PATHOPHYSIOLOGY OF CENTRAL NERVOUS SYSTEM INJURY
Spinal cord injuries are classified clinically according to their segmental level, as
depicted in Figure 2.5; as complete or incomplete depending upon which sensory and
motor functions are spared; and according to the mechanism leading to injury. [11] The
human spinal cord is approximately 45 cm (1.5 ft) with 30 levels, and each spinal level in
the spinal cord is around 1-2 cm. [14] Regeneration over even just one or two spinal
levels can possibly result in significant improvements in function.
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Figure 2.5 Spinal Levels and Effects of Injury
(Reprinted from Verma and Fawcett 2005 [14])

Because of clinical confusion as to the terminology associated with spinal cord
injury levels, severity, and classification, the American Spinal Injury Association (ASIA)
Impairment Scale (www.asia-spinalinjury.org) was developed with further classifications
of complete and incomplete injuries, resulting in more consistent terminology being used
to describe the findings in spinal cord injury around the world, depicted in Figure 2.6.
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Figure 2.6 ASIA Impairment Scale
(Reprinted from Thuret et al. 2006 [32])
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The ASIA Scale also includes other classifications of incomplete spinal cord injuries:
•

Central cord syndrome often is associated with a cervical region injury leading to
greater weakness in the upper limbs than in the lower limbs with sacral sensory
sparing.

•

Brown-Séquard syndrome often is associated with a hemisection lesion of the cord,
causing a relatively greater ipsilateral proprioceptive and motor loss with contralateral
loss of sensitivity to pain and temperature.

•

Anterior cord syndrome often is associated with a lesion causing variable loss of
motor function and sensitivity to pain and temperature, while proprioception is
preserved.

•

Conus medullaris syndrome is associated with injury to the sacral cord and lumbar
nerve roots leading to areflexic bladder, bowel, and lower limbs, while the sacral
segments occasionally may show preserved reflexes (e.g., bulbocavernosus and
micturition reflexes).

•

Cauda equina syndrome is due to injury to the lumbosacral nerve roots in the spinal
canal leading to areflexic bladder, bowel, and lower limbs.

The spinal column normally experiences four forces: flexion, extension, rotation,
and compression, and any combination of forces may lead to injury resulting in fractured
vertebral bodies or dislocated vertebrae. These injuries result in concussion, contusion,
or laceration of the spinal cord. Concussion produces no anatomical damage resulting in

19

transient loss of function. Both contusion and laceration injuries involve anatomical
damage resulting in permanent deficits, [11].
This primary, mechanical disruption of tissue is quickly followed by a secondary
injury cascade. Schwab and Bartholdi completed an extensive review of spinal cord
injury and have described three main phases of the secondary injury cascade: the acute
phase, the subacute phase, and the late phase. [11] The acute phase immediately follows
injury and is characterized by hemorrhage, local ischemia, and edema followed by
necrosis and inflammation. Hemorrhage begins in the highly vascularized gray matter
adjacent to the central canal or anterior horns and spreads radially to the posterior horns
and into white matter in a rostral and caudal direction. [33] The first signs of necrotic
endothelial, neuronal and glial cells appear within the first hour following injury and peak
within 6-12 hours of injury, along with necrosis of white matter axons. Local ischemia
may result from posttraumatic hypotension or loss of autoregulation and results in
predominantly anaerobic metabolism for the first 4 hours following injury followed by an
increase in metabolic rate between 4 and 24 hours. Injury results in circumferential
spreading of vasogenic edema into white matter caused by a disruption of the blood-brain
barrier; this disruption results in increased vascular permeability which allows an
abnormal accumulation of fluid in intercellular spaces of the spinal cord, which may
result in compression and an abnormal electrolyte environment consisting of excess
calcium and potassium followed by a chronic loss of potassium. Tissue damage may be
exacerbated by compression of the swollen spinal cord tissue against the vertebrae
causing an increase in ischemia.

The altered electrolyte environment coupled with
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oxygen free radical and lipid peroxidation reactions catalyzed by hemorrhage and the
resultant ischemia, as well as release of the excitatory amino acids glutamate and
aspartate, ultimately lead to necrotic cell death. Oxygen and glucose deprivation followed
by reoxygenation may also induce apoptosis of neurons. [33] The inflammatory response
begins within hours of injury and peaks within several days.
The subacute phase follows necrosis and is characterized by an ongoing
inflammatory response resulting from reactive gliosis by microglia and astrocytes, as well
as disruption of the blood-brain barrier which allows blood-borne immune cells from the
periphery to infiltrate the spinal cord.

Neuronal degeneration signals microglia to

upregulate cell surface proteins such as major histocompatability complex II (MHC II)
leading to transformation into macrophages, with markers being prominent by 3 days
following injury; however, these markers decline sharply after 3 days and are not evident
again until 18-20 days following dorsal root axotomy. [34] Reactive astrocytes begin
proliferating within 2 days following injury and begin to accumulate at the lesion margins
within 1 week, peaking at 14 days and still present at 28 days. Neutrophils infiltrate the
lesion first, within 6-12 hours following injury with maximum infiltration occurring
within 24 hours; however, neutrophils disappear from the lesion site at 3 days post-injury.
Macrophage infiltration from the periphery follows neutrophil infilatration, and
macrophages persist in the lesion site for weeks. Schwann cells, meningeal cells, and
fibroblasts from the periphery also infiltrate the injured spinal cord. Meningeal cells
proliferate following injury and migrate into the lesion to aid astrocytes in reestablishing
the blood-brain barrier. [35] Demyelination begins within 24 hours and increases over
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several days as Wallerian degeneration of distal axons progresses. Interestingly, an
accurate neurological examination requires patients to be at least 72 hours post-injury, or
in the subacute phase of injury. [2]
The late phase, also termed chronic injury, occurs weeks to months following
injury and is characterized by well-defined cyst formation by two weeks, with some cysts
containing fluid, followed by resolution of the inflammatory response with a
disappearance of macrophages. In post-traumatic cystic cavitation, the size and severity
of a CNS injury progress from a small area of direct trauma to a greatly enlarged
secondary injury due to persistent inflammation. [36] Reactive astrocytes that migrate to
the margin of the lesion site form the glial scar, which may also include reactive
microglial cells. The glial scar serves to repair the blood-brain barrier and encapsulate
the injury site in order to limit the inflammatory response and resulting cellular
degeneration. [37] Ablation of reactive astrocytes adjacent to a forebrain stab injury in
adult transgenic mice resulted in a failure of blood-brain barrier repair and a sustained
increase in infiltration of immune cells from the periphery. [38] The BBB remains
disrupted for up to 14 days following injury, with areas of greatest glial scarring
corresponding to areas with the most extensive BBB disruption. [39] Lastly, late phase
demyelination may continue to increase for a period of two weeks following injury, even
in spared axon tracts. [11]
In summary, spinal cord injury results in cell death, both of neuronal cells and
their supporting glial cell populations; destruction of the physical structure of axons and
myelin resulting from Wallerian degeneration; progressive cystic cavitation and the
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formation of glial scar tissue; and continued destruction of myelin relative to secondary
injury or lack of remyelination resulting in a loss of conduction in spared axons.

REGENERATIVE FAILURE OF THE ADULT CENTRAL NERVOUS SYSTEM
A number of mechanisms have been implicated in regenerative failure of the adult
CNS following injury and are broadly classified into two categories: intrinsic barriers, or
an inherent decline in growth capacity that occurs with neuronal cell maturation; and
extrinsic barriers, or the non-permissive regenerative environment in the adult CNS
following injury as compared to the permissive PNS and developing CNS environments.
Proposed mechanisms of intrinsic regenerative failure include a decrease in the rate of
retrograde transport of injury signals with increasing distance between axotomy site and
cell body, delayed synthesis and diminished anterograde transport of cytoskeletal proteins
required for growth cone and axon formation, a developmentally-regulated decrease in
endogenous levels of neuronal cyclic adenosine monophosphate (cAMP) in mature
neurons, and variable ability of different neuronal cell types to sustain expression of
regeneration-associated genes. [9-12] Surviving neurons in the CNS generally do sprout
axons in an attempt at regeneration; however, this attempt is quickly aborted upon
encountering the hostile external environment. [13] Proposed mechanisms of extrinsic
regenerative failure include delayed and incomplete clearance of axon and myelin debris;
exposure to myelin-associated inhibitory glycoproteins that are not present during early
stages of development; exposure to inhibitory chondroitin sulfate proteoglycans (CSPGs)
present in reactive astrocytic glial scar tissue; and a loss of the structural organization of
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the mature CNS, the formation of cystic cavities, and a lack of supporting neurotrophic
factors and growth-promoting adhesion ligands that are present during development.

Intrinsic Regenerative Failure
Embryonic neurons will grow axons when transplanted into the same environment
that blocks adult axon regeneration, but adult neurons do not regenerate into embryonic
environments [40, 41], suggesting intrinsic mechanisms for regenerative failure of mature
neurons.
Failure of Upregulated Gene Expression and Transport
Injury signals are transported retrogradely from the site of injury to the cell body
in the grey matter, and successful regeneration occurs only when the cell body is able to
increase the rate of transport. Axotomy at more distal sites results in a marked decrease
in retrograde transport, thus delaying changes in gene expression required for initiation of
regeneration. [42] This also corresponds to observations that PNS regeneration rates are
slower when lesions are far from the cell body. [27] The synthesis and anterograde
transport of cytoskeletal proteins, such as actin, tubulin, and neurofilaments, is essential
for the formation of growth cones and axons during development and regeneration.
These cytoskeletal proteins are transported from the cell body to the growth cone by slow
axonal transport, and successful regeneration occurs only when the cell body is able to
increase the rate of transport.

CNS neurons do not successfully upregulate gene

expression and transport rates following injury [43, 44] as compared to the upregulation
in gene expression demonstrated in the PNS following injury. [45]
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In addition to mRNA translation and protein synthesis by the cell body, recent
studies have shown that mRNAs are also transported from the cell body for local protein
synthesis in developing and mature axons [46, 47], although it is unclear if adult CNS
axons contain ribosomes. [48] Protein synthesis in developing axons may allow the distal
axon to autonomously respond to guidance cues by rapidly changing its direction of
outgrowth. Injury of mature axons triggers formation of a growth cone through locally
synthesized proteins and proteolysis in the proximal axon, and locally synthesized
proteins provide the retrogradely transported signaling complex that initiates the
regenerative response. Neurotrophins may have the potential to enhance the localized
protein synthesis of axons.
Reduced cAMP Levels
Myelin has been shown to inhibit regeneration from mature neurons; however,
embryonic or neonatal neurons are capable of growth on myelin inhibitory molecules.
Neuronal cyclic adenosine monophosphate (cAMP) is a cyclic nucleotide whose
endogenous levels are dramatically higher in young neurons, suggesting that the switch
from permissive to non-permissive growth on myelin during development is due to a
developmentally regulated decrease in cAMP levels. [10] Lesion models of dorsal root
ganglion neurons that project axons in both the PNS and CNS have shown that a
conditioning lesion of the peripheral segment one to two weeks prior to a lesion of the
central segment enables central processes to regenerate with no modification of the
external environment. One theory regarding the conditioning lesion is that it allows CNS
axons to overcome inhibition by myelin via a transient increase in cAMP, and that
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elevation of cAMP is not only necessary but sufficient to promote regeneration. [49, 50]
Spencer et al. “primed” postnatal CNS neurons overnight with neurotrophins and found
that they were able to regenerate on inhibitory myelin substrates, and an increase in
cAMP levels was able to mimic the effect of this neurotrophin “priming”; in fact, an
increase in endogenous cAMP levels followed neurotrophin treatment. [50] In vivo
injection, prior to injury, of cyclic AMP (cAMP) into DRG neurons resulted in
regenerative sprouting of sensory axons following CNS lesion, with an elongated pattern
of neurite outgrowth. [51] Protein kinase A (PKA) is a downstream effector of cAMP,
and activation of PKA may phosphorylate Rho thus rendering it inactive. [52, 53] Figure
2.7 depicts a summary of signaling pathways related to myelin inhibitory molecules.
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Figure 2.7 Signaling Pathways in Myelin-Related Growth Cone Collapse
(Reprinted from He et al. 2004 [52])

A conditioning lesion of DRG peripheral segments one to two weeks prior to a
lesion of the central segment enables central processes to regenerate, suggesting that PNS
injury activates a “growth program” that improves the inherent growth capacity of mature
CNS neurons. [54]

Growth-associated protein 43kDa (GAP-43) and cortical

cytoskeleton-associated protein 23kDa (CAP-23) are proteins localized to the growth
cone that influence axonal growth and synaptic plasticity. In vivo concomitant
overexpression of both GAP-43 and CAP-23 has been shown to promote significant
regeneration of central DRG axons into peripheral nerve implants in transgenic mice,
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although not as extensive as the regeneration produced by a conditioning lesion. Also,
overexpression of either protein alone failed to promote regeneration, demonstrating that
each proteins is necessary, but not sufficient for regeneration. [55]

The transient

elevation in cAMP levels following a conditioning lesion may, in part, be responsible for
the improvement in the mature CNS growth capacity, possibly mimicking that of
embryonic or newborn neurons whose endogenous cAMP levels are higher. Obviously, a
conditioning lesion made prior to spinal cord injury is useless clinically; however,
Neumann et al. have demonstrated that conditioning lesions made at the time of spinal
cord injury and again one week later promoted regeneration within and beyond the lesion
site, perhaps by elevating cAMP levels or by accelerating retrograde and anterograde
transport rates, thus enhancing and sustaining intrinsic growth capacity. [56]
Axonal type also affects regeneration as different axons have different intrinsic
regeneration capabilities. Cerebellar Purkinje cells of the brain appear to have no
regenerative response to axotomy; however, spinal motor neurons mount a robust
regenerative response. [14] Dorsal root ganglia sensory axons regenerate vigorously into
permissive environments. [48] Deumens et al. presented a detailed review of the
sprouting responses of descending axon tracts in response to injury and descending axon
tract-specific regenerative therapies. [12]
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Extrinsic Regenerative Failure
Delayed and Incomplete Clearance of Axon and Myelin Debris
One drawback to the “immune-privilege” of the CNS is a delay in phagocytic
clearance of degenerating axon and myelin debris, in part due to the delay in infiltration
of blood-borne immune cells from the periphery and in fewer numbers than seen in the
PNS; macrophages are rapidly recruited in large numbers to peripheral injury sites. [9] In
addition, resident reactive microglia that transform into macrophages in the CNS abort
their phagocytic response at 3 days post-injury. [34] Sensory axon and myelin debris are
almost completely cleared from peripheral nerve roots by 30 days post-injury; however,
axon and myelin debris in sensory axons of the spinal cord are still visible 90 days after
injury. [34] Another factor contributing to differences in clearance is that Schwann cells
in the PNS exhibit the unique ability to aid in phagocytosis following injury, being the
primary contributors in the first two days. Myelinating Schwann cells in the distal nerve
are induced to dedifferentiate into non-myelinating Schwann cells by axon and myelin
debris and proliferate extensively. In the CNS, however, adult oligodendrocytes will
either undergo apoptosis or enter a state of rest following injury. [57] Unlike Schwann
cells in the PNS, oligodendrocytes do not participate in phagocytosis of axon and myelin
debris in the CNS.
Inhibitory Molecules in the CNS
Interaction of regenerating CNS axons with inhibitory molecules results in two
forms of stalled growth: growth cone collapse and formation of dystrophic endbulbs.
Growth cone collapse occurs when mature regenerating axons encounter myelin debris
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and oligodendrocytes following injury. Myelin inhibitors are only exposed after damage;
adult sensory neurons implanted into degenerating white matter of the adult rat spinal
cord extended long axons on the outer surface of undamaged myelin. [58] Myelin
inhibitory molecules arrest normal growth cone progression, causing collapse and often
retraction into a shrunken, quiescent growth cone.

Growth cones form dystrophic

endbulbs upon encountering the glial scar and it is thought that they are an aberrant
growth cone that adult neurons form in order to survive in a hostile environment. These
endbulbs have been shown to be highly active structures capable of returning to active
growth states after extended periods of time with the appropriate stimuli. [39] Myelin
inhibitors are early impediments to regeneration immediately following injury, before the
formation of the glial scar.
Inhibitory myelin-associated proteins
Regeneration of injured axons recapitulates development to a certain extent;
however, the regenerating axons are exposed to molecules not seen during early stages of
development. Spinal cord lesions in embryos and newborns of higher vertebrates are
capable of robust regeneration following injury; however, axons are no longer able to
regenerate post-injury in embryonic chicken following myelin formation in the spinal
cord, suggesting that oligodendrocytes and myelin play an important role in inhibition of
CNS regeneration. [59]

These myelin inhibitory molecules are thought to prevent

aberrant sprouting of mature CNS neurons in order to prevent axon connection to
inappropriate targets; however, following CNS injury, incomplete clearance of myelin
debris results in growth cone collapse of regenerating axons. Some studies suggest that
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myelin inhibitory molecules serve to orient neurite outgrowth in a parallel direction [60,
61] and in vitro studies demonstrated that disruption of axon tract geometry in
relationship to myelin is sufficient to inhibit neurite outgrowth. [61]
The inhibitory molecules in myelin debris of the adult CNS include Nogo-A, -B,
and -C; Nogo-66, a 66 amino acid sequence found in the extracellular domain of all three
Nogo isoforms thought to be responsible for their inhibitory function; myelin-associated
glycoprotein (MAG); and oligodendrocyte-myelin glycoprotein (OMgp). [13, 48, 62-64]
Additional myelin inhibitory molecules include Semaphorin4D and versican, a
chondroitin sulfate proteoglycan. [48] Nogo, MAG, and OMgp have been found to
compete for binding to the same Nogo receptor, NgR, suggesting redundancy in their
action. [65] The Nogo receptor NgR lacks an intracellular signaling domain and partners
with the p75 neurotrophin receptor, the TROY receptor, and possibly other currently
unknown receptors to activate Rho and its downstream target ROCK, which has
demonstrated inhibitory influences on axon growth. [66, 67]

Another intracellular

component of Nogo signaling involves calcium-dependent cytoplasmic protein
phosphorylation mechanisms; however, the role of calcium in myelin inhibition is not
completely understood. [52, 68, 69]
Many groups of CNS axons are capable of regenerating into peripheral nerve
grafts, suggesting that there are differences in CNS and PNS myelin and that CNS myelin
is selectively inhibitory. For example, Nogo has been shown to be highly expressed by
CNS oligodendrocytes but not by PNS Schwann cells. [70] In fact, regulated transgenic
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expression of Nogo-A by PNS Schwann cells impaired axonal regeneration and
functional recovery after sciatic nerve crush. [71]
Inhibition by the glial scar
An unfortunate complication of CNS injury occurs due to the secondary injury
cascade when a small area of trauma progresses to a much larger cystic cavity that may
be fluid-filled and is surrounded by glial scar tissue. In Chapter 3 of “CNS
Regeneration”, Fitch and Silver provide a review of the mechanisms by which glial cells
contribute to CNS failure to regenerate. For many years, it was thought that the glial scar
was simply a mechanical barrier to regeneration because axons will not traverse a purely
fluid environment [72]; however, regeneration does not occur even in the absence of a
fluid-filled cyst at the lesion site, suggesting that there are additional causes of inhibition
by the glial scar. [9]
The glial scar is comprised of a lesion core populated by meningeal fibroblasts,
vascular endothelial cells, and oligodendrocyte precursor cells (OPCs); and a surrounding
area comprised of reactive astrocytes, OPCs, and microglia. [48]

It has been

demonstrated that neonatal astrocytes are supportive of axon growth in vitro, whereas
mature reactive astrocytes are nonpermissive substrates for axon growth; typically
dendrites but not axons form on reactive astrocyte substrates. [9] In response to injury,
mature reactive astrocytes produce extracellular matrix components of the glial scar,
including proteoglycans and tenascin, which may inhibit neurite outgrowth. The ECM of
the glial scar also consists of hyaluronic acid, the most abundant ECM protein in the
CNS.
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Proteoglycans consist of a protein core with covalently attached polysaccharide
chains termed glycosaminoglycans (GAGs) and are characterized by their GAG
compositions as chondroitin sulfate, heparin sulfate, keratin sulfate, and dermatan sulfate.
[9] Chondroitin sulfate proteoglycans (CSPGs) have been shown to be upregulated
following injury; they persist in the extracellular matrix of the glial scar and inhibit
neurite outgrowth.

The hyalectan family of CSPGs includes neurocan, aggrecan,

versican, brevican and these molecules share a common structure that includes an Nterminal hyaluronic acid binding site and a C-terminal with epidermal growth factor
(EGF). [73] Other CSPGs include NG2, versican, [73] and biglycan, as well as other
inhibitory molecules including ephs/ephrins and semaphorins. [48]

Ephrins and

semaphorins are primary axon guidance molecules that demarcate non-permissive
regions of the developing CNS for certain classes of neurons. [23]
Neurocan is expressed by astrocytes and OPCs. Versican appears to only be
expressed by immature oligodendrocytes (OPCs) in the adult CNS. Brevican is one of
the most abundant CSPGs in the adult CNS and is expressed by astrocytes and mature
oligodendrocytes and is present in myelin debris contained in the glial scar. NG2 is
expressed by OPCs and may be expressed by reactive astrocytes following injury.
Phosphacan expression is limited to neuronal tissues and is expressed by both astrocytes
and OPCs. Deletion of ephs/ephrins in animals almost completely abolished reactive
gliosis by astrocytes thus improving regeneration, and meningeal cells produce
semaphorins as well as NG2. [48]
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CSPGs may inhibit neuronal outgrowth through several mechanisms. Neurocan
and phosphacan have high affinity for L1 and NCAM via the chondroitin sulfate
sidechains, and binding may potentially inhibit homophilic interactions of these cell
adhesion molecules, thus inhibiting regeneration. [73] CSPGs are also capable of binding
to laminin, potentially masking its growth-promoting properties. An interesting feature
of CSPGs in the glial scar is that they signal through the Rho/ROCK pathway, the same
signaling pathway used by myelin inhibitory molecules. [74]
Loss of Organized Structure and Lack of Growth-Promoting
Neurotrophic Factors and Adhesion Ligands
In humans, peripheral axons regenerate at a rate of approximately 2-5 mm/day
following crush injury that leaves the endoneurial tube structure intact [27, 75]; however,
transection injury without surgical intervention typically results in slower regeneration
rates and lack of functional recovery, suggesting that PNS regeneration is highly
dependent on the ensheathed nerve anatomy for guidance. Following degeneration of the
PNS distal axons, Schwann cells remaining in the phagocytosed endoneurial tubes
proliferate and align along the basement membrane of the endoneurial tube into linear
arrays known as Bands of Büngner, providing a spatial scaffold for axon regeneration. In
addition to their phagocytic activities following injury, Schwann cells also increase their
synthesis of surface cell adhesion molecules (CAMs), such as NCAM, NgCAM, and L1;
they secrete extracellular matrix (ECM) molecules such as collagen, laminin, fibronectin,
and tenascin; and they produce and spatially present neurotrophic factors such as nerve
growth factor (NGF), neurotrophin 4/5 (NT-4/5), brain-derived neurotrophic factor
(BDNF), and glial-cell derived neurotrophic factor (GDNF). [26]
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Although the CNS does not exhibit the ensheathed nerve anatomy like the PNS,
there is evidence of temporal and spatial alignment of immature glial cells during
development that provides a bridge-like structure along with ECM molecules,
predominantly laminin; cell adhesion molecules, such as NCAM and L1; and
neurotrophic factors. [28, 76, 77] Several studies highlight the importance of organized
expression of growth-promoting molecules by glial cells during development.
Temporospatial expression of neural cell adhesion molecule (NCAM) produced by
neuroepithelial cells aligned to form tunnel-like structures is involved in guidance of
optic and olfactory axons, and lack of NCAM functions as an axon-refractory barrier.
[78-80] During development of the corpus callosum, there is evidence of an aligned glial
bridge-like structure to guide axons across the midline that disappears neonatally. [81]
Immature astrocytes oriented perpendicular to corticospinal tract (CST) axons align in
longitudinal tiers and participate in axon guidance during rat CST development. [82, 83]
Additionally, laminin produced by aligned immature astrocytes serves to guide optic
nerve and corpus callosum axons. [76] Mechanically lesioned neuron-astrocyte mouse
cortical cocultures treated to prevent glial scarring demonstrated neuron migration and
neurite outgrowth with increased astroglial laminin production [84], thus reinforcing the
idea that “unreactive” astrocytes generate an environment permissive to growth. Aligned
glial/biomatrix bridges developed by culturing neonatal astrocytes on PLA and
PLA/PLA-b-PEO matrices directed in vitro neonatal cerebral cortex neurite outgrowth
over the aligned glial cells, thus highlighting importance or temporal and spatial
alignment in directing neurite outgrowth. [85]. The glial structures that guide developing
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axons in the CNS disappear upon maturation and are not reformed by mature reactive
astrocytes following spinal cord injury. Non-native fibroblasts and meningeal cells that
migrate in from the periphery following injury may deposit collagen, but no organized
deposition of ECM occurs. [9] Finally, incomplete phagocytosis of axon and myelin
debris and fluid-filled cystic cavities that form at injury sites severely disrupt the
organized structure of the uninjured mature CNS.
Schwann cells are the one-stop-shop for PNS neurons providing them with
guidance, ECM molecules, CAMs, and growth factors required for successful
regeneration following injury; however, glial cells of the mature CNS play a major role in
mediating the secondary injury cascade following injury, and as a result, mature CNS
neurons lose the glial support that is evident during CNS development and is required for
successful regeneration.

REPORTED EXPERIMENTAL APPROACHES TO REGENERATION
Experimental approaches to regeneration includes pre-clinical in vitro and animal
models and focus on modification of the non-permissive external environment of the
CNS and limited studies into modifying the intrinsic regeneration capability of CNS
neurons.
Improvement of Clearance
Clearance of axon and myelin debris occurs rapidly and efficiently in the PNS
following injury, in part, because of the rapid infiltration of peripheral macrophages into
the lesion site; therefore, several groups have studied transplants of macrophages
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activated by exposure to PNS or skin tissue in the injured spinal cord of animal models
and have demonstrated partial functional recovery. [86-89] Although this approach is
controversial because macrophages are believed to contribute to worsening of damage by
the inflammatory cascade [90], clinical trials of autologous transplants are being pursued
by two groups: Schwartz and Yoles [91, 92] and Knoller et al. in conjunction with
Proneuron Biotechnologies (Procord). [93])

Neutralization of the Inhibitory Environment
Neutralization of the inhibitory molecules in myelin and the glial scar for CNS
regeneration involves many different approaches. [14, 48, 62, 94]
A monoclonal murine IgM antibody (mAB IN-1) has been shown to block the
myelin inhibitory molecule Nogo-A; in vivo application in the adult rat CNS resulted in
substantial axon sprouting and some long-distance corticospinal regeneration following
complete transection of the corticospinal tract, which is significant as no spontaneous
regeneration of corticospinal fibers is typically observed. [95] A recombinant, partially
humanized IgG version of the IN-1 antibody (rIN-1 Fab) has demonstrated long-distance
regeneration of corticospinal axons in adult rats [96], also observed in the marmoset
monkey following thoracic lesions treated with mAB IN-1. [97] Clinical trials using antiNogo antibodies are in the planning stages in association with Novartis. [98]
Intrathecal administration of NEP1-40 derived from Nogo-66, a competitive
antagonist of the Nogo receptor common to all myelin inhibitors, improved corticospinal
axon growth and functional recovery following mid-thoracic spinal cord hemisection in
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adult rats. [99] An anti-Nogo receptor monoclonal antibody has been shown to promote
neurite outgrowth of P3 rat DRG neurons culture on CNS myelin substrates. [100]
Biogen Idec Inc. has licensed Nogo receptor-related therapeutics and may pursue clinical
trials. [94]
Semaphorins are inhibitory molecules produced at sites of CNS injury and they
signal through plexin and neuropilin receptors expressed in neurons. An in vitro model
of the astrocyte/meningeal cell interface found that meningeal cells expressed NG2,
versican, and semaphorins 3A and 3C, and antibody blocking of NG2 and neuropilin 2
but not neuropilin 1 promoted DRG axon growth from astrocytes to meningeal cells.
[101] Ephrins expressed on astrocytes have been shown to inhibit regeneration, and adult
mice lacking EphA4 exhibited reduced gliosis and regeneration of corticospinal and
rubrospinal tracts across the lesion site following spinal cord hemisection, as evidenced
by anterograde and retrograde tracing. [102] Astrocyte EphA4 was also blocked by
monomeric EphrinA5-Fc to produce longer neurite outgrowth in this study.
Chondroitin sulfate proteoglycans (CSPGs) exist in large quantities in the
damaged CNS, particularly the glial scar. [48] Chondroitinase ABC (Ch-ABC) is a
bacterial enzyme that catalyzes hydrolysis of chondroitin sulfate GAG chains into
dissacharides that diffuse away, thus reducing the inhibitory effects of CSPGs.
Administration of Ch-ABC has been shown to induce axonal growth and functional
recovery in adult rats [103, 104], as well as promote autonomic motor recovery. [105]
Blocking Rho has the unique potential to overcome inhibition by both myelin and
glial scar inhibitory molecules, since their signaling pathways appear to converge on this
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downstream effector. Blocking RhoA with C3 transferase (botulinum toxin) enabled
regeneration following over-hemisection of the adult mouse spinal cord. [106]

In

addition to enhancement of regeneration, inactivation of Rho is also believed to offer
neuroprotection by protecting cells from apoptosis, and inactivation of Rho kinase may
alleviate pain following injury. [107] Cethrin® (BioAxone Therapeutic, Inc.) is a Rho
antagonist currently undergoing clinical trials. [98, 108]
Neuronal cyclic adenosine monophosphate (cAMP) is a key player in the intrinsic
inability of the CNS to regenerate, perhaps by influencing its ability to overcome
inhibition by myelin and glial scar molecules. The pharmaceutical rolipram, originally
developed as an anti-depressant, is a phosphodiesterase inhibitor that prevents hydrolysis
of cAMP, and it has been shown to prevent the reduction in endogenous cAMP levels in
adult rats following spinal cord contusion, and combined with Schwann cell grafts
improved axon sparing and myelination. [109] Rolipram delivery in conjunction with
implantation of embryonic spinal tissue improved axon growth into the implant and
attenuated reactive gliosis. [110]
The application of treatments to block inhibition by the CNS external
environment must be approached with great care and designed to only affect injured
neurons, as they not only enhance regeneration but also promote significant sprouting and
plasticity, which may account for functional recovery. Maladaptive sprouting and growth
of non-injured neurons may be an undesirable side effect of these types of treatments.
Hyperalgesia is one side effect that has resulted from aberrant sprouting of uninjured
small pain fibers in nerve growth factor-treated animal models. [111]
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Delivery of Neurotrophic Factors
Neurotrophic factors are key nervous system regulatory proteins that modulate
neuronal survival, axonal growth, synaptic plasticity, and neurotransmission. They have
also been shown to promote and direct growth cone motility [112]; they exhibit a
chemotactic effect for axon guidance, and they aid in sensory nerve growth across the
PNS-CNS transition zone. As a result, their role in axon development and regeneration is
being studied extensively for application in spinal cord repair [28, 94, 113-115].
The family of neurotrophic factors includes nerve growth factor (NGF), brainderived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5),
ciliary neurotrophic factor (CNTF), glial cell line-derived growth factor (GDNF), and
acidic and basic fibroblast growth factor (aFGF, bFGF). Schwann cells produce
neurotrophic factors following PNS injury; however, levels following spinal cord injury
are almost undetectable. The neural responses promoted by neurotrophic factors are
summarized in Table 2.1. [28]
NEURAL RESPONSES PROMOTED
Motor neuron survival
Motor neuron outgrowth
Sensory neuron survival
Sensory neuron outgrowth
Spinal cord regeneration
Peripheral nerve regeneration

NEUROTROPHIC FACTORS
BDNF, NT-3, NT-4/5, CNTF, GDNF
BDNF, NT-3, NT-4/5, CNTF, GDNF
NGF, NT-4/5, GDNF
NGF, BDNF, NT-3
NGF, NT-3, CNTF, FGFs
NGF, NT-3, NT-4/5, CNTF, GDNF,
FGFs
NGF, NT-3, GDNF, FGFs

Sensory nerve growth across PNS-CNS
transitional zone

Table 2.1 Neural Responses Promoted by Neurotrophic Factors [28]
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There is a significant amount of overlap in the responses promoted by
neurotrophic factors, and this must be taken into account when considering their use in
therapeutic applications.

For example, NGF was the first and most widely studied

neurotrophic factor and is best known for its essential role during the development of
peripheral sensory and sympathetic neurons [116]; however, it has been shown to be
clinically useless for regeneration of peripheral nerves because it affects pain-sensitive
neurons, resulting in hyperalgesia, or increased sensitivity to pain. [117] NT-3 is useful
for regenerating corticospinal axons [77]; however, NT-3 can trigger apoptosis of BDNFdependent neurons. [118]
Neurotrophins have a very short half-life, are digested in the gastrointestinal tract,
and do not pass the blood-brain barrier; as a result, oral or systemic delivery will not
promote regeneration of CNS neurons and may result in unwanted side effects due to
nonspecific delivery. In addition, there is rapid clearance of drugs injected directly into
the spinal cord due to the constant exchange of cerebrospinal fluid (CSF). As a result,
delivery methods must be tailored to provide biologically relevant amounts of long-term,
localized neurotrophins at the site of injury in order to avoid unwanted side effects.
Reviews of reported methods of delivery include direct injection, continuous infusion, in
situ gene therapy, and transplantation of ex vivo genetically engineered cells. [28, 113,
114]
Direct

injection

to

the

cerebrospinal

fluid

(CSF)

by

means

of

intracerebroventricular, intraparenchymal, or intrathecal infusion does not provide longterm delivery of growth factors because there is rapid clearance due to the constant
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exchange of CSF and does not provide localized delivery. [114] Continuous infusion
using an implanted osmotic minipump may be used as a temporary intervention strategy
following spinal cord injury or to study the effects of neurotrophins; however, it is not a
solution for extended delivery because depleted pumps have to be replaced at 4 weeks,
and it also does not provide localized delivery. [119, 120]
In situ gene therapy via vector-mediated expression of neurotrophic factors to the
spinal cord has advantages over local or systemic administration.

Vectors can be

delivered to the spinal cord by single injection, expression can be targeted to lesioned
neurons, and vector expression of a neurotrophic factor mimics their physiological
production. [114] Two types of vector systems exist: viral vectors and nonviral vectors.
Viral vectors include: (1) herpes viral vectors (HSV), (2) adenoviral vectors, (3) adenoassociated viral vectors (AAV), and (4) lentiviral vectors (LV). Nonviral vectors are
typically not used for this application due to their inefficiency. Table 2.2 is a summary of
research groups studying the viral-mediated vector expression of neurotrophins. AAV
and LV vectors do not display detectable inflammatory or cytotoxic responses and may
be a good choice for future gene therapy; however, HSV and adenoviral vectors are not
suitable because they require immunosuppression and are cytotoxic.

1.
2.
3.
4.

GROUP
Geschwind et al., 1994 [121]
Zhang et al., 1998 [122]
Ruitenberg et al., 1998 [123]
Hottinger et al., 2000 [124]

VECTOR
HSV vector
Adenoviral vector
AAV vector
LV vector

GROWTH FACTOR
NGF
NT-3
BDNF
GDNF

Table 2.2 Groups Researching In Situ Gene Therapy
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Ex vivo gene therapy is a combination therapy involving in vitro genetic
modification of autologous cells to deliver a specific growth factor, followed by
transplantation of the cells back into the host. This approach eliminates the risk of
immunological rejection and may provide a high concentration of long-term, localized
growth factor delivery to a site of injury [113]. Table 2.3 is a summary of research
groups studying this method of neurotrophic factor delivery.

1.
2.
3.
4.
5.
6.

GROUP
Grill et al., 1997 [125]
Tuszynski et al., 2002 [126]
Lu et al., 2003 [127]
Tuszynski et al., 2003 [128]
Blesch et al., 2004 [129]
Lu et al., 2005 [130]

CELLS
Fibroblasts
Fibroblasts
Neural stem cells
Fibroblasts
Fibroblasts
Marrow stromal cells

GROWTH FACTOR
NT-3
NGF
NT-3
NT-3
NT-4/5
BDNF

Table 2.3 Groups Researching Ex Vivo Genetically Engineered Cells

Groups 1, 3, and 5 reported partial amelioration of functional deficits by the
Basso, Beattie, and Bresnahan (BBB) locomotor rating scale for rats or other functional
test methods.

Groups 2, 4, and 6 reported extensive axonal growth following cell

transplantation. Additional examples of genetically-modified cells used for neurotrophic
factor delivery have been reported by Schmidt and Leach. [28] None of the groups
reported axon growth beyond the graft, thus demonstrating the need for additional
strategies.
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Bridging Strategies
The idea of bridging strategies in the CNS arose from the need to restore structure
and provide necessary adhesion molecules and growth factors in order to promote
regeneration of axons, much in the same way immature CNS glia provide these elements
for developing axons and PNS Schwann cells provide these elements for developing and
injured PNS neurons. Several approaches are currently under investigation, including
transplantation of fetal and embryonic tissue, mechanically-engineered nervous tissue
constructs, peripheral nerves, and cells.
Nervous Tissue Transplantation
Neural tissue transplants from human embryos and fetuses have shown promise in
promoting CNS regeneration in animal models.

Transplants of fetal spinal cord

following resection lesions of adult rat spinal cord and contused adult rat and cat spinal
cord demonstrated short-distance regeneration into the grafts and attenuation of scar
tissue but limited regeneration across the host/graft interface. [131-133] These neural
tissue transplants have the potential to not only replace cells but may also provide sources
of growth factors, improvement of conduction by remyelination, or neuroprotection.
Despite the inherent issues in scale-up as well as the ethical challenges, human fetal
spinal cord tissue has been grafted into human patients with syringomyelia in clinical
trials. [134, 135]
Mechanically-Engineered Nervous Tissue Constructs
Another unique approach involves the development of transplantable tissue
constructs comprised of DRG axons induced to grow by application of mechanical stretch
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to the central portion of the axon, thus mimicking the growth of integrated nerves and
axon tracts that do not have growth cones and are under mechanical strain during
development. [136] Pfister et al. created 5 cm long axon tracts in 8 days, encased them in
an 80% collagen hydrogel, and inserted them into a poly(glycolide) (PGA) conduit
(Neurotube®). Nervous tissue constructs could be grown at the rate 1 cm/day up to 10 cm
in length using this stretch-growth system.

Collagen hydrogel-coated 10 mm long

constructs were implanted into rats 10 days following modified lateral hemisection injury
and were found to survive 4 weeks following implantation and to extend axons into the
host spinal cord tissue. [137] This approach not only serves to bridge the injury site but
may also circumvent the issue of long-distance regeneration in the inhibitory CNS
environment by potentially allowing the creation of new intraspinal connections.
Peripheral Nerve Grafts
In the 1980’s, Richardson et al. established that regeneration of CNS axons into
autologous peripheral nerve grafts in rats could be accomplished as evidenced by
retrograde tracing, although functional recovery was lacking, the axons did not leave the
graft, and corticospinal axons did not grow into the graft. [138, 139] These studies
reinforced the idea of the permissive regeneration environment of the PNS, and in fact,
peripheral nerve contains Schwann cells that aid in phagocytosis, production of ECM and
cell adhesion molecules as well as neurotrophic factors, and remyelination following
peripheral nerve injury.
Autologous peripheral nerve grafts are typically derived from cutaneous nerves,
such as the sural or saphenous nerve, with up to 40 cm available length and 2-3 cm
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diameter. [28] It is interesting to note that the sural and saphenous nerves are two of the
most vascularized peripheral nerves and are therefore considered extremely suitable for
vascularized grafting. [29] Autologous grafts are advantageous because they reduce the
risk of immune rejection; however, donor site morbidity is a major drawback, and noncritical sensory nerves must be chosen thus limiting availability.

Peripheral nerve

allografts are an alternative and have the advantages of large supply and no donor site
morbidity; however, there is a risk of disease transmission and immunosuppression is
required during the time it takes cells in the allograft to be replaced with host cells. Even
so,

allografts

have

been

used

clinically

and

may

not

require

long-term

immunosuppression. [140]
Autologous intercostal nerves with fibrin glue and acidic fibroblast growth factor
(aFGF) were implanted into monkeys after lateral spinal hemisection and demonstrated
regeneration of myelinated CNS axons into the graft but not beyond the lesion site. [141]
Cheng et al. demonstrated regeneration of corticospinal axons into intercostal nerve
implants with fibrin glue, aFGF, and compressive wiring in adult paraplegic rats [142],
and extended their studies to one case of peripheral nerve transplant into a human
paraplegia patient with a 4-year old ASIA-C injury. [143] The subject received a sural
nerve graft with fibrin glue and aFGF. Two and one-half years following the surgery his
functional status improved from wheelchair-bound to ambulatory and ASIA-D
classification. Although this case included no control subjects and is contradictory, it
does suggest that combination therapies may be of real benefit to patients, even those
with chronic spinal cord injury.
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Cell Transplantation
Several cell types are under investigation for use in bridging strategies, including
Schwann cells, olfactory ensheathing cells (OECs), and stem cells. [28, 94, 144, 145]
Schwann Cells
Schwann cells are key players in the success of peripheral nerve regeneration and
in the success of CNS regeneration into peripheral nerve grafts, so it is no surprise that
grafts of these cells are being pursued as a spinal cord therapy.

Richardson et al.

documented one of the earliest attempts at bridging a spinal cord injury in the 1980’s
where regeneration of CNS axons into autologous peripheral nerve grafts in rats was
accomplished as evidenced by retrograde tracing. [138, 139]

Schwann cell

transplantation for CNS repair was a logical next step and has demonstrated varying
degrees of axonal regeneration and partial functional recovery in animal models. [94,
145, 146]
These cells also migrate into the injured spinal cord, possibly from the dorsal and
ventral roots, upon disruption of the blood-brain barrier and have been found in long-term
human spinal cord injuries, indicating that they are able to survive in the human CNS
environment as abnormally-organized tumors termed Schwannomas, but in a detrimental
manner causing compression of CNS axons. [147] Schwann cells in the PNS provide
spatial alignment via linear arrays known as Bands of Büngner; however, Schwann cells
do not migrate along CNS white matter tracts, suggesting that they may not provide
spatial alignment for CNS axons. [148] Schwann cells may also have the unique ability
to aid CNS axons in remyelination following regeneration; however, it has been
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demonstrated that the cues for myelination in the CNS and PNS are different, and that
nerve growth factor (NGF) promotes myelination by Schwann cells but reduces
myelination by oligodendrocytes [149], a factor that warrants further investigation and
should be taken into account when designing combination therapies with Schwann cell
grafts. Genetic engineering of Schwann cells to alter interactions with migration and
myelination cues is a potential way to account for these differences. [146]
Challenges facing Schwann cell grafts include failure to regenerate axons out of
the graft, lack of remyelination of axons beyond the injury site, and unfavorable
interactions with astrocytes leading to increased inhibitory CSPG production. [146] As a
result, several groups are studying ex vivo genetic modification of Schwann cells in order
to overcome these challenges. Schwann cells genetically modified to secrete upregulated
concentrations of NGF were grafted into the midthoracic region of the uninjured adult rat
spinal cord and were found to survive for up to one year and to induce robust growth and
myelination of neurotrophin-receptive sensory axons; however, it was noted that
Schwann cell grafts may enlarge over time, possibly attributable to immortalization of the
cells after multiple passages in vitro. [150] Expression of neural cell adhesion molecule
L1 on Schwann cells and axons correlated with axon-Schwann cell ensheathment, and
transduction of Schwann cells to overexpress NGF robustly increased axonal growth,
following implantation into adult rat spinal cord injury. [151] Schwann cells genetically
modified to secrete upregulated concentrations of BDNF enabled supraspinal axon
regeneration across and beyond the transection site in an adult rat model. [152] Genetic
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modification may be a viable method of overcoming the inherent challenges in Schwann
cell transplantation strategies.
Olfactory Ensheathing Cells
One of the major issues impacting all bridging techniques is that regenerating
axons do not want to leave the permissive substrate and reenter the inhibitory CNS
environment to reconnect with their target synapses. Olfactory ensheathing cells (OECs)
are glial cells of the olfactory system, and the olfactory system has the distinctive
capacity to support neurogenesis throughout life [153]. OECs have the unique intrinsic
ability to guide and ensheath, but not myelinate, new olfactory receptor axons into the
CNS across the normally inhibitory PNS-CNS transition zone [154, 155], and are thought
to have the potential to aid regenerating axons in navigating inhibitory environments.
Another theory is that OECs aid in preventing an astrocytic response, thus limiting
expression of inhibitory CSPGs. [28, 145] OECs are thought to be capable of migrating
through glial scar regions, as studies utilizing suspension transplants of OECs enabled
regenerating corticospinal axons to cross the lesion site in adult rats [156, 157]; however,
a combination of Schwann cells and OECs plus administration of chondroitinase ABC
following complete spinal cord transection in adult rats produced improvements in
functional scores but no evidence of regeneration of corticospinal or reticulospinal tracts.
[158] Major concerns with studies of this cell type include the methods of preparation.
[153] Animal studies conducted have used neonatal and adult cells as well as different
purification methods, such that the impact of other cell types on results cannot be
elucidated. [154] There is also recent controversy as to whether these cells actually
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enable axons to regenerate past the lesion site, or if the functional recovery seen is a
result of plasticity and neuroprotection, as there is little evidence to support that OEC
grafts are able to reestablish functional connections as of yet [159], and migration of
injected OECs does not appear to be different than migration of injected bone marrow
stromal cells or fibroblasts. [160]
Another caveat of this approach is that centrally-derived autologous cell sources
from the olfactory bulb have been used in most animal studies; however, harvest of these
cells compromises the host’s sense of smell, so peripherally-derived OECs from olfactory
endothelium are being explored as a viable alternative. [28] These peripherally-derived
cells may not behave the same as the centrally-derived cells and will require further
testing.

Even with the discrepancies in reported results from animal models,

transplantation of human fetal and adult OECs is currently one of the largest human
clinical trials, being pursued in China. [161-164]
Embryonic and Adult Stem Cells
Significant loss of neurons and glial cells occurs following spinal cord injury.
Pluripotent stem cells are sources for new cells in embryos that are capable of indefinite
self-renewal and differentiation into any cell type. In adults, multipotent progenitor cells,
also called adult stem cells, are sources for new cells that are capable of differentiation
into a limited number of cell types. [94, 165] These cells have the potential to not only
bridge the injury site, but may also be able to replace cells that have been lost to injury.
Embryonic stem (ES) cells have the advantage of being a potential indefinite cell
source and are being studied extensively for their potential use in spinal cord injury. [140,
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166] ES cells from mice were committed to the nervous system lineage by exposure to
retinoic acid and transplanted into rats more than 9 days following injury; the
transplanted cells differentiated into neurons, astrocytes, and oligodendrocytes and
promoted some functional recovery and remyelination, although regeneration has not
been demonstrated yet. [167] Major concerns with embryonic stem cells include the
ethical debate regarding their use and the long-term immunosuppression that is required
following the transplant of foreign cells. Spinal cord injured patients are vulnerable to
infection, and long-term immunosuppression in these patients is contraindicated. One
method that is being developed to avoid the use of foreign cells is somatic-cell nuclear
transfer, which allows the generation of “autologous” embryonic stem cells by replacing
the nucleus of a human egg with the nucleus from a somatic cell of the patient, then
allowing the embryo to develop to the blastocyst stage from which ES cells can be
harvested and grown in culture. [140]
Another source of new cells is the endogenous stem cells in the mature CNS that
are capable of differentiating into neurons and glial cells, termed neural progenitor cells
(NPCs) [168], but typically only produce oligodendrocytes and astrocytes in the spinal
cord. [14, 140, 169] These cells reside around the central canal of the spinal cord. [140]
Mouse NPC grafts were found to constitutively secrete several neurotrophins and
promoted extensive axon growth in adult rats following dorsal column lesions. [127]
Glial cell progenitors are multipotent cells with restricted fates, and include cells capable
of differentiating into myelinating Schwann cells in the PNS or oligodendrocytes in the
CNS. Transplantation of these cells has been shown to remyelinate axons but has not
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demonstrated axonal regeneration. [170] Disadvantages of these cell types is that their
populations may also be significantly reduced upon injury to the spinal cord, biopsy is
required to obtain this cell source, and it does take time to grow enough cells in the
laboratory for transplantation; however, their advantages lie in that they are a true
autologous cell source in comparison to ES cells and it may be possible to stimulate their
response in vivo, thus avoiding transplantation altogether. [94]
The ability of embryonic and endogenous stem cells to proliferate and their multipotentiality make them ideal candidates for CNS regeneration; however, preventing
proliferation of undesirable cell and tissue masses through controlled differentiation is of
utmost importance and is a significant factor in designing implantation strategies. [171]

CLINICAL THERAPIES AND TRIALS
Current Clinical Therapies for Spinal Cord Injury
Methylprednisolone sodium succinate (MPSS) was the first and is currently the
only treatment for the management of acute spinal cord injury, and has been adopted as
the standard of care since 1990 in most of North America [2]; however, no official FDA
review of the drug for this indication has been sought and the analysis of the data
supporting its use for SCI has been criticized. [172]

This steroid drug, when

administered within 8 hours of injury, is thought to attenuate the secondary injury
cascade and improve functional recovery; however, the National Acute Spinal Cord
Injury Studies (NASCIS) II and III only showed modest improvement in patients
receiving MPSS, with extensive complications including sepsis, pneumonia, and potential
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steroid myopathy. [2, 14, 98]) Although controversy regarding the effectiveness and
safety of MPSS remains, establishment of the 8 hour “therapeutic window” by the
NASCIS clinical trials led to evaluation of other neuroprotective pharmacological
therapies, including GM-1 ganglioside (Maryland and Sygen) and numerous other
candidates. [173] Researchers are also investigating the neuroprotective effects of mild
hypothermia (about 92°F) for several hours immediately following spinal cord injury. [3]
One major issue confounding results from pharmaceutical clinical trials for acute SCI is
inconsistency in the use of methylprednisolone in conjunction with the new
pharmaceutical agents being tested and lack of control for the use of methylprednisolone
in the studies. [2]
The ultimate goal for a spinal cord injured patient is recovery of function, which
may result from axonal regeneration, nervous system plasticity, restoration of conduction
by remyelination of spared axons, or any combination of these factors. Rehabilitation
following spinal cord injury is a clinical therapy that may improve motor recovery of
postural and locomotor tasks, such as standing and stepping, by taking advantage of
peripheral sensory information that can be used by the spinal cord without involving the
brain, thus demonstrating the remarkable plasticity of spinal motor neural circuits to
“learn” tasks. [174] Although rehabilitation is not a useful strategy in and of itself to
promote axonal regeneration, it has the capacity to improve patient quality of life now,
depending upon the type of injury sustained [175], and its potential to limit muscle
atrophy may ultimately improve functional recovery from reinnervation of muscle targets
by regenerated motor axon tracts.
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Standardization of Animal Studies and Clinical Trials
Common animal spinal cord injury models include contusion, transection,
compression, ischemic, and combinations of these four. [94] Contusion injuries represent
the largest sect of human spinal cord injuries. One major problem with most animal
contusion models is that they are applied to the dorsal surface following laminectomy
resulting in a posterior compression injury, which standardizes the location and severity
of injury; however, most human injuries are the result of ventral impact associated with
anterior compression of the vertebrae. [33] Another issue is the contusion device speed is
much slower and results in less impact than what is typical for most human injuries. In
addition, the compressive force in contusion models is typically removed immediately
after injury whereas it may be hours or days before a human injury is decompressed.
[108] The Basso, Beattie, and Bresnahan (BBB) locomotor rating scale has been widely
accepted as a method to assess locomotor function in rats following spinal cord contusion
injury [176]; however, there is no correlation of the BBB scale to the ASIA scale used for
human injuries, and differences in innate immune and inflammatory responses to injury
compromise the predictive value of findings in rats. [108] Primate models are being
explored but their expense is a significant limiting factor. True regeneration is difficult to
ascertain in contusion models.

Complete transection models allow undeniable

determination of regeneration, but these models are not representative of the majority of
human injuries nor do they generate the cystic cavitation more commonly seen with
contusion injuries. [94]
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It has been demonstrated repeatedly that functional improvement does not
necessarily correlate to axonal regeneration, and axonal regeneration does not necessarily
produce functional improvement.

Demonstration of functional regeneration (axonal

regeneration with functional recovery) must be validated by several criteria, including
anatomical tracing, specific behavioral tests corresponding to the regenerated axon
phenotype, electrophysiology to confirm connectivity, and ultimately, subsequent
reinjury of the regenerated axons to demonstrate their requirement for functional
recovery. [13]
There is a great need for standardization of human clinical trials for spinal cord
injury, as is evidenced by several reviews dedicated to discussing issues with past and
current human clinical trials. [2, 98, 108, 177] In response to the lack of standardization,
the International Campaign for Cures of Spinal Cord Injury Paralysis (ICCP) supported
an international panel charged with reviewing the methodology for clinical trials in spinal
cord injury, and they have established guidelines for future clinical trials. [178-181]

Worldwide Clinical Trials
As discussed previously, clinical trials investigating implantation of activated
autologous macrophages (ProCord®; Proneuron Biotechnologies) and the Rho pathway
antagonist, Cethrin® (BioAxone Therapeutic, Inc.) in patients with thoracic and cervical
SCI are currently underway. [98, 173] Also, a large-scale clinical trial investigating
transplantation of human fetal and adult OECs is currently being pursued in China. [98,
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161, 163, 164] Figure 2.8 represents a summary of recent human clinical trials around
the world. [98]

Figure 2.8 Worldwide Clinical Trials
(Reprinted from Tator 2006 [98])
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CONCLUSION
Most of the current approaches in human clinical trials involve either peripheral
nerve grafts or cell transplantation. Peripheral nerve grafts face challenges of limited
availability and donor site morbidity associated with autografts, and the immune
complications inherent to allographic or xenographic transplantation, along with potential
complications arising from cell types within peripheral nerve that are foreign to the CNS.
Inflammation within the CNS is particularly detrimental and may exacerbate existing
injury. Cells are an excellent source of the myriad of factors required for regeneration;
however, a major limitation of all cell transplantation approaches is the time required to
isolate, purify, genetically modify, and expand suitable autologous cells for
transplantation, or the immune complications inherent to allographic or xenographic
transplantation. Cells may produce undesirable side effects and do not allow for specific
delivery of molecules without genetic modification. Cell transplantation strategies also
face the unique challenges of cell survival and migration and do not necessarily address
the disorganized structure of the injured CNS; however, current approaches seek to
address these challenges by incorporating cells within biomaterial-based scaffolds with
channels to improve cell survival, limit migration, and provide guidance for extending
axons. [15-17] The next chapter will discuss biomaterial-based bridging strategies in
further detail.
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CHAPTER THREE
BIOMATERIAL-BASED BRIDGING STRATEGIES

INTRODUCTION
Most of the current approaches in human clinical trials involve either peripheral
nerve grafts or cell transplantation; however, biomaterial-based bridging strategies are an
alternative approach with a wide range of applications for neural repair. This chapter will
briefly review the incorporation of biomaterial scaffolds into cell transplantation
approaches in order to improve cell survival, limit migration, and provide guidance to
regenerating axons, but will ultimately focus on acellular biomaterial-based bridging
strategies with combination therapy for synergistic improvement of neural regeneration.

BIOMATERIALS FOR NEURAL APPLICATIONS
Biomaterials used for bridging strategies may be classified into two main
categories: natural materials, including ECM components and other natural polymers;
and synthetic polymers . [28, 171].
Natural Materials
Table 3.1 is a summary of natural scaffold materials being investigated for neural
applications.

58

MATERIAL
ECM proteins
Proteoglycans
Glycosaminoglycans
Fibrinogen/fibrin gels
Self-assembling
peptide scaffolds
Alginate
Agarose
Chitosan
Matrigel™

MOLECULES/SOURCE
Collagen, fibronectin, laminin,
Permissive heparin sulfate proteoglycans (HSPGs) [182]
Hyaluronic acid
Blood clotting
Various peptides [183]
Brown algae (seaweed, giant kelp)
Red algae or seaweed
Chitin/exoskeleton of crustaceans (shrimp, crabs) and
insects, bacterial and fungal cell walls
BD Biosciences

Table 3.1 Natural Polymers used for Neural Scaffolds [28, 171]

Type I collagen and laminin have proven to be useful molecules for spinal cord
repair; however, fibronectin has not demonstrated significant promise. [171] Fibronectin
in the CNS is associated with macrophages and endothelial cells and increased deposition
has been found in active multiple sclerosis lesions [184], so it is not an ideal substrate for
CNS repair. Matrigel™ is a commercially available hydrogel material generated from
mouse Englebreth-Holm-Swarm (EHS) sarcoma that not only contains basement
membrane components such as collagen, laminin, and proteoglycans; but also matrix
degrading enzymes, their inhibitors, and growth factors. Alginate hydrogels and alginate
hydrogels with fibronectin have been shown to possess less bioactivity than Matrigel in
inducing proliferation of cultured cells, maintaining morphology, and inducing DRG
neurite outgrowth. [185]

Also, alginate is not strictly biodegradable; however,

modification by crosslinking with calcium enables dissolution through calcium chelation,
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and ultra purified sources of alginate must be used due to cytotoxic impurities present in
commercial sources. [171]
Natural polymers are biodegradable because they form hydrogels that are
susceptible to enzymatic degradation; however, this also limits their mechanical and
design properties and they typically require some type of adhesive (e.g., fibrin glue) to
hold them in place. Disadvantages of these materials include a lack of control over
degradation rates, potential inconsistencies in material quality between different batches,
and potential for microbe or virus contamination. [186] Chitosan purity is of utmost
importance for those individuals with shellfish allergy due to the risk of anaphylactic
shock.
Synthetic Materials
Synthetic biomaterials are currently under investigation for use in bridging
strategies for spinal cord repair because of the ability to customize their chemical and
physical properties, including degradation rate, porosity, and mechanical strength. For
example, these materials can be designed to be tear resistant for ease in handling and
gluing or suturing. Another advantage of synthetic biomaterials is the ability to fabricate
them into virtually any design through a variety of polymer processing methods. Table
3.2 shows a summary of synthetic biomaterials being explored for use in nerve
regeneration strategies.
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POLYMER
Poly(glycolide)
Poly(lactide)
Poly(lactide-co-glycolide)
Poly(D,L-lactide)
Poly(caprolactone)
Biodegradable
poly(urethane)
Poly(organo phosphazene)
Poly(ethylene glycol)
Polycarbonate
Poly(3-hydroxybutyrate)
Poly(vinylidene fluoride)
Poly(pyrrole)

ABBREV
PGA
PLA
PLGA
PLLA
PCL

DEGRADABLE
Biodegradable
Biodegradable
Biodegradable
Biodegradable
Biodegradable
Biodegradable
Biodegradable
Biodegradable
Biodegradable
Biodegradable
Nondegradable
Biodegradable

PEG

PVDF
PPy

Silicone

Nondegradable

Expanded
Poly(tetrafluoroethylene)
Poly(2hydroxyethylmethacrylate)
Poly(2hydroxyethylmethacrylateco-methylmethacrylate)
Poly[N-(2-hydroxypropyl)
methacrylamide
Poly(acrylonitrile-covinylchloride)

ePTFE
(GoreTex)
PHEMA

Nondegradable

PHEMAMMA

Nondegradable

PHPMA

Nondegradable

PAN/PVC

Nondegradable

COMMENTS
FDA approved
FDA approved
FDA approved
FDA approved

FDA approved

Piezoelectric
Electrically
conducting
FDA approved
Inert, impermeable
Inert, impermeable

Nondegradable

Table 3.2 Synthetic Polymers used for Neural Scaffolds [28, 171]

Silicone has been studied in research and clinical settings since the early 1960s;
silicone and ePTFE are impermeable materials that limit nutrient and waste transport into
and out of the scaffold and cell permeation of the scaffold.

Although porous

nondegradable materials have been developed, nondegradable materials used as implants
traditionally pose a high risk of infection and chronic inflammation, and when used for
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neural scaffolds, they cause chronic reactive gliosis and compression of regenerated
nerves as they remyelinate [187, 188]; therefore, biodegradable materials are preferred.
Tunable biodegradation is important not only to ensure that the material remains intact
long enough for regeneration of axons through and out of the graft, but also to ensure that
the material is sufficiently degraded before remyelination of axons occurs to avoid
compressing the newly regenerated nerves.

DESIGN OF NEURAL SCAFFOLDS
Gels and Sponges
Gels and sponges have limited applicability in long-distance spinal cord
regeneration therapies and are not suitable to provide guidance to regenerating axons;
therefore, they will be briefly discussed. Gels are viscous, cross-linked liquids and are
useful for filling small cavities such as cystic cavities formed from contusion injury or
small gaps between transected nerves. For example, PEG fusiogens coupled with PEG
hydrogels as a tissue adherent have been used to fuse severed nerve endings together to
maintain continuity. [189] Sponges are porous structures with slightly higher mechanical
strength that can fill a slightly wider defect than gels. In situ thermoreversible gelation of
agarose gels has been used for simultaneous neurotrophin delivery and conformational
repair of an irregular spinal cord defect, and supported adult rat neurite extension into the
implant.

[190]

Collagen impregnated poly-2-hydroxyethyl methacrylate sponges

implanted into complete adult spinal cord lesions limited cystic cavitation and enabled
axon penetration into the sponge. [191]
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Tubes and Fibers
Tubes and fibers are potentially the most appropriate scaffold for long-distance
regeneration of axons because of their guidance capabilities. Figure 3.1 demonstrates
some of the properties of such devices for nerve guidance that have demonstrated
improvement of neurite outgrowth.

Figure 3.1 Desired Properties of Bridges for Nerve Guidance
(Reprinted from Schmidt and Leach [28])

Electrical Activity
Electric fields (EFs) resembling those in the developing and regenerating nervous
systems steer growth cones towards the cathode, and recent research is examining the
role of galvanotactic mechanisms in neurite outgrowth and the specific signaling
molecules involved. Growth cone steering by EFs has been shown to require dynamic
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microtubules, microfilaments and regulation of filopodia and lamellipodia by the
GTPases Cdc42 and Rac. [192] In bovine corneal epithelial cells, attenuation of Cdc42
signaling abolished galvanotaxis and enhanced contact guidance whereas attenuation of
Rho signaling enhanced galvanotaxis and Rho stimulation enhanced contact guidance.
[193, 194] These are the same molecules implicated in glial scar and myelin inhibition of
neurite outgrowth, and the negative charge of glycosaminoglycans on sulfated
proteoglycans may contribute to their inhibitory effect on neurite outgrowth. Cationic
biopolymers such as chitosan have demonstrated longer neurite outgrowth than anionic
biopolymers such as alginate. [195-197] Polypyrrole (PPy) is an electrically conducting
polymer that has been shown to support neurite outgrowth through electrical stimulation
of the membrane [198, 199] Poled PLGA tubes implanted into a 1 cm rat sciatic nerve
gap demonstrated increased numbers of regenerated and myelinated axons as compared
to unpoled tubes 4 weeks postlesion. [200]
Mechanical Properties
Mechanical properties are a somewhat overlooked design element for neural
scaffolds, in part because the response of spinal cord tissue to mechanical loading is not
well understood; however, recent studies are focused on characterizing the viscoelastic
behavior of the spinal cord. [201-204] Although scaffolds must be designed to resist
collapse upon implantation, materials that are significantly stiffer than the surrounding
tissue may lead to necrosis and inflammation. [205]
Several groups have reported discrepancies in the values of elastic (Young’s)
modulus of the spinal cord using different measurement methods. The reported modulus
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as measured in dogs and cats is estimated to be between 200-600 kPa; however,
significant increases in modulus were found to occur quickly after death, making accurate
measurement a difficult task. [206] Ozawa et al. reported that the spinal cord gray and
white matter have similar moduli of elasticity as measured by the pipette aspiration
method in rabbits. The axial direction of gray and white matter, respectively, measured
3.4 ± 1.4 kPa and 3.4 ± 0.9 kPa, the frontal section measured 3 ± 0.3 kPa and 3.5 ± 0.5
kPa, and the sagittal section measured 3.5 ± 0.9 kPa and 2.8 ± 0.4 kPa. [207] This same
research group reported that rabbit spinal cord with intact pia mater has an elastic
modulus of 2.3 MPa whereas the spinal cord parenchyma elastic modulus is
approximately 5 kPa. [208]

Bilston and Thibault reported that human spinal cords

averaged 1.4MPa with the pia mater intact and 89 kPa with incised pia mater. [203] It is
interesting to note that the elastic modulus of human tibial nerves has been reported to be
16 MPa, significantly higher than any of the reported values for the spinal cord. [209]
Although no consensus has been reached regarding the appropriate Young’s
modulus for neural scaffolds, reports have demonstrated improved adult rat axonal
regeneration into poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) [pHEMAMMA] channels with elastic moduli of 263 kPa and 311 kPa as compared to 177 kPa.
[210, 211]

Peptide-modified poly(2-hydroxyethyl methacrylate-co-2-aminoethyl

methacrylate) [pHEMA-co-AEMA] with elastic modulus of 192 kPa demonstrated chick
DRG adhesion and neurite outgrowth comparable to PLL/laminin controls. [212]
Growth cone advance is thought to be mediated by forward propulsion as a result
of filopodial contractions [213, 214], and the elastic modulus of scaffolds has been
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demonstrated to impact neurite outgrowth. Hydrogels with increasing concentrations of
PEG-diacrylate from 50 mg/mL to 200 mg/mL exhibited increasing elastic modulus but
little change in ultimate tensile stress. Neurite extension from PC12 cells seeded on these
hydrogels with equal concentrations of RGD peptides decreased as the elastic modulus
increased, indicating that flexible materials with elastic modulus in the range of
approximately 50-200 kPa may be more conducive to neurite outgrowth. [215]
Intraluminal Channels
Entubulation strategies are particularly useful for PNS repair as they mimic the
ensheathed structure of the PNS, and they may hold promise for long-distance
regeneration in the CNS because of the success of peripheral nerve implants for CNS
repair. Degradable, hollow, large diameter conduits were first developed due to the ease
of fabrication, but faced challenges of collapse upon implantation. [15, 216] Large
diameter conduits also do not accurately mimic nerve architecture, and led to the idea of
filling large diameter hollow conduits filled with smaller hollow conduits, not only
reduce the susceptibility of collapse but provide more surface area for cell and growth
cone

attachment.

Implantation

of

poly(2-hydroxyethyl

methacrylate-co-methyl

methacrylate) [pHEMA-MMA] channels with 4.19±0.04 mm outer diameter encasing 4
smaller tubes with 790±45 µm inner diameter into adult rat complete spinal cord
transections at T8 (4 mm gap) improved regeneration of vestibular neurons and showed
consistent improvement in locomotor function at 7 and 8 weeks. [210, 211]
In order to design conduits with appropriately sized channels for neural
regeneration, consideration of cell and nerve fiber diameters must be taken into account.
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Mammalian cells typically range from 10-100 µm in diameter and Table 3.3 shows the
diameters of various mammalian nerves. [217]
MYELINATION?

FIBER TYPE

Myelinated

A-α

Myelinated
Myelinated

A-β
A-γ

Myelinated

A-δ

Myelinated

B - Autonomic

Unmyelinated
Unmyelinated

C - Dorsal root
C - Sympathetic

FUNCTION

DIAMETER
(µm)
Proprioception; somatic 15-20
motor
Touch, pressure
5-12
Motor to muscle
3-6
spindles
Pain, temperature,
2-5
touch
Preganglionic
<3
autonomic
Pain, reflex responses
0.4-1.2
Post ganglionic
0.3-1.3
sympathetics

Table 3.3 Mammalian Nerve Fiber Types [217]

Because of the difficulty in fabricating conduits with small diameter linear
channels [212, 218, 219], an alternative entubulation approach involves filling guidance
channels with filaments to produce small diameter channels to more accurately mimic
nerve fiber diameters. Guidance channels developed for PNS repair with 16 PLLA
microfilaments within each PLA or silicone tube (1.5 mm inner diameter) were filled
with Matrigel, implanted into 14 mm and 18 mm rat sciatic nerve lesions, and at 6 weeks
postlesion, improved Schwann cell migration and regenerated nerves across the gap could
be seen in all animals with microfilament-filled tubes, as compared to reduced efficiency
of nerve formation in tubes without microfilaments. [220] In addition, more axons were
demonstrated to penetrate PLA tubes due to the porosity of PLA as compared to
nonporous silicone tubes, thus highlighting the importance of nutrient and waste transfer
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for neural regeneration. PLA tubes of 1.5 mm diameter filled with PLLA microfilaments
of 60-70 µm diameter administered to 6 mm rat dorsal root lesion along with spinal NGF
virus injection demonstrated recovery of function to almost normal levels at 7-8 weeks
postlesion; cutting the dorsal root through the center of the conduit reversed the recovery,
thus demonstrating regeneration through the conduit was responsible for restoration of
function. [221]
Poly(acrylonitrile-co-vinyl chloride) [PAN/PVC] hollow fiber membranes
(HFMs) with 900 µm inner diameter were filled with polypropylene filaments with
smooth inner surface of supracellular size (500 µm to 100 µm), cellular size (30 µm), and
subcellular size (5 µm) and were seeded with DRG explants for 7 days; neurite outgrowth
on 500 µm filaments was organized into fascicles, and defasciculation and increasingly
uniform linear alignment of Schwann cells and neurites was demonstrated as filament
size decreased to 5 µm, with corresponding improvement in length of the neurites. [222]
HFMs were also developed using PLGA and polyurethane with the incorporation of
aligned grooves on the inner surface of the filaments. [223, 224]
Fibers offer an alternative to filament-filled conduits. Poly(l-lactide) (PLA) and
polyethylene terephthalate (PET) capillary channel fibers (CCFs) containing eight open
grooves with depth of 5-15 µm and width of 10 µm oriented rat skin fibroblast and aortic
smooth muscle cell alignment and deposition of ECM proteins within the grooves parallel
to groove direction; the alignment and fluid wicking capabilities of these fibers make
them a potentially useful scaffold for nerve guidance strategies. [225, 226] In addition,
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the size of the fiber grooves is customizable and the variety of groove sizes on each fiber
may enable regeneration of multiple motor and sensory axons.

BIOMATERIAL SCAFFOLDS FOR CELL TRANSPLANTATION
Many biomaterial approaches have been investigated to improve Schwann cell
survival and limit migration while also improving regeneration. PLGA foam conduits for
peripheral nerve repair were created by a low-pressure injection molding technique
producing aligned channels with diameters ranging from 60-550 µm; conduits coated
with laminin and seeded with Schwann cells were implanted across a rat 7 mm sciatic
nerve gap and demonstrated comparable neurite outgrowth to implanted autografts at 6
weeks postlesion. [227] Although this approach may be useful for peripheral nerve
repair, there is less evidence supporting its use in CNS repair.
Freeze-dried PLA macroporous scaffolds with channel diameters of 75-200 µm
seeded with Schwann cells in fibrin solution were implanted into 4 mm rat transections;
Schwann cells underwent apoptosis by 1 week post-implantation and at 6 weeks,
myelinated axons were found within the graft but none exited into the caudal spinal cord,
probably attributable to the limited survival of the Schwann cells. [17] Xu et al. reported
survival of Schwann cells in 3.0 mm long PAN/PVC guidance channels beyond 30 days
following implantation into adult rat spinal cord with limited migration for short
distances into rostral and caudal host spinal cord; however, limited extension of axons
beyond the distal graft-host interface was observed at 90 days. [16] Porous PLGA
scaffolds were created by injection molding followed by rapid solvent evaporation with
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channel diameters of 450±9 µm and 600±10 µm and were seeded with Schwann cells
suspended in Matrigel; histological analysis of the channels one month after implantation
into rat spinal cord injury revealed a centralized core of axons and capillaries surrounded
by fibrous tissue and macrophages. [228]
Schwann cells are not native to the CNS and lead to unfavorable interactions with
astrocytes leading to increased inhibitory CSPG production and the astroglial response.
[146] Although several groups are studying ex vivo genetic modification of Schwann
cells in order to overcome these challenges, acellular biomaterial-based bridges with
combination therapies offers an alternative approach to avoid the immune complications
and glial scarring response inherent to PNS glial cell transplantation in the CNS while
still delivering the bioactive soluble and adhesive molecules produced by these glial cells.
A major advantage of the acellular approach is the ability to provide controlled
presentation of bioactive stimuli through controlled release, gene therapy, and
recombinant protein immobilization.

ACELLULAR SYNTHETIC BIOMATERIAL BRIDGES
Neurite outgrowth is dependent upon a delicate balance of chemotactic,
haptotactic, and contact guidance cues, and careful consideration of specific
combinations of molecules must be made depending upon which axon tracts are to be
regenerated. [12] Bridges must also be designed to promote axon growth into and
through the scaffold via continued availability of active biomolecules, to be selective for

70

axons while inhibiting attachment of other cells, and to promote axon growth out of the
bridge into the inhibitory host environment. [18]

Bioactive Stimuli for Combination Therapies
During PNS development and following injury, Schwann cells increase their
synthesis of surface cell adhesion molecules (CAMs), such as NCAM, NgCAM, and L1;
they secrete extracellular matrix (ECM) molecules such as collagen, laminin, fibronectin,
and tenascin; and they produce and spatially present neurotrophic factors such as nerve
growth factor (NGF), neurotrophin 3 (NT-3), neurotrophin 4/5 (NT-4/5), brain-derived
neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), glial-cell derived
neurotrophic factor (GDNF), and acidic and basic fibroblast growth factor (aFGF, bFGF).
[26, 28]
Adhesion Molecules
The extracellular matrix (ECM) protein laminin and the L1 neural cell adhesion
molecule (NCAM) are of particular interest for spinal cord regeneration strategies
because of their significant contributions during CNS development.
Laminin
Laminin is a protein that is abundantly expressed by immature astrocytes in the
developing CNS [76] and by Schwann cells in the developing and regenerating PNS [26],
making it an attractive candidate for use in combination therapies.

Deister et al.

demonstrated that laminin concentration had the most impact on neurite extension from
explanted dorsal root ganglia cultured within co-gels made from laminin, fibronectin,
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collagen I, and hyaluronic acid and that the combinatorial effects were additive rather
than synergistic, suggesting that the presence of laminin rather than interactions among
the extracellular matrix components is key for neurite outgrowth. [229]
Laminin is a large 900 kDa protein with at least 15 different types in mammals
and structurally it is an αβγ trimer, with each trimer containing binding sites for
predominantly integrins.

Human diseases caused by genetic mutations in laminin

proteins give some insight into their importance in proper nervous system development
and function. Deficiencies in laminin α2 chains result in abnormal radial sorting of PNS
axons to be myelinated by Schwann cells and abnormal myelin thickness and length,
resulting in congenital muscular dystrophy (MDC) 1A; CNS white matter tracts in
patients with MDC1A also demonstrate abnormal myelination, demonstrating the
importance of laminin to CNS oligodendrocytes. [230] In addition, oligodendrocytes in
knockout mice lacking the laminin integrin receptor α6β1 have reduced survival rates,
and laminin-receptor

signalling selectively enhances the survival

of mature

oligodendrocytes, not oligodendrocyte precursor cells (OPCs); however, Schwann cells
lacking the β1 receptor proliferate and survive normally but fail to sort and myelinate
axons.[230]

Laminin has also been shown to enhance the migration, expansion,

differentiation, and elongation of neurites in both mouse and human neural stem cells as
compared to poly-L-orthinine, fibronectin, and Matrigel through integrin receptors α3,
α6, α7, β1, and β4. [231] Mouse neural stem cells from the ventricular zone express high
levels of laminin integrin receptor α6β1. [232]
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Peptides are short, linear amino acid sequences that are useful for bridging
strategies because of their small size and more specific cell interactions; however, they
may not reproduce the bioactivity of the entire protein. [18]. Although laminin is an ideal
substrate for many different cell types because it is a ubiquitous constituent of basement
membranes, it is this lack of specificity that makes it less than ideal for neural
regeneration strategies, in particular because it does not inhibit astrocyte interactions.
Laminin contains at least two peptide sequences that are not favorable for astrocyte
interactions and bind integrin receptors on neuronal cells: Isoleucine-Lysine-ValineAlanine-Valine (IKVAV), an α1 chain peptide sequence that promotes adhesion and
neurite outgrowth of some neuronal cell types; and Tyrosine-Isoleucine-Glycine-SerineArginine (YIGSR), a β1 chain peptide sequence that promotes neuronal attachment but
does not necessarily promote neurite outgrowth. [233]
Numerous applications of these laminin peptide sequences have been used to
characterize neural cell attachment and neurite outgrowth of cell lines, including
pheochromocytoma cells (PC12) that develop properties of sympathetic neurons in the
presence of nerve growth factor (NGF) and neuroblastoma tumor cells derived from the
sympathetic nervous system, as well as primary chick and rat dorsal root ganglia (DRG)
neurons. IKVAV and YIGSR sequences covalently immobilized to fluorinated ethylene
propylene (FP) films mediated localized PC12 and NG108-15 neuroblastoma cell
attachment and neurite outgrowth to patterned pathways [234, 235]; improved neurite
outgrowth, cell adhesion and viability of rat embryonic day 18 hippocampal neurons
[236]

The neurite outgrowth of chick dorsal root ganglia on expanded
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poly(tetrafluoroethylene) fibers was enhanced with IKVAV and YIGSR peptides and the
optimal fiber diameter for guidance was 30-50 µm. [237]
Gunn and Turner examined PC12 response to PEG-diacrylate hydrogels with
IKVAV and YIGSR peptides and found that neurites extended in response to IKVAVconjugated gels but only attached without neurite extension to YIGSR-conjugated gels.
[215]

Copolymerized 2-hydroxylethyl methacrylate (HEMA) and 2-aminoethyl

methacrylate (AEMA) gels (P(HEMA-co-AEMA) scaffolds) with covalently bound
YIGSR and IKVAV were fabricated in aqueous conditions, thus avoiding organic solvent
use, and demonstrated enhanced neural cell adhesion and guided neurite outgrowth of
chick dorsal root ganglia neurons. [212]
L1 Neural Cell Adhesion Molecule
L1 is a key player in the overall development of both the CNS and PNS and
functions in neuronal adhesion and migration; axon growth, guidance, and fasciculation;
as well as target selection, synapse formation, plasticity, survival, and myelination. [238243] L1 is also expressed by Schwann cells of the peripheral nervous system. [244]
L1 is a 220 kDa vertebrate neural cell adhesion molecule belonging to the L1
subfamily of the immunoglobulin superfamily (IgSF), with members sharing a common
structure of six immunoglobulin (Ig) domains followed by three to five fibronectin type
III (FNIII) repeats. [245] Genetic deletions or mutations of the L1 gene result in severe,
sometimes lethal, neurological deficits in humans and defects in the corticospinal tract
and corpus callosum of L1 knockout mice. [246-249] There is also evidence that injury
induces reexpression of L1, as three months following complete spinal cord transection in
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neonate rats, L1 expression remained substantially increased surrounding the lesion site
and L1 was reexpressed on descending fibers of the corticospinal tract above the lesion.
[250]
Several in vitro and in vivo experiments have demonstrated the value of L1 in
spinal cord regeneration strategies, in both soluble and substrate-bound forms.

Rat

cerebellar neurons on PLL extended longer neurites in response to soluble L1-Fc as
compared to controls, and the response was inhibited by pretreatment of the neurons with
antibodies to L1 or fibroblast growth factor (FGF) receptor. [251] L1 attached to a
nitrocellulose membrane stimulated chick tecta and mouse cerebellum neurite outgrowth
while inhibiting astrocyte, oligodendrocyte and fibroblast attachment. [252] Reduced L1Fc immobilized to polystyrene surfaces through Pluronic-pyridyl disulfide (F108-PDS)
modification supported significantly higher levels of rat dorsal root ganglia, cerebellar,
and hippocampal neurite outgrowth relative to fibronectin and PDL, while inhibiting the
attachment of astrocytes, meningeal cells, and fibroblasts. [253]

Oliva et al.

micropatterned the chimeric protein L1-Fc, consisting of the ectodomain of L1 linked to
the Fc fragment of immunoglobulin G (IgG), onto poly-L-lysine coated glass by
microcontact printing of bacterial protein A, which binds the Fc fragment, and
demonstrated preferential growth of embryonic rat hippocampal axons into the L1-Fc
patterned regions. [254]

Poly(glycolide) (PGA)-chitosan conduits coated with

recombinant L1-Fc implanted into adult rats following optic nerve transection exhibited
higher numbers of regenerated fibers and a significant increase in myelination of the
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regenerated fibers as compared to PGA-chitosan conduits alone. [255] These studies
suggest the usefulness of L1 in both controlled release and immobilized strategies.
Neurotrophic Factors
Neurotrophic factors are key nervous system regulatory proteins that modulate
neuronal survival, axonal growth, synaptic plasticity, and neurotransmission. They have
also been shown to promote and direct growth cone motility [112]; they exhibit a
chemotactic effect for axon guidance, and they aid in sensory nerve growth across the
PNS-CNS transition zone. As a result, their role in axon development and regeneration is
being studied extensively for application in spinal cord repair [28, 94, 113-115].
Diffusion and Controlled Release from Biomaterials
Porous PLG single and multiple lumen conduits were created utilizing porogen
(NaCl) and a gas foaming technique, and NGF was incorporated either by mixing with
PLG microspheres prior to gas foaming or by encapsulating into the microspheres;
sustained release of NGF from the scaffolds was demonstrated for 42 days and could be
controlled by the method of incorporation and polymer molecular weight. [256]
The network crosslinking density of photopolymerized acrylated PLA-b-PEG-bPLA hydrogels was utilized to control release rates of CNTF, BDNF, and NT-3 with total
release times reported as ranging from weeks to several months, and simultaneous
delivery of multiple neurotrophins was developed by mixing microspheres of NT-3
encapsulated in poly(lactide-co-glycolide) using a double emulsion technique into the
hydrogel solution containing CNTF and photopolymerizing to produce constructs
containing NT-3 in the microsphere phase and CNTF in the hydrogel phase; the release
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profiles show very rapid release of the neurotrophin in the hydrogel phase and a slow
continuous release from the degradable microspheres. [257]
Controlled release of BSA from photopolymerized PEG hydrogels has been
demonstrated using the metal chelating ligand iminodiacetic acid (IDA) to reversibly
bind BSA in the presence of Cu2+ ions as well as protect the protein from free radicals
produced during photopolymerization [258, 259]; these methods may be useful for
application in controlled release of polyhistidine-tagged neurotrophic factors.
Immobilization to Biomaterials
MacInnis and Campenot [260] reported that a neuronal survival signal can reach
the cell bodies unaccompanied by the NGF that initiated it. The discovery that growth
factors do not have to be internalized by the cell body in order to promote survival
opened the door for research into immobilized growth factors. Neurotrophins have a very
short half-life and immobilization is one method to provide a high concentration of longterm, localized growth factor delivery to an injury site by preventing degradation,
clearance, or internalization of the neurotrophins.
Kapur and Shoichet [261] immobilized NGF concentration gradients within
poly(2-hydroxyethyl-methacrylate) [pHEMA] microporous gels using a modified,
commercially-available gradient maker (CBS Scientific, Temecula CA). PHEMA was
chosen because its material properties are good for soft tissue engineering, it has been
used clinically, and NGF has been stably encapsulated in it for other applications; it was
also modified with poly(allyamine) [pAA] to make it cell adhesive. In this research,
gradient

stability,

immobilized

NGF

bioactivity,
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and

axon

extension

of

pheochromocytoma (PC12) cells to the immobilized NGF gradients were tested. Their
results showed that PC12 cells adhere to the pHEMA-NGF-pAA gels, and respond to
immobilized NGF by extending neurites in a manner similar to previous research with
soluble NGF. [262, 263] It was observed that PC12 neurites were thicker when cultured
on immobilized NGF than when cultured in the presence of soluble NGF.

Review of Combination Therapies
It is likely that combinations of therapies with synergistic effects will be required
for long-distance regeneration of axons. Review of combination strategies that have been
tested gives some insight into the responses that may be expected from different
combinations of growth-promoting stimuli.

Combinations of neural cell adhesion

molecules L1 and neurofascin and growth and differentiation-5 factor (GDF-5)
demonstrated synergistic effects on neurite outgrowth of embryonic chick dorsal root
ganglia (DRG) neurons. [264] Chick embryonic DRG cultured in anisotropic threedimensional (3D) agarose scaffolds with photoimmobilized gradients of laminin
exhibited maximal neurite extension as compared to isotropic scaffolds with uniform
distribution of laminin [265]; these anisotropic agarose scaffolds with gradients of
laminin and nerve growth factor (NGF) exhibited comparable regeneration to peripheral
nerve grafts across a 20 mm sciatic nerve gap in rats. [266]. Semipermeable polysulfone
tubes with laminin and nerve growth factor (NGF) demonstrated comparable
regeneration, myelination, and functional recovery as compared to autologous peripheral
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nerve grafts two months after implantation into a 10 mm sciatic nerve gap in adult rats.
[267]

CONCLUSION

A synergistic combination of pharmaceutical interventions and therapeutic
approaches to spinal cord injury will likely be required to overcome the multitude of
factors contributing to CNS regenerative failure and to ultimately achieve functional
regeneration. This research is focused on the development of acellular synthethic
biomaterial-based bridges because of the flexibility in design and fabrication of scaffold
properties coupled with the ability to use different combinations of bioactive adhesive
and soluble stimuli suitable for regeneration of a wide variety of neural populations.
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CHAPTER FOUR
PROJECT RATIONALE

INTRODUCTION
The human spinal cord is approximately 45 cm long (1.5 ft) with 30 levels, and
each spinal level is around 1-2 cm. [14] The most common injury level for a tetraplegic
is C5, thus requiring regeneration over 25 levels, or approximately 25-50 cm, for
complete restoration of white matter axon tracts. The most common injury level for a
paraplegic is T12, requiring regeneration over 10 levels, or approximately 10-20 cm. In
1981, David and Aguayo reported axonal elongation of 3 cm into autologous peripheral
nerve “bridges” between the medulla and spinal cord in adult rats. [268] The maximum
length to date of CNS regeneration demonstrated in animal models is around 4 cm, with
most studies demonstrating only 1-2 cm of regrowth. [154, 269] This fact emphasizes the
need for better combinations of therapies with synergistic effects for long-distance
regeneration of axons.

RATIONALE FOR BIOACTIVE BIOMATERIAL-BASED APPROACH
The long-term objective of this project is a biomimetic, multi-factorial approach
utilizing grooved fibers to restore structure and provide guidance for regenerating axons
coupled with bioactive adhesive molecule delivery via immobilization to a hydrogel
within the fiber grooves and controlled release of neurotrophic factors from the hydrogel
(Figure 4.1).
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Figure 4.1 Proposed Implant Design

A major obstacle of all implant-based bridging techniques is the invasive nature
of implantation and stimulation of the astroglial response; however, a unique advantage
of this proposed fiber implant is the possibility to reroute regenerating axons around an
existing glial scar through the use of specialized surgical techniques that are currently
being used for peripheral nerve grafts [270, 271], and perhaps incorporation of a
complementary strategy to modify the inhibitory environment, using ChondroitinaseABC or Rho antagonist, or to modify growth cone signaling pathways, will minimize the
resultant astroglial response from implantation. [272, 273]
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Synthetic degradable materials are potentially ideal for neural regeneration
strategies, because tunable biodegradation enables the design of an implant that will
support axonal regeneration through and out of the graft but degrade prior to axon
remyelination to avoid compression of newly regenerated nerves.
Fibers are potentially ideal scaffolds to provide guidance for long-distance
regeneration of axons, and the proposed PLA capillary channel fibers (CCFs) contain
eight open grooves of adjustable depths and widths and have demonstrated orientation of
rat skin fibroblast and aortic smooth muscle cell alignment and deposition of ECM
proteins within the grooves parallel to the groove direction. [225, 226]
Bioactivity will be incorporated by delivery of adhesion ligands and neurotrophic
factors from a hydrogel coating within the fiber grooves, to mimic the bioactivity that
peripheral nerve implants have demonstrated in CNS regeneration. L1 is a particularly
attractive candidate for neural regeneration because it is critical for proper nervous
system development; genetic deletions or mutations of the L1 gene result in severe,
sometimes lethal, neurological deficits in humans, including hypoplasia of the
corticospinal tract [248, 249], and injury induces reexpression of L1 in the corticospinal
tract. [250] Recombinant human L1 has been shown to be a potent promoter of neurite
outgrowth in both soluble and substrate-bound forms, to support selective neuronal
adhesion in the presence of astrocytes when coupled to low-protein binding supports, and
to function as a neuronal survival factor. [239, 253] The selectivity of neuronal adhesion
to L1 in the presence of astrocytes is particulary important, as astrocytes are the key
players in nervous system inflammation and mediate the glial scar response. All six
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immunoglobulin domains of L1 have been shown to be required for full bioactivity [274];
therefore, based on the increased number and distribution of bioactive regions in L1,
selection of an appropriate immobilization chemistry is likely to be critical for full
retention of bioactivity.
Neurotrophic factors have a very short half-life, are digested in the
gastrointestinal tract, do not pass the blood-brain barrier, and are rapidly cleared from
cerebrospinal fluid (CSF); as a result, oral, systemic, or intrathecal delivery will not
promote regeneration of CNS neurons and may result in hyperalgesia or other unwanted
side effects due to nonspecific delivery. [117] Controlled release of neurotrophins from
the proposed implant has the potential to provide biologically relevant amounts of longterm, localized growth factors at the site of injury while avoiding unwanted side effects.
NT-3 is an attractive candidate for regeneration of corticospinal tract neurons, a major
motor axon tract with limited intrinsic regenerative potential. [77, 118]

RATIONALE FOR HYDROGEL FABRICATION AND PROTEIN
IMMOBILIZATION APPROACHES
Tetronic® 904 (T904, BASF) is a tetrafunctional poly(ethylene oxide) –
poly(propylene oxide), PEO/PPO, block copolymer that is a nonionic surfactant
terminating in primary hydroxyl groups.

Selected Pluronics® and Tetronics® are

commonly used in contact lens cleaning solutions and mouthwash, and are unique
surfactants that are resistant to protein adsorption, have low cytotoxicity, and elicit a
reduced immune response.

Modified Pluronic® surfactants have been utilized to

immobilize histidine-tagged proteins [275], and fibronectin and L1-Fc. [253, 276]
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Tetronics® (poloxamines) were chosen over linear Pluronics® (poloxamers) because their
four-arm, or star-shaped, structure contains more and shorter side chains as compared to
linear block copolymers with similar molecular weight, thus allowing for increased
functionality and higher degree of crosslinking with lower polymer concentrations, with
single hydrolytically degradable ester bonds at each end. [277] In addition, control over
swelling and protein release has been demonstrated with multi-arm PEG acrylates. [278]
Michael addition polymerization using acrylated polymers is an established
method of hydrogel fabrication in the absence of ultraviolet (UV) light [278-280] and
may also be used in protein immobilization strategies. [281-287] A long-term goal of
this project is to polymerize T904-acrylate hydrogels within the capillary channel fiber
grooves, and Michael addition polymerization may enable more uniform and complete
polymerization within the grooves than is attainable with photopolymerization. The fiber
grooves also exhibit capillary-like properties that may be used for uptake of hydrogel
solutions. Another long-term goal of this project is controlled release of neurotrophins
from the hydrogels, and Michael addition polymerization avoids potential damage to the
protein structure from excessive heat that may occur with photopolymerization.

ADVANTAGES OF PROPOSED IMPLANT DESIGN
Biomaterial-based approaches to spinal cord repair are missing from clinical trials
in large part because of the limited approval of devices incorporating biomaterials by the
U.S. Food and Drug Administration (FDA). Approval of a device with novel materials is
costly and requires additional documentation associated with manufacture, quality
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control, durability and safety; however, PLA has been FDA-approved and is being
studied for neural applications, and Pluronics® and Tetronics® are under investigation for
drug delivery applications. [216, 288-290] Entubulation strategies face challenges of
channel collapse and obstruction of nerve regeneration, and the difficulty in fabricating
conduits with small diameter linear channels [212, 218, 219] led to an alternative
entubulation approach of filling guidance channels with filaments to produce small
diameter channels. The proposed fiber implant does not require entubulation, and the
open channel design allows for unlimited transport of nutrients and waste.
The hydrophobicity of PLA not only negatively impacts cell adhesion to the
surface, but also favors protein adsorption that is detrimental to efforts to incorporate
bioactivity

into

biomaterials

through

covalent

protein

immobilization.

PLA

hydrophilicity has been improved through methods such as copolymerization with PEG,
which required solvents and high temperatures not suitable for encapsulation of proteins;
surface chemical modification via alkali treatment, which increased PLA bulk
degradation rate; and plasma treatment, which demonstrated instability of the surface
layer. [291] Otsuka et al. demonstrated surface functionalization of PLA via spin coating
of acetal-PEG/PLA block copolymers in toluene. [292] Surface coating of PLA with
T904-acrylate takes advantage of the hydrophobic interaction of the Tetronic PPO blocks
and PLA to enable a functionalized hydrophilic PEG surface that more closely mimics
the viscoelastic properties of neural tissue. The simplicity in manufacturing grooved
PLA fibers via a melt-spin process (US Patent 1990, 4,954,398), coupled with capillary
uptake of a hydrogel coating crosslinked in the absence of solvents and ultraviolet light
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via Michael addition, make this a novel approach for application in neural regeneration
strategies. In addition, the implant design lends itself to lyophilization, making it suitable
for long-term storage. The ability to customize scaffold properties and incorporate
different combinations of adhesive stimuli and growth factors, and the simplicity in
manufacturing and long-term storage ability, maximizes the potential of this approach to
provide readily available, “off-the-shelf” implants for patients with any type of nerve
injury.

RESEARCH OBJECTIVES
Because neurotrophic factors are not sufficient for growth cone or cell adhesion to
a biologically inert material, this research focused on covalent immobilization of the cell
adhesion molecule L1 to acrylated Tetronic® hydrogels for neurite outgrowth with future
plans of neurotrophic factor incorporation to further enhance survival and regeneration
rates. The objectives of this research were: (1) cloning and expression of a bioactive
140kDa fragment of L1 neural cell adhesion molecule, chosen for its critical role in
proper nervous system development and because it has demonstrated selectivity of
neuron adhesion in the presence of astrocytes, which play a major role in nervous system
inflammation, (2) synthesis and purification of acrylated Tetronic macromers and the
development of Michael addition methods for hydrogel crosslinking and protein
immobilization, (3) evaluation of hydrogel cytocompatibility, immobilized protein
bioactivity, and immobilization efficiency in terms of cell spreading and proliferation
using NIH 3T3 fibroblasts and fibronectin because of the well-known RGD-dependent
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interaction, to demonstrate the feasibility of this system for neural repair, and (4)
assessment of neuronal cell line and primary neuron response to L1, evaluation of the
cytocompatibility of T904-acrylate hydrogels with neural cells, and development of
immobilization methods for L1.
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CHAPTER FIVE
CLONING AND EXPRESSION OF RECOMBINANT L1

INTRODUCTION
L1 is a vertebrate neural cell adhesion molecule belonging to the L1 subfamily of
the immunoglobulin superfamily (IgSF), with members sharing a common structure of
six immunoglobulin (Ig) domains followed by three to five fibronectin type III (FNIII)
repeats. [245]

The L1 subfamily is also comprised of the vertebrate members

neurofascin, NrCAM and CHL1 and the invertebrate members neuroglian and tractin.
[293] L1 is a transmembrane glycoprotein consisting of six Ig domains, five FNIII
repeats, a transmembrane region, and a highly conserved cytoplasmic domain. [241, 294,
295]

Unglycosylated L1 has a molecular weight of 140-150 kDa, with 21 N-

glycosylation sites on the extracellular portion of the protein, resulting in a 200-220 kDa
protein depending upon how many residues are glycosylated. [296] L1 also contains two
proteolytic cleavage sites: plasmin-mediated cleavage in the third fibronectin repeat
resulting in an approximate 140 kDa soluble form of L1, and ectodomain cleavage via the
metalloprotease ADAM10 resulting in an approximate 200 kDa soluble form of L1. [297300] Figure 5.1 depicts the structure of the L1 protein. [241]
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Figure 5.1 Structure of L1
(Reprinted from Haspel and Grumet 2003[241])

L1 is primarily expressed on the surface of neurons and is concentrated in growth
cones and axons during development. L1 functions in neuronal adhesion and migration;
axon growth, guidance, and fasciculation; as well as target selection, synapse formation,
plasticity, survival, and myelination. [238-241] It is also expressed by Schwann cells of
the peripheral nervous system, a subclass of leukocytes, intestinal crypt cells, and kidney
tubule epithelia [244]; however, L1 expressed by neurons and glia includes an
alternatively spliced YEGHH sequence at the N-terminus encoded by exon 2. [301] The
140 and 200 kDa L1 cleavage fragments have been detected in developing rat brain,
cerebrospinal fluid (CSF), and the extracellular matrix. [302-304] L1 is capable of
interacting with multiple extracellular and intracellular binding partners.

The

extracellular region may exhibit homophilic binding with L1 on the surface of other cells
or soluble L1 or heterophilic binding with other neural cell adhesion molecules, integrins,
extracellular matrix constituents (laminin, phosphacan, neurocan), or signaling receptors.
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[241, 305] The cytoplasmic region interacts with the actin cytoskeleton via an ankyrin
linkage. [306] Homophilic interaction of L1 is closely linked to its ability to induce
neurites in culture [305] and the cytoplasmic domain is not required for homophilic
adhesion. [307]
Genetic deletions or mutations of the L1 gene result in severe, sometimes lethal,
neurological deficits in humans, including X-linked hydrocephalus, mental retardation,
aphasia, shuffling gait, adducted thumbs (MASA) syndrome, spastic paraplegia type I,
and X-linked mental retardation. [246, 247] L1 mutant mice exhibit defects in the
corticospinal tract and corpus callosum. [248, 249]

L1 is a key player in the overall

development of both the central and peripheral nervous systems, making it an attractive
candidate for promoting neural regeneration.

L1 expressed ectopically by mouse

astrocytes was shown to enhance neurite outgrowth on both astrocyte monolayer cultures
and on optic nerve cryosections derived from the transgenic mice; this increase in
outgrowth was inhibited by polyclonal L1 antibodies. [308] Purified full-length and
recombinant L1 containing the entire extracellular region have been shown to stimulate
neurite outgrowth in both soluble and substrate-bound forms. [252, 309]

Neurites

induced by L1 in vitro were 2-3 times longer than those cultured on poly(ethyleneimine),
although stronger neurite-promoting activity was shown on laminin. [309]. However,
substrate-bound L1 has been shown to selectively support the adhesion of CNS-derived
neurons in the presence of astrocytes, meningeal cells, and fibroblasts. [253] Significant
axonal regeneration was observed in a hemisection lesion of rat spinal cord two weeks
following transplantation of fibroblasts genetically modified to produce L1. [310]
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Soluble L1-Fc administered intrathecally to rat spinal cords following contusion injury
promoted locomoter recovery. [311]
Production of recombinant L1 has been described in both mammalian and
bacterial systems, although bioactive, bacterially-derived L1 is not glycosylated, and
there has been debate regarding its mechanism of action. Studies using bacteriallyderived L1 have shown that the Ig2 domain is necessary and sufficient for homophilic
binding. [312]

Studies of mammalian-derived L1 have shown that Ig domains 1-6

reproduce the full biological activity of the entire L1 extracellular region, while Ig
domains 1-4 are the minimum regions necessary for homophilic binding. [274] Haspel
and Grumet theorized that these differences may be the result of non-authentic
homophilic interactions that can be generated in isolated Ig domains as a result of
nonnative folding pathways in bacterial systems. [241] Insect-cell expression systems
offer several potential advantages for the production of recombinant neural cell adhesion
molecules, including generally higher yield relative to mammalian systems and improved
posttranslational modification and glycosylation relative to bacterial systems. A recent
study described stable expression of the complete L1 extracellular domain and an Ig5-6
fragment in Sf9 cells and demonstrated the neurite outgrowth promoting bioactivity of
both proteins using NT2N neurons derived from the NT2 human embryonic carcinoma
cell line. [313] The objective of this study was to express the L1 140 KDa physiological
cleavage fragment in the baculovirus expression system and to evaluate its neurite
outgrowth-promoting bioactivity relative to commercially available mammalian-derived
L1-Fc in primary cultures of central nervous system neurons. A C-terminal 6X histidine
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tag was incorporated for purification and as a basis for oriented immobilization to
biomaterial surfaces for neural regeneration applications.

MATERIALS AND METHODS
Figure 5.2 is a brief summary of the materials and methods used to produce and
evaluate the bioactivity of insect-cell derived L1.

PCR cloning
140kDa L1 fragment

Transform PCR
product into E.Coli
and purify plasmids

Verify plasmid
size, orientation,
and sequence

Generate
recombinant
baculovirus/
C-term 6x His

Amplify virus in
SF9 insect cells/
end point
dilution assay

Localization of
recombinant protein/
kinetics of soluble
expression

Large-scale
infection of High
Five cells

Purification/
Quantification

Bioactivity
White leghorn chicken
E8 forebrain neurons

Figure 5.2 Materials and Methods Flowchart

Insect Cell Culture
Sf9 cells (Spodoptera frugiperda) were purchased from Invitrogen and routinely
maintained at 27°C in Sf-900 II Serum-Free Medium (Gibco) supplemented with 25
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I.U./mL penicillin and 25 µg/mL streptomycin of penicillin-streptomycin (Mediatech).
High Five™ cells (Trichopulsia ni) were a gift from Dr. Mark Kindy (MUSC,
Charleston, SC) and were routinely maintained at 27°C in Express Five® Serum-Free
Medium (Gibco) supplemented with 25 I.U./mL penicillin and 25 µg/mL streptomycin
(Mediatech) and 90 µL/mL of 200 mM L-glutamine (Hyclone).

PCR Cloning of the L1 Extracellular Fragment
Freeze-dried E.coli containing a plasmid encoding the full-length human L1 open
reading frame (ORF) was purchased from ATCC (Clone #65996). The bacteria were
thawed and grown overnight in 15 mL tubes at 37°C. Plasmids were purified using the
QIAprep® Spin Miniprep Kit (Qiagen). Gene-specific forward (5’-ATG GTC GTG GCG
CTG CGG TAC GTG T-3’) and reverse (5’-CTT CCT CTG ACT GCC CTC CCT CCA3’) primers were used to amplify an approximately 2500 bp sequence encoding the L1
140 kDa plasmin cleavage fragment by polymerase chain reaction (PCR) using Platinum
Taq DNA Polymerase High Fidelity (Invitrogen). PCR was performed for 30 cycles
(denaturation: 30 seconds, 94ºC; annealing: 25 seconds, 64 ºC; extension: 160 seconds,
68 ºC) with a final 20 minute hold at 68 ºC. The formation of a single product of
expected size was confirmed by agarose gel electrophoresis.

Preparation of Entry Clone
The PCR product was ligated by T/A cloning into the pCR®8/GW/TOPO®
(Invitrogen) Gateway Entry vector containing a spectinomycin resistance gene and
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transformed into One Shot® chemically competent E.coli (Invitrogen). The bacteria were
plated on LB-spectinomycin (100 µg/mL) agar plates and grown overnight at 37°C.
Individual colonies were selected and expanded and plasmids were purified. A clone
with appropriate orientation and sequence was identified by DNA sequencing using an
ABI 3730 sequencer (DNA laboratory, Arizona State University). The clone sequence
was identical to human L1CAM (GenBank accession no. NM_000425) with the
exception of a single non-coding base difference at position 855.

Construction of Recombinant Baculovirus
Recombinant baculovirus was generated by an enzyme-catalyzed recombination
reaction between the entry vector and BaculoDirect™ C-Term Linear DNA (Invitrogen)
containing a C-terminal 6xHis fusion tag and herpes simplex virus thymidine kinase and
and lacZ genes for negative selection and analysis of viral purity, respectively.

A

mixture of 100 ng of the pCR®8/GW/TOPO® entry clone, 300 ng of BaculoDirect™
Linear DNA, 4 µL of 5X LR Clonase™ Reaction Buffer, 1 µL of TE Buffer pH 8.0, and
4 µL LR Clonase™ enzyme mix was incubated at 25ºC overnight. After overnight
incubation, 2 µL of Proteinase K solution was added to the mixture and incubated at 37ºC
for 10 minutes.

Transfection and Amplification of Recombinant Baculovirus
Sf9 cells were plated in 6-well plates (8.0 x105 cells/well) and allowed to adhere
for one hour at 27ºC. A transfection mixture consisting of 5 µL of the baculovirus
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recombination reaction, 200 µL of Grace’s Insect Medium, Unsupplemented (Gibco), and
6 µL of Cellfectin® Reagent (Invitrogen) was prepared, mixed, and incubated at room
temperature for 45 minutes. The cells were washed with Unsupplemented Grace’s Insect
Medium, and the transfection mixture was diluted with 800 µL additional medium and
added dropwise. After 5 hours incubation at 27ºC, the transfection mixture was removed
and replaced with Sf-900 II Serum-Free Medium (Gibco) supplemented with antibiotics
and 100 µM ganciclovir. The cells were monitored daily, and the P1 viral stock was
collected when late stage infection characteristics were observed (8 days).
P2 viral stock was generated by infecting 8.0 x105 Sf9 cells/well with 10 µL of P1
viral stock and was collected on day 5.

The infected cells were stained for β-

galactosidase expression using the β-Galactosidase Enzyme Assay System with Reporter
Lysis Buffer (Promega) to confirm the absence of non-recombinant virus. P3 viral stock
was generated by infecting 1.0 x 107 cells/flask in T-75 flasks with 25 µL of the P2 viral
stock and was collected after 96 hours. End-point dilution assay was used to determine
viral titer (multiplicity of infection, MOI) of the P3 viral stock, as previously described.
[314]

Localization of Recombinant L1 Expression in Insect Cells
Sf9 and High Five™ cells were plated in 6-well plates (1.5 x106 cells/well) and
infected with 11 µL of P3 recombinant baculovirus stock (MOI 0.2). The supernatants
were harvested at 48 hours and 72 hours postinfection, complete EDTA-free protease
inhibitor added (CPI, Roche, 2.5 µL 7X CPI stock solution per mL supernatant),

95

centrifuged (3000 x g for 5 mins) to remove cell debris, and immediately frozen at -80
°C.

Cells were lysed with RIPA buffer containing CPI at 48 hours and 72 hours

postinfection, the lysates centrifuged (3000 x g for 10 mins) to remove cell debris, and
immediately frozen at -80 °C. For gel electrophoresis, total protein concentrations of
supernatant and lysate samples were determined by BCA assay (Pierce) using BSA
standards and sample volumes were adjusted to achieve final protein loading amounts of
30 µg/well supernatant and 3 µg/lane lysate.

Kinetics and MOI Analysis of Recombinant L1
Expression in High Five Cells
High Five™ cells were plated in T-175 flasks (2.73 x107 cells/flask) and infected
with P3 recombinant baculovirus stock at varying MOI (.002, .02, .2, 2). The supernatant
was harvested at 48 hours, 72 hours, and 96 hours postinfection, CPI added, cell debris
pelleted (3000 x g for 5 mins), and samples collected for Western Blot analysis (9 µL
supernatant + 3 µL 4X reducing buffer) and immediately frozen at -80°C.

SDS-PAGE and Western Blot Analysis
Protein samples were separated by SDS-PAGE on 6% polyacrylamide gels
using Tris-glycine buffer under reducing conditions at 100V for 150 minutes. Proteins
were then transferred to PVDF membranes at 4°C overnight at 30V. Western blotting
was performed using the WesternBreeze® Chromogenic Kit (Invitrogen). Membranes
were blocked, incubated with polyclonal goat anti-human L1 primary antibody (R&D
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Systems, 1:200 dilution), incubated with rabbit anti-goat IgG alkaline-phosphatase
conjugated secondary antibody (Molecular Probes, 1:10,000 dilution), and developed
with chromogenic substrate. Western Blots were imaged and analyzed using a GS-700
densitometer and QuantityOne® software (Bio-Rad).

Expression of Recombinant L1 in High Five™ Cells
High Five™ cells were plated in T-175 flasks (2.5 x107 cells/flask) and infected
with recombinant baculovirus at an MOI of 0.2. The supernatant was harvested 72 hours
postinfection, CPI added, cell debris pelleted (3000 x g for 5 mins), and supernatant
immediately frozen at -80°C.

Protein Purification
The supernatant of infected cells was thawed and dialyzed against 50 mM
Na2HPO4, 300 mM NaCl buffer, pH 8.0, for 48 hours with one buffer exchange using
regenerated cellulose dialysis tubing with a molecular weight cut-off (MWCO) of 6-8
kDa (Fisher). CPI was added immediately prior to dialysis and at the buffer exchange.
The dialyzed supernatant was adjusted to 500 mM NaCl, 5 mM imidazole prior to
binding.

Pre-equilibrated 50% Ni-NTA agarose slurry (Qiagen) was added to the

dialyzed supernatant (450 µL equilibrated slurry / 4 flasks), mixed overnight on a shaker
plate at 4°C, and transferred to a PolyPrep chromatography column (BioRad). Beads
were washed with 4 mL each of 50 mM Na2HPO4, 500 mM NaCl, pH 8.0 buffer with
increasing imidazole concentrations (0mM, 5mM, 10mM). Bound proteins were then
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eluted in three 600 µL fractions using a 50 mM Na2HPO4, 500 mM NaCl, 250 mM
imidazole, pH 8.0 buffer. The three elutions were combined and a buffer exchange to
phosphate buffered saline (PBS) was performed using Zeba desalt columns (Pierce)
according to manufacturer’s instructions.

The purified protein was sterile-filtered

through a 0.2 µm syringe filter and stored at 4°C. Samples of the supernatant, wash
buffer flow through, and eluted protein were normalized to the original supernatant
volume and separated by SDS-PAGE. Gels were silver stained (SilverSNAP® Stain Kit
II, Pierce) and imaged using a Kodak Electrophoresis Documentation and Analysis
System 120. The yield of purified recombinant L1 was determined by BCA assay
(Pierce) using BSA standards.

Bioactivity Assay
Sterile recombinant insect cell-derived L1 and commercial mammalian-derived
L1-Fc (R&D Systems) were adsorbed onto 96-well ethylene-oxide sterilized polystyrene
plates in 2 µL dots at 25 µg/mL concentration for 1 hour. Control wells were coated with
50 µL of 0.1% poly-l-lysine (PLL) for 1 hour (n=4 wells / group). White leghorn chicken
embryonic day 8 forebrain neurons were isolated as previously described [315] and
cultured on the adsorbed L1, L1-Fc, and PLL at a density of 30,000 cells/well in Basal
Medium Eagle (BME, Gibco) supplemented with 6 mg/mL glucose (Sigma), 1%
antibiotic/antimycotic 100X stock solution (Gibco), 10% fetal bovine serum (FBS,
Invitrogen), and 2 mM L-glutamine (Hyclone) for 24 hours. Cells were then fixed for 1
hour in 4% paraformaldehyde and stained for actin microfilaments using Alexa Fluor®
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594 phalloidin (Molecular Probes, 0.161 µM) and nuclei using DAPI (Molecular Probes,
3 µM). Neurite outgrowth was quantitatively measured from digital fluorescent images
using ImagePro software (n=60 neurites / experimental group, comprised of an average
of 15 measurements from each of 4 independent wells). Neurite outgrowth data were
statistically analyzed by ANOVA using Tukey’s method for post-hoc comparisons with
p<0.05 considered statistically significant.

RESULTS AND DISCUSSION
Efficient expression and purification of bioactive, recombinant L1 is critical for
its further investigation and development as a therapeutic molecule for stimulating axonal
regeneration following brain and spinal cord injury.

Native human L1 contains 6

disulfide bridges in the Ig domains and extensive glycosylation, which accounts for
approximately 25% of molecular mass. Baculovirus-mediated insect cell expression
offers several potential advantages for recombinant L1 expression, including improved
posttranslational processing relative to prokaryotic systems and relatively higher yields as
compared to mammalian systems. [316]

Physiologically, L1 is expressed as a

transmembrane protein that can be proteolytically cleaved to generate two soluble
extracellular fragments. The objective of this study was the cloning and baculovirus
expression of the 140 kDa extracellular plasmin cleavage product and the evaluation of
its bioactivity relative to mammalian-derived L1-Fc containing the entire extracellular
region. L1 was expressed with a C-terminal 6X histidine tag for ease of purification and
as a basis for oriented immobilization to biomaterial surfaces.
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Localization of Recombinant L1 Expression in Insect Cells
L1 contains a 19 amino acid N-terminal signal sequence that targets it for
membrane insertion. We hypothesized that a truncated extracellular fragment lacking the
transmembrane region would be secreted as a soluble protein. To investigate protein
expression and localization, small-scale cultures of Sf9 and High 5 cells were infected
with recombinant baculovirus at MOI of 0.2. Western blot analysis using an antibody to
human L1 detected immunologically reactive protein in both cell lysates and supernatants
derived from both cell lines (Figure 5.3). In both Sf9 and High 5 supernatants, L1 was
detected as a distinct single band of approximately 140 kDa (Figure 5.3A), corresponding
to the approximate molecular weight of the native human plasmin cleavage fragment.
Densitometry analysis of L1 demonstrated an approximate 1.5-2.0 -fold increase in
secreted L1 expression in High Five cells relative to Sf9 cells (Figure 5.3B). These
results are consistent with previous observations of increased secreted protein expression
in High Five cells relative to Sf9 and Sf21 cells, although the level of increase was less
than previously reported. [317, 318] Intracellular protein exhibited a broader distribution
of molecular weight with a distinct band around 110 kDa and a broad band between 135150 kDa (Figure 5.3C).

These bands observed in the intracellular protein likely

correspond to unglycosylated protein immediately following translation (110 kDa) and
protein at varying stages of glycosylation (135-150 kDa).

Densitometry analysis

indicated that intracellular L1 expression was substantially higher in High Five cells at 48
hours, but relatively similar at 72 hours (Figure 5.3D).
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Figure 5.3 Western blot and densitometry analysis of recombinant L1 localization
in Sf9 and High Five cells using anti-human L1 polyclonal antibody. Gels were
loaded with equal quantities of total protein (supernatants: 30 µg/lane; lysates: 3
µg/lane). Blots are representative of 3 independent experiments. (A) Representative
western blot of Sf9 and High Five media supernatants. Lane 1, molecular weight
marker; lane 2, 48 hr Sf9 supernatant; lane 3, 48 hr High Five supernatant; lane 4,
72 hr Sf9 supernatant; lane 5, 72 hr High Five supernatant. (B) Comparison of
mean relative density of bands of secreted L1. (C) Representative western blot of Sf9
and High Five cell lysates. Lane 1, molecular weight marker; lane 2, 48 hr Sf9
lysate; lane 3, 48 hr High Five lysate; lane 4, 72 hr Sf9 lysate; lane 5, 72 hr High Five
lysate. (D) Comparison of mean relative density of bands of intracellular L1.
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Kinetics and MOI Analysis of Recombinant L1
Expression in High Five Cells
Following confirmation of L1 expression in insect cells, we investigated
optimization of secreted recombinant protein production. High Five cells cultured in T175 flasks were infected at varying MOI, and the supernatants were sampled and
analyzed by Western blotting at varying timepoints postinfection (Figure 5.4A). Secreted
protein expression generally increased with increasing MOI and time postinfection, with
the exception of 96-hour samples at 2.0 MOI, in which expression decreased relative to
the 72-hour time point (Figure 5.4B).

Although gel loading was based on equal

supernatant volumes to normalize expression levels to initial cell number, total protein
analysis demonstrated that all supernatants contained approximately comparable protein
levels (30.7 +/- 2.5 µg/sample). Infections at 2.0 MOI resulted in the highest levels of
protein production, however, light staining of lower molecular weight bands was
consistently observed at all time points, as well as at the 96 hour time point for 0.2 MOI
infection. These observations may be attributable to the high density of darkly colored
cells observed at 2.0 MOI and the 0.2 MOI 96 hour time point which may be indicative
of cell necrosis resulting in the release of intracellular L1 prior to completion of posttranslational modification and/or release of proteolytic enzymes.

On the basis of

providing maximum expression in the absence of lower molecular weight bands, 0.2 MOI
with harvest at 72 hours was selected for use in large-scale expression and purification.
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Figure 5.4 Western blot and densitometry analysis of the kinetics of secreted
recombinant L1 expression from baculovirus-infected High Five cells using antihuman L1 polyclonal antibody. Gels were loaded with equal total volumes in order
to normalize protein to initial cell density. Blot is representative of 3 independent
experiments. (A) Representative western blot of secreted L1 at varying infection
conditions. Lane 1, molecular weight marker; lane 2, .002 MOI 48 hr; lane 3, .002
MOI 72 hr; lane 4, .002 MOI 96 hr; lane 5, .02 MOI 48 hr; lane 6, .02 MOI 72 hr;
lane 7, .02 MOI 96 hr; lane 8, .2 MOI 48 hr; lane 9, .2 MOI 72 hr; lane 10, .2 MOI
96 hr; lane 11, 2 MOI 48 hr; lane 12, 2 MOI 72 hr; lane 13, 2 MOI 96 hr. (B)
Comparison of mean relative density of bands of secreted L1 at varying infection
conditions.
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Purification and Yield of Recombinant L1 in High Five™ Cells
Secreted recombinant L1 was purified from culture supernatants using immobilized
metal-affinity chromatography.

Due to the presence of disulfide bridges in the Ig

domains, all purification procedures were conducted under non-denaturing conditions.
Chemically-defined culture medium was used to avoid contamination by serum proteins.
Preliminary experiments demonstrated that recombinant protein could not be efficiently
recovered directly from culture supernatants (data not shown). Dialysis against 50 mM
Na2HPO4, 300 mM NaCl buffer, pH 8.0 was performed to increase pH and to remove low
molecular weight competing species. The final purification procedure was documented
by silver-stained SDS-PAGE (Figure 5.5), revealing a single band of recombinant L1 at
approximately 140 kDa.
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Figure 5.5 Documentation of the purification procedure for secreted recombinant
L1 expression from the supernatant of baculovirus-infected High Five cells.
Proteins were separated utilizing SDS-PAGE and silver stained. Lane 1, molecular
weight marker; lane 2, serum-free supernatant of baculovirus-infected High Five
cells; lane 3, flow through; lane 4, 0 mM imidazole buffer wash; lane 5, 5 mM
imidazole buffer wash; lane 6, 10 mM imidazole buffer wash; lane 7, combined 250
mM imidazole elutions 1-3. All samples were normalized to the original
supernatant volume. Representative of 3 independent experiments.

BCA analysis demonstrated average yield of approximately 250-300 µg per 1x10
High Five cells.

8

Although diversity exists among expression methods and protein

structure, this yield is approximately comparable to levels reported for other relatively
high molecular weight, highly glycoylated proteins in insect cells. Secreted human
xylosyltransferase I (96 kDa) expression levels in High Five cells were reported as 5 mg /
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1.0-2.5 x 109 cells [319], while intracellular expression levels of DNA (cytosine-C5)methyltransferase-1 (190 kDa) in Sf9 were reported at 1 mg / 3 x 108 cells[320]. Most
comparable to our own study, a recent report of stable L1 expression in Sf9 cells using
the honeybee melittin secretion signal achieved secreted protein yields of 3 mg / 4 x 109
cells for the complete extracellular domain (203 kDa) and 32 mg / 4 x 109 cells for the Ig
5-6 fragment (45 kDa). [313]

In general, insect cell expression levels are lower than

prokaryotic systems and higher than mammalian systems. Expression levels of L1-Fc in
HEK 293 cells were reported as 1-5 mg/L, however the cell density was not reported and
supernatant was repeatedly collected from stably transfected cells over a 4 week period.
[274] Yields of L1 extracellular fragments (30-85 kDa) expressed in E. Coli have been
reported in the range of 3-5 mg/L. [312, 321]

L1 Functional Bioactivity
As a cell-cell adhesion ligand, the most critical functional activity of L1 during
development and as a potential therapeutic molecule is the promotion of axonal growth.
Neurite outgrowth from primary central nervous system neurons was evaluated as a
functional measure of protein bioactivity. The bioactivity of the secreted insect cellderived 140 kDa extracellular L1 fragment was compared to mammalian-derived L1-Fc
containing the entire extracellular region and poly-l-lysine (PLL), a routine substrate for
neuronal cell culture. Chick embryonic forebrain neurons were selected based on their
ease of preparation at high yield and purity, allowing clear analysis of neuron-ligand
interactions without interference from neuron adhesion and growth on contaminating cell
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types. Previous studies have also demonstrated that neurite outgrowth of chick-derived
neurons on mammalian L1 occurs through homophilic binding of mammalian L1 and its
chick homologue, NgCAM. [305] Both insect cell-derived L1 and mammalian-derived
L1-Fc promoted robust neurite outgrowth at 24 hours that was much greater than
observed on PLL (Figure 5.6). No neurite outgrowth was observed in blank control wells
not coated with L1 or PLL (data not shown), indicating that the observed neurite
outgrowth was mediated specifically by the protein/polymer coating applied to the wells.
In addition, no neurite outgrowth was observed on intracellular L1 purified from High
Five lysates under non-reducing conditions, indicating a lack of bioactivity probably due
to incomplete glycosylation of the protein (data not shown).

Figure 5.6 Demonstration of L1 bioactivity. Embryonic day 8 chick forebrain
neurons cultured on a 96 well polystyrene plate with (A) adsorbed 0.1% PLL, (B)
adsorbed mammalian-derived L1-Fc (25 mg/ml), and (C) adsorbed insect cellderived L1 (25 µg/ml). Cells were cultured 24 hours and then stained for actin (red)
and nuclei (blue). Scale bar = 100 µm.

Average measured neurite lengths at 24 hours were 40 µm for PLL, 155 µm for
insect cell-derived L1, and 150 µm for mammalian-derived L1-Fc (Figure 4.5). Neurite
outgrowth was significantly greater for both insect cell-derived L1 and mammalian-
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derived L1-Fc than PLL; however, no statistically significant difference was observed
between insect cell-derived L1 and L1-Fc.

250

Neurite Length (µm)

200
150
100
50
0
PLL

Mammalianderived L1-Fc

Baculovirusderived L1

Figure 5.7 Neurite outgrowth on L1. Neurite lengths (mean +/- standard deviation)
of embryonic day 8 chick forebrain neurons cultured on a 96 well polystyrene plate
with adsorbed 0.1% PLL, adsorbed mammalian-derived L1-Fc (25 µg/ml), and
adsorbed insect cell-derived L1 (25 µg/ml).

CONCLUSION
These studies describe the expression of a 140 kDa extracellular fragment of L1
in the baculovirus/insect cell expression system. Recombinant L1 was secreted as a
soluble protein into the culture medium and through the incorporation of a C-terminal 6X
histidine tag, it could be efficiently recovered at high purity by metal affinity
chromatography. Currently, L1 used for experimental studies is primarily expressed as a
recombinant Fc-fusion protein in mammalian cells or directly purified from brain lysates
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by immunoaffinity chromatography. The baculovirus expression and native purification
approaches described here provide an alternative source of recombinant L1 with
improved yield and equivalent bioactivity.

Continuing studies described in this

dissertation examined the immobilization of L1 to biomaterial surfaces and investigated
their application in promoting axonal regeneration in the injured nervous system.
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CHAPTER SIX
NIH 3T3 RESPONSE TO ACRYLATED TETRONIC®
HYDROGELS WITH IMMOBILIZED FIBRONECTIN

INTRODUCTION
The objectives of these experiments were (1) synthesis and purification of
acrylated Tetronic macromers, (2) development of Michael addition methods for
hydrogel crosslinking and protein immobilization, and (3) evaluation of hydrogel
cytocompatibility, immobilized protein bioactivity, and immobilization efficiency in
terms of cell spreading and proliferation using NIH 3T3 fibroblasts and fibronectin.
This work established methods for adding acrylate groups to Tetronic® 904 and
fabricating hydrogels using a Michael addition reaction. [322] Michael addition is not
only useful for hydrogel fabrication, but may also be used for protein immobilization.
Murphy et al. immobilized calmodulin within Peg-tetraacrylate gels via Michael type
addition of cysteine thiols to the acrylate groups [281], and Rydholm et al. have
demonstrated that pendant thiols on thiol-acrylate polymers may be useful for postpolymerization functionalization. [282]

Additionally, peptide acrylation is a well-

established method for covalent immobilization of peptides within hydrogels [283-285],
and protein acrylation has been used in methods to conjugate antibodies and collagen
type I to polymer surfaces [286, 287]
Three methods of protein immobilization to T904-acrylate hydrogels were
evaluated (Figure 6.1): (A) Michael type addition of cysteine thiols from encapsulated
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reduced protein to acrylate groups within the hydrogel, (B) Michael type addition of
cysteine thiols from reduced protein to unreacted pendant acrylate groups on the hydrogel
surface, and (C) Michael type addition of acrylated proteins using acrylate-PEG-NHS (Nhydroxysuccinimide) with unreacted pendant thiol groups on the hydrogel surface.

A. Encapsulated reduced
protein

B. Pendant acrylate groups
with reduced protein

C. Pendant thiol groups with
acrylated protein
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Figure 6.1 Protein Immobilization Methods

NIH 3T3 cells originated from Swiss mouse embryo tissue, and the cell line was
established in 1962 by George Todaro and Howard Green at the Department of Pathology
in the New York University School of Medicine. [323] These fibroblast cells double
every 24 hours and reach a saturation density of approximately 50,000 cells per cm2, and
they are widely used in research laboratories. Fibronectin exists in two main forms: 1) as
an insoluble glycoprotein dimer in the ECM, made by fibroblasts, chondrocytes,
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endothelial cells, macrophages, as well as certain epithelial cells; and 2) as a soluble
disulphide linked dimer found in the plasma, synthesized by hepatocytes. Fibronectin is
secreted as a disulfide-bonded dimer of approximate 440 kDa molecular weight, and each
subunit contains three types of repeating modules: FN-I, FN-II, and FN-III, with disulfide
bonds in FN-1 and FN-II but not FN-III modules. [324, 325] It is widely known that the
Arginine-Glycine-Aspartic Acid (RGD) integrin binding tripeptide in the FN-III repeat
10 is an important bioactive site that induces fibroblast attachment to fibronectin via
integrin binding [326-328], although there is also evidence of multiple functional synergy
sites within the fibronectin protein. [329-332] Fibronectin has free cysteine residues and
numerous disulfide bonds that can participate in Michael addition and thiol/disulfide
exchange reactions. [333] It also contains multiple lysine residues making it an attractive
candidate for acrylation through conjugation to the heterobifunctional PEG derivative,
acrylate-PEG-NHS.

MATERIALS AND METHODS
Synthesis and Purification of T904-Acrylate
Figure 6.2 is a schematic of the synthesis of acrylated Tetronic macromers [322],
and the protocol is included in Appendix A.
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Figure 6.2 Synthesis of Acrylated Tetronic Macromers [322]

Briefly, Tetronic® 904 (MW 6700) was dissolved in toluene, azeotropically
distilled, and toluene was removed via solvent evaporation with a rotary evaporator. The
T904 was then dissolved in dehydrated dichloromethane and reacted with 4X molar
excess triethylamine (TEA) and 8X molar excess acryloyl chloride for 24 hours at 4°C.
At the completion of the reaction, the product was filtered, dichloromethane was removed
via solvent evaporation, and it was precipitated in a 50/50 ether/hexane mixture. Upon
settling of the precipitated product, ether/hexane was decanted and the product was
redissolved in dichloromethane, washed with NaHCO3 to neutralize the pH followed by
multiple water washes, and water was removed using anhydrous sodium sulfate.
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Dichloromethane was removed via solvent evaporation, and the product was precipitated
in a 50/50 ether/hexane mixture two times followed by two 100% ether precipitations to
ensure removal of all hexane. Upon settling of the precipitated product, ether/hexane was
decanted, the product was dried overnight in a cold dessicator on ice under vacuum to
remove ether, and 1H-NMR (Brucker 300 MHz, CDCl3) was taken to evaluate the
acrylation efficiency. All T904-acrylate products were stored at -20°C protected from
light.
NIH 3T3 Cell Culture
NIH 3T3 mouse fibroblasts were purchased from ATCC (American Type Culture
Collection) and were routinely maintained 75 cm2 T-flasks in a humidified chamber at
37°C with 7% CO2 atmosphere in 50/50 Dulbecco’s Modified Eagle’s Medium and
Ham’s F-12 with L-glutamine (DMEM/F12 1X, Mediatech) supplemented with 10% v/v
bovine growth serum (BGS, Hyclone) and 50 I.U./mL penicillin and 50 µg/mL
streptomycin (Mediatech). Culture medium was changed once every two days and cells
were passaged weekly.

For hydrogel experiments, monolayers of fibroblasts were

trypsinized, centrifuged, resuspended, counted in a hemacytometer, and adjusted to the
appropriate final concentrations based on pilot studies.

Preparation of T904-Acrylate Solution
T904-acrylate was mixed with 50mM PBS pH 7.4 to make a 28.75% solution
(287.5mg T904 + 712.5µL PBS) and was allowed to dissolve overnight with stirring at
room temperature protected from light. Because of batch-to-batch inconsistencies in
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T904-acrylate pH due to variable efficiency of washing steps during synthesis and
because of the dependency of solution pH on temperature, the solution was adjusted to
pH 7.2 at room temperature with 6N hydrochloric acid to ensure consistent, appropriate
pH for the Michael addition polymerization reaction. Following pH adjustment, the
solution was carefully filtered with a 25mm 0.2µm syringe filter (Nalgene) for removal of
contaminants and sterilization. The sterile solution was stored at 4°C protected from
light, but was brought to room temperature prior to making hydrogels because of its basic
pH at colder temperatures.

Preparation of Hydrogels
Prior to making hydrogels, all components were sterilized. Uncharged glass
coverslips (Fisher) were UV sterilized for 20 minutes in the cell culture hood. Binder
clips, 1mm thick Teflon spacers, vacuum grease, spatulas, and forceps were autoclaved
prior to use. All experiments were conducted in the cell culture hood using aseptic
technique.
Hydrogel crosslinking via Michael addition reaction was initiated by the addition
of dithiothreitol (DTT), as depicted in Figure 6.3.
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Figure 6.3 Michael Addition Polymerization Scheme [322]

Hydrogels for all conditions tested were fabricated by mixing the 28.75% T904acrylate solution previously described with 10% v/v fibronectin solution (encapsulated
protein) or 50mM PBS solution (surface-immobilized protein) and 10% v/v DTT solution
for a final concentration of 23% T904 acrylate (i.e., 80µL T904 acrylate + 10µL of
fibronectin/50mM PBS + 10µL DTT = 23% T904-acrylate hydrogel for a 100µL
hydrogel).
T904 has a molecular weight of 6700 g/mol. T904-acrylate has an estimated
molecular weight of 6916 g/mol and 4 moles of acrylate per mole of T904 acrylate
assuming 100% acrylation efficiency. DTT has a molecular weight of 154.26 and 2
moles of thiol per mole of DTT. For encapsulated protein, the DTT concentration
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required was calculated based on a 1:1 T904 acrylate:DTT thiol ratio, thus requiring 1.03
mg of DTT per 23 mg of T904 acrylate. For surface-immobilization of acrylated peptide
or protein, the DTT concentration required was calculated based on a 1:1.1 T904
acrylate:DTT thiol molar ratio in order to leave unreacted pendant thiols on the hydrogel
surface, thus requiring 1.13 mg of DTT per 23 mg of T904 acrylate. For surfaceimmobilization of reduced protein, the DTT concentration required was calculated based
on a 1.1:1 T904 acrylate:DTT thiol molar ratio in order to leave unreacted pendant
acrylate groups on the hydrogel surface, thus requiring 0.93 mg of DTT per 23 mg of
T904 acrylate. A new DTT stock solution was made for every experiment and was
sterilized by filtering through a 13mm 0.2µm syringe-filter (Nalgene).

T904-Acrylate Hydrogels with Surface-Immobilized Reduced Fibronectin
These experiments are based on the immobilization method depicted in Figure
6.1B.
Reduction of Fibronectin
Analysis of GenBank Accession No. P07589, bovine fibronectin (Appendix A)
revealed that fibronectin contains 62 cysteines per mol. Fibronectin is a 440 kDa protein,
and a 1 mg/mL solution is equivalent to 0.00227 mmol/L concentration of protein.
Protein solutions are typically reduced with 1mM to 10 mM DTT. A 2.5 mM DTT
solution was used to reduce fibronectin [276], resulting in an approximate 1000 molar
excess of DTT to fibronectin, or an approximate 35-molar excess of DTT thiols to
fibronectin cysteines. A 10X 25mM stock solution of DTT in 50mM PBS pH 7.4 buffer
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was made, 10% by volume was added to the 1mg/mL fibronectin solution for a final 2.5
mM DTT concentration, and reacted for 1 hour at room temperature. Unreacted DTT
was removed by column filtration using a PD-10 column and 50mM PBS pH 7.4 buffer
followed by analysis of protein concentration via measurement of absorbance at 280nm.
Protein samples were kept on ice following filtration and during protein concentration
analysis.
Preparation of Hydrogels
PBS and DTT were directly added to room temperature 28.75% T904-acrylate
solution, and the gel solution was vortexed briefly, tap-spinned, and 70µL was
immediately pipetted directly into 96-well TCPS plate and allowed to polymerize via
Michael addition in the dark for 1 hour at room temperature. After 1 hour, reduced
fibronectin solution (100µL per well) of 100 µg/mL concentration was added and left for
an additional hour at room temperature. Hydrogel crosslinking and fibronectin reduction
were coordinated such that reduced fibronectin solution was added to the hydrogels
immediately upon completion of reduced fibronectin concentration analysis, to minimize
the possibility of disulfide bond reformation. Hydrogels without reduced fibronectin were
used as negative controls. Blank 48-well TCPS wells and 96-well bacterial polystyrene
wells with 10 µg/mL reduced fibronectin adsorbed overnight were seeded as positive
controls for visual confirmation of cell health and bioactivity of reduced protein.
Following 1 hour incubation in reduced protein at room temperature, the plate was
parafilmed and transferred to 37°C overnight with shaking. The next morning, gels were
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rinsed with 200µL of sterile PBS three times and hydrated in 100µL of sterile PBS per
well at 37°C until cell seeding.
Cell Seeding
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with Lglutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL
streptomycin and observed at 24 hours post-seeding for attachment and spreading.

T904-Acrylate Hydrogels with Surface-Immobilized Acrylate-PEG-RGD
A pilot study was conducted using stock 10 µmol/mL acrylate-PEG-RGD
previously synthesized in our lab using 70µL hydrogels polymerized directly in 96-well
TCPS plates.
Immobilization of Acrylate-PEG-RGD
PBS and DTT were directly added to room temperature T904-acrylate solution,
and the gel solution was vortexed briefly, tap-spinned, and 70µL was immediately
pipetted directly into 96-well TCPS plate and allowed to crosslink via Michael addition at
dark for 1 hour at room temperature. After 1 hour, acrylate-PEG-RGD solution (diluted
to 1 µmol/mL) was added and left for an additional hour at room temperature. Additional
hydrogels were incubated in acrylate-PEG-RGD solution (1 µmol/mL) diluted in a 100X
molar excess sodium acrylate solution to determine if this inhibited binding of acrylatePEG-RGD to the hydrogel surface. Negative control samples included hydrogels without
acrylate-PEG-RGD. Positive control samples (for visual confirmation of cell health only)
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included blank 96-well TCPS wells and encapsulated fibronectin gels. All conditions
used a sample size of n=3 independent gels.
Following 1 hour incubation at room temperature, the plate was parafilmed and
transferred to 37°C overnight with shaking. The next morning, gels were rinsed with
200µL of sterile PBS three times and hydrated in 100µL of sterile PBS per well at 37°C
until cell seeding.
Cell Seeding
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with Lglutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL
streptomycin.
Cell Staining and Imaging
At 24 hours post-seeding, cells were fixed in 4% paraformaldehyde in PBS for
one hour at room temperature, permeabilized with 0.5% Triton X-100 for 2 minutes, and
stained for actin filaments with rhodamine phalloidin (Molecular Probes). Hydrogels
were carefully removed from the wells and flipped over onto a glass slide for imaging,
and digital fluorescent images were obtained using a 10X objective for each condition.

Preparation of Acrylated Fibronectin
Acrylation Reaction
Bovine plasma fibronection (1mg/mL, Sigma-Aldrich) is supplied in 0.5 M NaCl,
0.05 M Tris, pH 7.5.

Tris contains primary amines that interfere with fibronectin

acrylation using acrylate-PEG-NHS because of competitive binding with the protein
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lysine amines; therefore, prior to using the protein solution, a buffer exchange into 50mM
PBS, pH 7.4 was performed utilizing 0.5 mL Zeba desalt columns (Pierce) according to
the manufacturer’s instructions.
Standard reaction conditions for NHS-containing crosslinkers call for 0.1-10 mM
concentrations. Fibronectin is a 440 kDa protein, and a 1 mg/mL solution is equivalent to
0.00227 mmol/L concentration of protein. Typically, 2 to 50-fold molar excesses of
crosslinker are used for reactions, and the 0.1M concentration of acrylate-PEG-NHS
(Nektar, 3450 Da) used for this reaction resulted in a 44 molar excess of crosslinker to
fibronectin. A 10X solution of 3.45 mg/mL acrylate-PEG-NHS in anhydrous DMSO was
made fresh for each reaction, 10µL of this solution was added to 100 µL of 1mg/mL
fibronectin for an organic solvent carryover of 10% final volume in the aqueous reaction,
and reacted for 2 hours at room temperature with shaking. At the completion of the
reaction, a buffer exchange into 50mM PBS, pH 7.4 was again performed to remove
unreacted crosslinker and solvent contamination, and the acrylated protein was stored at
4°C protected from light.
Electrophoresis of Acrylated Fibronectin
Samples of acrylated and non-acrylated fibronectin were immediately collected
for SDS-PAGE (sodium dodecyl polyacrylamide gel electrophoresis) analysis (12 µL
protein + 4 µL 4X reducing buffer) and immediately frozen at -80°C. Protein samples
were separated by SDS-PAGE on a 6% polyacrylamide gel using Tris-glycine buffer
under reducing conditions at 100V for 150 minutes. The gel was stained with 0.2%
Coomassie Brilliant Blue in Water:Methanol:Acetic Acid with volume ratios 5:4:1 for 45
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minutes followed by destaining in Water:Methanol:Acetic Acid with volume ratios 5:4:1
for 3 hours. The gel was imaged using a Kodak Electrophoresis Documentation and
Analysis System 120.
T904 Acrylate Hydrogels with Encapsulated and Surface-Immobilized
Acrylated Fibronectin
These experiments are based on the immobilization methods depicted in Figure
6.1A and C. Two separate experiments were conducted in order to quantify fibroblast
spreading and proliferation in response to hydrogels with encapsulated fibronectin and
surface-immobilized acrylated fibronectin (as depicted in the project rationale Figure
4.3A). The dose dependent response of cells to varying concentrations of fibronectin was
characterized by analyzing fibroblast spreading at an intermediate time point of 18 hours
post-seeding, prior to the typical cell doubling timepoint of 24 hours. A cell proliferation
assay was then conducted with protein concentrations chosen based on fibroblast
spreading results.
Dose Dependent Response Assay
For hydrogels with encapsulated fibronectin, pilot studies were conducted to
determine the optimum timepoint of fibronectin reduction with DTT prior to addition to
the T904-acrylate solution (0, 2.5, 5, 10, 15, and 30 minutes) with encapsulated
100µg/mL fibronectin hydrogels. Hydrogels for the dose dependent response assay were
made with varying concentrations of encapsulated fibronectin (1.0, 2.5, 5.0, 7.5, 10, 25,
50, 75, 100 µg/mL) with n=3 independent gels per condition.

Hydrogels without

fibronectin (n=3 independent gels) were used as negative controls. Blank 48-well TCPS
wells and 96-well bacterial polystyrene wells with 10 µg/mL reduced fibronectin
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adsorbed overnight were seeded as positive controls for visual confirmation of cell health
and bioactivity of reduced protein. Fibronectin was mixed with DTT for 5 minutes at
room temperature with shaking.

This protein/DTT mixture was added to room

temperature T904 acrylate solution, the gel solution was vortexed briefly, tap-spinned,
and 60µL was immediately pipetted in between two glass slides separated by 1mm Teflon
spacers. The hydrogels were allowed to crosslink via Michael addition in the dark for 2
hours at room temperature followed by overnight at 37°C in parafilmed petri dishes with
sterile water to provide a humid environment. The next morning, vacuum grease was
added to the bottom of 48-well TCPS plates and sterilized under UV light for 20 minutes.
The hydrogels were carefully removed from the glass slides by rinsing with sterile PBS
and were placed in the wells, gently pressing them down onto the vacuum grease to
prevent floating, and hydrated in 1 mL of PBS per well at 37°C until cell seeding.
For hydrogels with surface-immobilized acrylated fibronectin, PBS and DTT
were directly added to room temperature T904-acrylate solution, and the gel solution was
vortexed briefly, tap-spinned, and 70µL was immediately pipetted directly into 96-well
TCPS plate and allowed to crosslink via Michael addition in the dark for 1 hour at room
temperature. After 1 hour, acrylated fibronectin solution (100µL per well) of varying
concentrations (1.0, 2.5, 5.0, 7.5, 10, 25, 50, 75, 100 µg/mL) was added and left for an
additional hour at room temperature, with n=3 independent gels per condition. Negative
control samples included hydrogels without acrylated fibronectin (n=3 independent gels)
and hydrogels with non-acrylated fibronectin (n=3 independent gels). Blank 96-well
TCPS wells were seeded as positive controls for visual confirmation of cell health.
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Following 1 hour incubation in acrylated protein at room temperature, the plate was
parafilmed and transferred to 37°C overnight with shaking. The next morning, gels were
rinsed with 200µL of sterile PBS three times and hydrated in 100µL of sterile PBS per
well at 37°C until cell seeding.
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with Lglutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL
streptomycin.
Cell Proliferation Assay
Three timepoints were chosen for cell proliferation analysis: 24 hours (1 day), 72
hours (3 days), and 120 hours (5 days) post seeding. Based on the results of the dose
dependent response assay, hydrogels were made with varying concentrations of
encapsulated fibronectin (2.5, 5.0, 25, 100 µg/mL) and acrylated fibronectin (7.5, 10, 25,
100 µg/mL) with n=3 independent gels per condition. Negative control samples included
hydrogels without encapsulated and acrylated fibronectin (n=3 independent gels) and
hydrogels with non-acrylated fibronectin (n=3 independent gels). Blank 96-well TCPS
wells were seeded as positive controls for visual confirmation of cell health.
NIH 3T3 cells were seeded at a density of 312.5 cells/mm2 in DMEM/F12 with Lglutamine supplemented with 10% BGS and 50 I.U./mL penicillin and 50 µg/mL
streptomycin. Media was changed daily to maintain an adequate supply of cell nutrients.
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Measurement of Fibroblast Spreading
Fibroblast spreading at 18 hours post-seeding was analyzed via measurement of
the surface area of the cells. Cells were fixed in 4% paraformaldehyde in PBS for one
hour at room temperature, permeabilized with 0.5% Triton X-100 for 2 minutes, and
stained for actin filaments with rhodamine phalloidin (Molecular Probes). Hydrogels
were carefully removed from the wells and flipped over onto a glass slide for imaging.
Twenty digital fluorescent images per well using a 10X objective covering the entire
hydrogel surface were recorded for each condition. Cell surface area was quantitatively
measured from the digital fluorescent images using ImagePro software (n=21
measurements / experimental group, comprised of an average of 7 measurements from
each of 3 independent wells).
DNA Content Analysis
PicoGreen (Molecular Probes) is a fluorescent binding dye and is an established
method of characterizing cell proliferation based on DNA content. [284, 334-336]
Hydrogel samples were analyzed in triplicate for DNA content at 1, 3, and 5 days to
assess cell proliferation. The cell-seeded hydrogels were rinsed with PBS, and fibroblasts
were lysed by freeze/thaw of the samples at -80°C three times. Samples were suspended
in 2mL of cold 10mM EDTA pH 12.3 solubilization buffer (2mL for encapsulated
fibronectin samples, 200µL for acrylated fibronectin samples) as previously described.
[337] Following 20 minute incubation at 37°C, the samples were cooled on ice and the
pH was neutralized with 1M potassium phosphate pH 4.19 (150µL for encapsulated
fibronectin samples, 15µL for acrylated fibronectin samples). Samples were analyzed
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according to the manufacturer’s instructions using a SpectraMAX Gemini fluorometer
(excitation filter at 480 nm and emission filter at 520 nm) based on standard curves
derived from serial dilutions of the same cells and their DNA content.
Statistical Analysis
The data was analyzed by ANOVA using Tukey’s method for post-hoc
comparisons with p<0.05 considered statistically significant. All results are expressed as
mean ± standard deviation.

RESULTS AND DISCUSSION
Synthesis and Purification of T904-Acrylate
Figure 6.4 depicts the NMR from a typical T904-acrylate product. A 30g reaction
typically yielded approximately 15g of final product and 1H-NMR (CHCl3) demonstrated
an approximate 83% acrylation efficiency.
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Figure 6.4 Structure and 1H-NMR Spectrum of Acrylated T904 Macromer

NIH 3T3 Response to Surface-Immobilized Reduced Fibronectin
Fibroblasts showed little evidence of attachment and no spreading on hydrogels
with reduced fibronectin, comparable to hydrogels with no protein. Positive controls of
blank 48-well TCPS and 96-well bacterial polystyrene with 10 µg/mL reduced
fibronectin adsorbed overnight demonstrated significant spreading and proliferation of
fibroblasts. Acrylate groups are inherently hydrophobic because their CH=CH2
carbonaceous side groups are non-polar and thus do not attract water strongly. We
hypothesize

that

this

immobilization

technique
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failed

because

the

inherent

hydrophobicity of the acrylate groups contributes to their retreat within the hydrogel upon
application of the hydrophilic reduced fibronectin solution, thus hindering the Michael
addition protein conjugation reaction. An alternative explanation is that the filtration
method used may not be sufficient to remove all excess DTT, possibly resulting in a
reformation of fibronectin disulfide bonds prior to adding the solution to the hydrogels.
No further experiments were conducted utilizing reduced fibronectin.

NIH 3T3 Response to Surface-Immobilized Acrylate-PEG-RGD
This pilot study was conducted in order to demonstrate the feasibility of
immobilizing acrylated protein to hydrogels through Michael addition reaction by
demonstrating cell attachment to an immobilized acrylated peptide, and to prove that the
cellular response was, in fact, a result of acrylate binding to unreacted pendant thiols on
the hydrogel surface via a competitive binding assay using sodium acrylate. (Figure 6.5)
Figure 6.5A depicts significant fibroblast attachment and spreading on hydrogels with
immobilized acrylate-PEG-RGD at 24 hours.

Figure 6.5B depicts fibroblasts on

hydrogels incubated in acrylate-PEG-RGD diluted in 100X molar excess of sodium
acrylate, and significant inhibition of cellular response is shown with only slight
improvement in fibroblast attachment and spreading over the negative control with no
peptide depicted in Figure 6.5C, thus demonstrating that the RGD peptide immobilized
by Michael addition is responsible for fibroblast spreading.
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A

B

C

Figure 6.5 Proof of Michael addition surface conjugation of RGD peptide. NIH 3T3
cells cultured on hydrogels with immobilized (A) acrylate-PEG-RGD (1 µM), (B)
acrylate-PEG-RGD (1 µM) diluted in 100 molar excess sodium acrylate, and (C) no
peptide. Cells were stained for actin with rhodamine phalloidin. Scalebar = 100
µm.

Acrylation of Fibronectin
As stated previously, plasma fibronectin is a disulfide-bonded dimer consisting of
a pair of 220 kDa subunits [324, 325]; therefore, a molecular weight marker with an
upper limit of 250 kDa could be used with reducing SDS-PAGE for determination of
molecular weight. [338] Analysis of GenBank Accession No. P07589, bovine fibronectin
(Appendix A) revealed that fibronectin contains 122 lysines per mol, and the acrylatePEG-NHS used to acrylate fibronectin has a molecular weight of 3450 Da. Conjugation
of 1-4 lysines per mol of fibronectin with acrylate-PEG-NHS should result in an
estimated 3-13kDa increase in molecular weight.

Figure 6.6 demonstrates an

approximate 8-10 kDa increase in molecular weight of the acrylated protein as evidenced
by lane 2. This data demonstrates successful acrylation of the fibronectin protein.
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Figure 6.6 Documentation of fibronectin acrylation. Proteins were separated
utilizing SDS-PAGE and stained with 0.2% Coomassie Brilliant Blue. Lane 1,
molecular weight marker; lane 2, acrylated fibronectin; lane 3, non-acrylated
fibronectin. Gels were loaded with equal quantities of total protein (12 µg/lane).
Data is representative of three independent experiments.

NIH 3T3 Response to Encapsulated and Surface-Immobilized
Acrylated Fibronectin
Dose Dependent Response of Fibroblast Spreading
The purpose of this assay was to determine if fibroblasts display a dose dependent
spreading response to hydrogels with varying concentrations of encapsulated and
acrylated fibronectin, in order to determine the optimal fibronectin concentrations for cell
spreading and to determine conditions for analysis of proliferation rates.
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Positive controls of blank 48-well TCPS and 96-well bacterial polystyrene with
10 µg/mL reduced fibronectin adsorbed overnight demonstrated significant spreading and
proliferation of fibroblasts. For hydrogels with encapsulated fibronectin, pilot studies
were conducted to determine the optimum timepoint of fibronectin reduction with DTT
prior to addition to the T904-acrylate solution (0, 2.5, 5, 10, 15, and 30 minutes), and 5
minutes resulted in maximum cell adhesion to hydrogels with encapsulated 100µg/mL
fibronectin at 24 hours (data not shown). The 2.5 and 10 minute timepoints resulted in
limited cell adhesion at 24 hours and response greatly diminished at the 0, 15, and 30
minute timepoints, most likely a result of limited disulfide bond reduction at the 0
timepoint and reformation of disulfide bonds at the 15 and 30 minute timepoints.
Fibroblast spreading on hydrogels with encapsulated fibronectin is shown in
Figure 6.7. The data indicates a plateau beginning at 2.5 µg/mL, and the minimum cell
spread area in the plateau region was 2277 µm2 at 2.5 µg/mL. A statistically significant
difference was observed between 25 and 100 µg/mL with a maximum average cell spread
area of 3400 µm2. A statistically significant difference was also observed between 1.0
and 2.5 µg/mL concentrations; however, cell attachment upon visual observation was
significantly reduced at 1.0 and 0 µg/mL concentrations, and minimal cell spread areas of
697 µm2 and 310 µm2, respectively, were measured.
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Figure 6.7 Fibroblast spreading on hydrogels with encapsulated fibronectin.
Average cell areas (mean +/- standard deviation) of NIH 3T3 cells cultured on
hydrogels with encapsulated fibronectin of varying concentrations. Data is
representative of three independent experiments.

Figure 6.8 displays the cell spreading on hydrogels with encapsulated fibronectin
representative of the average measured area for each condition.
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Figure 6.8 Cytoskeletal organization of fibroblasts cultured on hydrogels with
varying concentrations of encapsulated fibronectin. (A) 100 µg/mL, (B) 75 µg/mL,
(C) 50 µg/mL, (D) 25 µg/mL, (E) 10 µg/mL, (F) 7.5 µg/mL, (G) 5.0 µg/mL, (H) 2.5
µg/mL, (I) 1.0 µg/mL, and (J) 0.0 µg/mL Cells were stained for actin with
rhodamine phalloidin. Images are representative of the average cell area for each
condition. Scalebar = 50 µm.

Fibroblast spreading on hydrogels with acrylated fibronectin is shown in Figure
6.9. The data indicates an increasing trend of cell spread area in response to increasing
fibronectin concentration with a maximum cell spread area of 3423 µm2 at 100 µg/mL. A
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statistically significant difference was observed between 25 and 50 µg/mL.

The

minimum cell spread area measured was 523 µm2 at 5.0 µg/mL, which is comparable to
the spreading seen on hydrogels with 1.0 µg/mL concentration of encapsulated
fibronectin. No measurements were taken below 5.0 µg/mL due to extremely limited cell
attachment.
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Figure 6.9 Fibroblast spreading on hydrogels with surface-immoblized acrylated
fibronectin. Average cell areas (mean +/- standard deviation) of NIH 3T3 cells
cultured on hydrogels with acrylated fibronectin of varying concentrations. No
hydrogels with acrylated protein concentration below 5 µg/mL were measured due
to extremely limited cell attachment and survival. Data is representative of three
independent experiments.
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Figure 6.10 displays the cell spreading on hydrogels with acrylated fibronectin
representative of the average measured area for each condition.
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F

Figure 6.10 Cytoskeletal organization of fibroblasts cultured on hydrogels with
varying concentrations of surface-immobilized acrylated fibronectin. (A) 100
µg/mL, (B) 75 µg/mL, (C) 50 µg/mL, (D) 25 µg/mL, (E) 10 µg/mL, and (F) 7.5
µg/mL. Cells were stained for actin with rhodamine phalloidin. Images are
representative of the average cell area for each condition. Scalebar = 50 µm.

For both encapsulated and acrylated fibronectin, concentrations of 50, 75, and 100
µg/mL promoted maximum fibroblast spreading, and both methods displayed a
maximum cell spread area of approximately 3400 µm2 with 100 µg/mL of fibronectin.
Encapsulated fibronectin supported fibroblast spreading at lower concentrations than
acrylated fibronectin; cell spread area of approximately 2000 µm2 was observed on
hydrogels with 2.5 µg/mL of encapsulated fibronectin and 25 µg/mL of acrylated
fibronectin.
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Prior studies using 100 µg/mL of thiolated fibronectin immobilized to polystyrene
surfaces through Pluronic-pyridyl disulfide (F108-PDS) modification demonstrated cell
surface areas >8000 µm2 [339]; therefore, future work may include higher concentrations
of fibronectin to determine if increased fibroblast spreading areas are attainable on
encapsulated and surface-immobilized acrylated hydrogels.

Fibroblast Proliferation Response
The purpose of this assay was to analyze cell proliferation in response to varying
concentrations of encapsulated and acrylated fibronectin over the course of 5 days.
Based on the results of the dose-dependent response assay for encapsulated fibronectin,
an optimum concentration of 100 µg/mL and three concentrations from the plateau region
were chosen based on statistically significant differences in cell spreading: 25 µg/mL, 10
µg/mL, and 2.5 µg/mL. Hydrogels with no encapsulated protein (0 µg/mL) were used as
a negative control for comparison. Fibroblast proliferation on encapsulated fibronectin
gels is shown in Figure 6.11.
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Figure 6.11 Fibroblast proliferation on hydrogels with encapsulated fibronectin of
varying concentrations. Cells were seeded at a density of 10,000 cells per well.
Error bars represent +/- standard deviation.
Data is representative of three
independent experiments.

The data indicates significant variability in cell proliferation between 2.5 µg/mL
and 25 µg/mL concentrations, which corresponds to the plateau region of fibroblast
spreading. Cell attachment at 2.5 µg/mL is comparable to the negative control. Although
similar numbers of cells are attached at Day 1 on the 10 µg/mL, 25 µg/mL, and 100
µg/mL conditions, only the 100 µg/mL condition displayed a continual increase in cell
proliferation from Day 1 to Day 5.
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Hydrogels with 100 µg/mL of encapsulated fibronectin exhibited the maximum
average cell spread area of 3400 µm2 with a 240% increase in proliferation from Day 1 to
Day 5. This data is consistent with reports that cell proliferation is improved with
increased cell spreading. [339-342]

The inconsistency in fibroblast proliferation at

fibronectin concentrations below 100 µg/mL may indicate an insufficient amount of
surface protein to support cell spreading and cytoskeletal organization, thus
demonstrating the importance of optimized surface-ligand densities for cell proliferation.
In addition, T904-acrylate hydrogels are hydrolytically degradable, and greater
connectivity of fibroblasts on hydrogels with 100 µg/mL fibronectin concentration may
have prevented detachment of cells from the degrading hydrogel.
Based on the results of the dose-dependent response assay for acrylated
fibronectin, an optimum concentration of 100 µg/mL and three concentrations below
optimum were chosen based on statistically significant differences in cell spreading: 25
µg/mL, 10 µg/mL, and 7.5 µg/mL. Hydrogels with no encapsulated protein (0 µg/mL)
were included as a negative control for comparison. Fibroblast proliferation on acrylated
fibronectin is shown in Figure 6.12. Although significant numbers of fibroblasts were
attached at Day 1 on both the 25 µg/mL and 100 µg/mL conditions, the data indicates no
cell proliferation occurred for any condition tested.
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Figure 6.12 Fibroblast proliferation on hydrogels with acrylated fibronectin of
varying concentrations. Error bars represent +/- standard deviation. Data is
representative of three independent experiments.

This result is in stark contrast to the positive proliferation response observed for
the encapsulated fibronectin 100 µg/mL condition at 3 and 5 days. The measured cell
areas at 18 hours post-seeding for the 50, 75, and 100 µg/mL conditions are comparable
for both encapsulated and acrylated fibronectin, indicating that surface ligand density is
high enough to support cell spreading and cytoskeletal organization that is critical to cell
proliferation. For both experiments, media was exchanged daily to ensure constant, fresh
supply of cell nutrients, so this result is directly correlated to the immobilization strategy
used. In a hydrogel with encapsulated fibronectin, hydrolytic degradation may not be
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detrimental to cell proliferation because it continually exposes the fibroblasts to
fibronectin, and our encapsulated 100 µg/mL fibronectin data supports this theory;
however, hydrolytic degradation of T904-acrylate hydrogels with surface-immobilized
acrylated fibronectin may result in loss of the surface-conjugated protein layer and
inhibition of proliferation.
Another phenomenon was observed in that hydrogels incubated in non-acrylated
fibronectin, an anticipated negative control, supported comparable fibroblast proliferation
to hydrogels with surface-immobilized acrylated fibronectin (Figure 6.13). Because of
the similarity in the lack of support for fibroblast proliferation, we can deduce that this is
a surface-mediated phenomena.
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Figure 6.13 Fibroblast proliferation on hydrogels with acrylated and non-acrylated
fibronectin of 100 µg/mL concentration. Error bars represent +/- standard
deviation. Data is representative of three independent experiments.

The experiment with acrylate-PEG-RGD (Figure 6.4) demonstrated that fibroblast
response was inhibited through competitive binding of sodium acrylate, proving the
peptide was immobilized through a Michael addition conjugation. Several studies have
demonstrated that fibronectin multimer formation occurs in vitro via the C-terminal free
thiols upon exposure to a thiol reagent [343, 344] and in vivo depending upon exposure to
metal ions. [345]

Another study has shown that homocysteine binding to plasma

fibronectin in vivo is mediated through thiol-disulfide exchange at the C-terminal
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disulfide bonds. [346]

We therefore hypothesize that non-acrylated fibronectin is

immobilized to our hydrogel surfaces through a thiol-disulfide exchange mediated
mechanism. For these experiments, fibronectin solution was added to the gel at an early
timepoint of 1 hour post-polymerization, possibly exposing the protein to reactive thiolate
species capable of reducing the easily accessible C-terminal disulfide bonds. In order to
clarify this phenomena, further experiments with extended gelation times could be
conducted to determine if more complete polymerization prior to addition of fibronectin
solution will inhibit binding of non-acrylated fibronectin.

CONCLUSION
In conclusion, these studies demonstrated that surface-immobilization of reduced
fibronectin to hydrogels with unreacted pendant acrylate groups is not feasible because of
the inherent hydrophobicity of acrylate groups. Surface-immobilization of acrylate-PEGRGD through Michael addition conjugation was demonstrated with a competitive binding
assay using sodium acrylate to bind unreacted pendant thiols on the hydrogel surface to
prevent RGD immobilization and limit fibroblast spreading and proliferation. NIH 3T3
fibroblasts exhibited maximum cell spreading at 18 hours and proliferation at 5 days on
hydrogels with 100 µg/mL fibronectin concentration. Future work may include higher
fibronectin concentrations beyond 100 µg/mL to further maximize the cell spreading and
proliferation response and to determine if higher protein concentrations will result in
more uniform proliferation rates and possibly a second plateau region of fibroblast
spreading response.

SDS-PAGE analysis demonstrated successful acrylation of the
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fibronectin protein.

NIH 3T3 fibroblasts seeded on acrylated fibronectin hydrogels

displayed a positive dose-dependent spreading response to increasing concentrations of
protein; however, long-term proliferation rates were significantly hindered, possibly by
the hydrolytic mechanism of hydrogel degradation.

In addition, a second potential

mechanism of fibronectin conjugation to hydrogel surfaces via thiol-disulfide exchange is
theorized, although it is likely that this mechanism will not be effective for proteins with
less accessible disulfide bonds. Even with these concerns, the covalent immobilization
techniques described are useful for the design of selectively adhesive substrates and may
be employed currently to study neural regeneration at early timepoints in a model system
to evaluate neuronal cell line and primary neuron response to immobilized neural cell
adhesion molecules.
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CHAPTER SEVEN
NEURONAL CELL LINE AND PRIMARY NEURON RESPONSE
TO ACRYLATED TETRONIC® HYDROGELS
WITH IMMOBILIZED L1

INTRODUCTION
The objectives of these experiments were to evaluate the feasibility of using HT22
mouse hippocampal B35 and rat neuroblastoma neuronal cell lines with immobilized L1,
to establish primary mammalian neuron dissection protocols, to evaluate the
cytocompatibility of acrylic-based Tetronic® hydrogels with primary neurons, and to
demonstrate the feasibility of using acrylic-based Tetronic® hydrogels with covalently
immobilized L1 for neural applications.
Inherent challenges of primary neuronal cell cultures include animal to animal
and developmental age variability and potential glial cell contamination; therefore, two
neuronal cells lines, HT22 mouse hippocampal and B35 rat neuroblastoma, were first
studied for their ability to respond to immobilized L1 and to differentiate into neuronal
phenotypes, in order to establish a model cell line to simulate neuronal response. Both
HT22 and B35 cells are typically maintained in media containing 10% serum to promote
rapid growth and proliferation; however, a differentiated neuronal phenotype is preferred
for these experiments in order to characterize neuronal response. Hippocampal neurons
are pyramidal cells, which is also the classification of neurons that are the primary
excitation units of the mammalian corticospinal tract. L1 is expressed on regenerating
hippocampal axons following injury [347], and neurite outgrowth of primary
hippocampal neurons has been demonstrated on adsorbed and immobilized L1-Fc. [253]
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HT22 cells are derived from mouse hippocampus, and both primary hippocampal and
HT22 cells are typically used in neuronal survival studies. [348] L1 has been described
as a survival factor for rat embryonic hippocampal neurons, as evidenced by the
prevention of apoptosis when cultured in serum-free media with both soluble and
substrate-bound L1 [239]; therefore, it was hypothesized that HT22 cells can attach to
immobilized L1 surfaces via homophilic interactions and can be induced to differentiate
into a neuronal phenotype in low or serum-free media. B35 cells express low levels of
NCAM, primarily the 140 kDa isoform without the variable alternatively spliced exon
(VASE) that downregulates neurite outgrowth, and close homologue of L1 (CHL1), but
no detectable levels of L1 [349]; however, L1 and NCAM can bind via heterophilic
interaction. [241, 350] [351] These cells are normally loosely adherent with round phasebright cell bodies and short processes, but they have demonstrated the ability to
differentiate reversibly and extend long neurites in low serum or with the addition of
dibutyryl cAMP [349] ; therefore, it was hypothesized that B35 cells could attach to
immobilized L1 surfaces via heterophilic interactions with NCAM and could be induced
to differentiate in low or serum-free media.
A protocol for embryonic day 8 chick forebrain dissection was established in
Chapter 5.

Although chick forebrain neurons are suitable for initial studies, it is

preferable to use mammalian-derived cells for future work; therefore, rat postnatal day 7
cerebellar and dorsal root ganglia dissection protocols were established.
Michael addition methods established in the previous chapter were used to
fabricate hydrogels and to evaluate immobilization of L1.
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MATERIALS AND METHODS
B35 and HT22 Cell Culture
B35 rat neuroblastoma and HT22 mouse hippocampal cells were a generous gift
from Dr. Karl Franek (Greenwood Genetics Center) and were routinely maintained in 75
cm2 T-flasks in a humidified chamber at 37°C with 7% CO2 atmosphere in 50/50
Dulbecco’s Modified Eagle’s Medium and Ham’s F-12 with L-glutamine (DMEM/F12
1X, Mediatech) supplemented with 10% v/v bovine growth serum (BGS, Hyclone) and
50 I.U./mL penicillin and 50 µg/mL streptomycin (Mediatech). Culture medium was
changed once every two days and cells were passaged weekly.

For experiments,

monolayers of cells were trypsinized, centrifuged, resuspended, counted in a
hemacytometer, and adjusted to the appropriate final concentrations.

Neuronal Differentiation of HT22 and B35 Cells
96-well bacterial polystyrene plates were sterilized with ethylene-oxide. The
laminin and fibronectin extracellular matrix proteins were included as positive controls
for cell attachment and as a comparison to L1 for evaluation of neuronal differentiation.
Laminin, fibronectin, and L1 were adsorbed overnight at room temperature to bacterial
polystyrene plates at 10 µg/mL concentration followed by two sterile PBS rinses. Serum,
reduced serum, and serum-free media formulations were tested: (1) DMEM/F12
supplemented with 10% v/v BGS and 50 I.U./mL penicillin and 50 µg/mL streptomycin,
(2) DMEM/F12 supplemented with 2% v/v BGS and 50 I.U./mL penicillin and 50 µg/mL
streptomycin, and (3) Neurobasal-A (Gibco) supplemented with 2% v/v B27 supplement
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(Gibco) and 2mM L-glutamine per manufacturer’s guidelines for tumor cell lines, and 50
I.U./mL penicillin and 50 µg/mL streptomycin. For the serum-free media condition,
three cell seeding methods were employed: (1) cells were directly seeded in serum-free
media, (2) cells were first seeded in 2% serum media for 2 hours followed by
replacement with serum-free media to enhance attachment and survival, (3) cells were
seeded according to condition 2 with the addition of 20ng/mL nerve growth factor (NGF)
to further enhance differentiation into a neuronal phenotype. HT22 and B35 monolayers
were trypsinized, centrifuged, resuspended, counted in a hemacytometer, and seeded at a
density of 10,000 cells per 96-well. At 24 hours post-seeding, the cells were fixed in 4%
paraformaldehyde in PBS for one hour at room temperature and and phase contrast
images were obtained with a 20X objective.

Primary Mammalian Neuron Dissection
Postnatal day 7 rat neuron dissection protocols were developed for both cerebellar
neurons [253, 352] and dorsal root ganglia (DRG) [353] and are included in Appendices
C and D, respectively.

Laminin (10 µg/mL) was adsorbed to 96-well bacterial

polystyrene plates overnight at room temperature. Cerebellar neurons were seeded at a
density of 20,000 cell per 96-well, and DRG were seeded at a density of 10,000 cells per
96-well. After 24 hours, cells were fixed for 1 hour in 4% paraformaldehyde and stained
for actin microfilaments using Alexa Fluor® 594 phalloidin (Molecular Probes, 0.161
µM) and digital fluorescent images were obtained.
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Cytocompatibility of T904-Acrylate Hydrogels with Primary Neurons
Poly-l-lysine (PLL) was absorbed to 24-well plates in a 0.1% concentration for
one hour followed by three water rinses and overnight drying.

A 23% T904-acrylate

hydrogel solution with a 1:1 acrylate:thiol ratio was prepared as previously described for
encapsulated fibronectin hydrogels in Chapter 6. A thin layer of hydrogel solution
(10µL) was spread over the surface of two wells coated with PLL and allowed to
polymerize via Michael addition for 2 hours at room temperature followed by overnight
at 37°C. Adsorbed 0.1% PLL wells were included as positive controls. Primary chick
forebrain neurons from embryonic day 8 chicks were dissected and prepared as described
in Chapter 5 and were seeded at a density of 80,000 cells per well with no rinsing of the
wells prior to seeding. After 24 hours, the cells were fixed in 4% paraformaldehyde in
PBS for one hour at room temperature and phase contrast images were obtained with a
10X objective.

T904-Acrylate Hydrogels with Encapsulated L1
These experiments are based on the immobilization method depicted in the
Chapter 6 (Figure 6.1A). The response of B35 and primary chick forebrain neurons to
70µg/mL of encapsulated L1 was evaluated using 1mm thick, 30µL hydrogels in 96-well
tissue culture polystyrene (TCPS) plates at 24 hours postseeding.
Sterilization of Components Used in Hydrogel Fabrication
Prior to making hydrogels, all components were sterilized. Uncharged glass
coverslips (Fisher) were UV sterilized for 20 minutes in the cell culture hood. Binder
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clips, 1mm thick Teflon spacers, vacuum grease, spatulas, and forceps were autoclaved
prior to use. All experiments were conducted in the cell culture hood using aseptic
technique.
Concentration of L1
The L1 protein produced as previously described in Chapter 5 typically displayed
a concentration range of 60-160 µg/mL; therefore, the protein was first concentrated to a
700µg/mL concentration in order be able to attain a 70µg/mL encapsulated L1
concentration within the hydrogels.

A buffer exchange of six 600µL aliquots of 150

µg/mL L1 protein into 50mM PBS, pH 7.4 with 21% salt concentration was performed
utilizing a 5.0 mL Zeba desalt column (Pierce) according to the manufacturer’s
instructions. The protein was frozen overnight at -80°C, lyophilized, resuspended in 771
µL of sterile water in order to maintain appropriate salt concentration, and stored at 4°C.
Preparation of Hydrogels
A 28.75% T904-acrylate hydrogel solution and a 1:1 acrylate:thiol ratio as
described for encapsulated fibronectin hydrogels in Chapter 6 was used for this
experiment. L1 was mixed with dithiothreitol (DTT) for 5 minutes at room temperature
with shaking. This protein/DTT mixture was added to room temperature T904-acrylate
solution, the gel solution was vortexed briefly, tap-spinned, and immediately pipetted in
between two glass slides separated by 1mm Teflon spacers. The hydrogels were allowed
to crosslink via Michael addition in the dark for 2 hours at room temperature followed by
overnight at 37°C in parafilmed petri dishes with sterile water to provide a humid
environment. The next morning, vacuum grease was added to the bottom of 96-well
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TCPS plates and sterilized under UV light for 20 minutes. The hydrogels were carefully
removed from the glass slides by rinsing with sterile PBS and were placed in the wells,
gently pressing them down onto the vacuum grease to prevent floating, and hydrated in
100 µL of PBS per well at 37°C until cell seeding. Hydrogels without protein were used
as negative controls. Bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL
reduced L1 adsorbed overnight were used as positive controls for visual confirmation of
cell health and bioactivity of reduced protein.
Cell Seeding
B35 cells were seeded at a density of 20,000 cells per 96-well in DMEM/F12 with
L-glutamine supplemented with 10% v/v bovine growth serum (Hyclone) and 50 I.U./mL
penicillin and 50 µg/mL streptomycin (Mediatech). Medium containing 10% serum was
chosen for initial experiments to enhance cell attachment to the hydrogels. Primary chick
forebrain cells derived from 8-day old chicks as previously described in Chapter 5 were
seeded at a density of 20,000 cells per 96-well based on successful results of this seeding
density on 96-well bacterial polystyrene wells with 10 µg/mL L1 adsorbed overnight.
Cells were observed at 24 hours post-seeding.

T904-Acrylate Hydrogels with Surface-Immobilized Reduced L1
These experiments are based on the immobilization method depicted in the
Chapter 6 (Figure 6.1B). The response of B35 and primary chick forebrain cells to
100µg/mL of surface-immobilized L1 was observed using 70µL hydrogels polymerized
directly in 96-well tissue culture polystyrene (TCPS) plates at 24 hours postseeding.
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Reduction of L1
Analysis of the amino acid sequence of the 140 kDa cloned fragment of L1
based on GenBank accession no. NM_000425 (Appendix E) revealed that L1 contains 14
cysteines per mol. A 150 µg/mL solution is equivalent to 0.0011 mmol/L concentration
of protein. Protein solutions are typically reduced with 1mM to 10 mM DTT. A 2.5 mM
DTT solution was used to reduce L1 [276], resulting in an approximate 2273 molar
excess of DTT to L1, or an approximate 325-molar excess of DTT thiols to L1 cysteines.
A 10X 25mM stock solution of DTT in 50mM PBS pH 7.4 buffer was made, 10% by
volume was added to the 1mg/mL fibronectin solution for a final 2.5 mM DTT
concentration, and reacted for 1 hour at room temperature. Unreacted DTT was removed
by column filtration using a PD-10 column and 50mM PBS pH 7.4 buffer followed by
analysis of protein concentration via measurement of absorbance at 280nm. Protein
samples were kept on ice following filtration and during protein concentration analysis.
Preparation of Hydrogels
A 28.75% T904-acrylate hydrogel solution and a 1:1.1 acrylate:thiol ratio as
described for reduced fibronectin hydrogels in Chapter 6 was used for this experiment.
PBS and DTT were directly added to room temperature T904-acrylate solution, and the
gel solution was vortexed briefly, tap-spinned, and 70µL was immediately pipetted
directly into 96-well TCPS plate and allowed to crosslink via Michael addition in the
dark for 1 hour at room temperature. After 1 hour, reduced L1 solution (100µL per well)
of 100 µg/mL concentration was added and left for an additional hour at room
temperature. Hydrogel crosslinking and L1 reduction were coordinated such that reduced
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L1 solution was added to the hydrogels immediately upon completion of reduced L1
concentration analysis, to minimize the possibility of disulfide bond reformation.
Following 1 hour incubation in reduced protein at room temperature, the plate
was parafilmed and transferred to 37°C overnight with shaking. The next morning, gels
were rinsed with 200µL of sterile PBS three times and hydrated in 100µL of sterile PBS
per well at 37°C until cell seeding. Hydrogels without protein were used as negative
controls. Bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL reduced L1
adsorbed overnight were used as positive controls for visual confirmation of cell health
and bioactivity of reduced protein.
Cell Seeding
B35 cells were seeded at a density of 20,000 cells per 96-well in DMEM/F12 with
L-glutamine supplemented with 10% v/v bovine growth serum (Hyclone) and 50 I.U./mL
penicillin and 50 µg/mL streptomycin (Mediatech). Medium containing 10% serum was
chosen for initial experiments to enhance cell attachment to the hydrogels. Primary chick
forebrain cells derived from 8-day old chicks as previously described in Chapter 5 were
seeded at a density of 20,000 cells per 96-well based on successful results of this seeding
density on 96-well bacterial polystyrene wells with 10µg/mL L1 adsorbed overnight.
Cells were observed at 24 hours post-seeding.
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Preparation of Acrylated L1
These experiments are based on the immobilization method depicted in the
Chapter 6 (Figure 6.1C).
Concentration of L1
The L1 protein produced as previously described in Chapter V typically displayed
a concentration range of 60-160 µg/mL; therefore, the protein first had to be concentrated
to a 1mg/mL concentration in order to prevent hydrolysis of the NHS-ester during
acrylation. A buffer exchange of two 1.5mL aliquots of 60 µg/mL L1 protein into 50mM
PBS, pH 7.4 with 6% salt concentration was performed utilizing 2.0 mL Zeba desalt
columns (Pierce) according to the manufacturer’s instructions. The protein was frozen
overnight at -80°C, lyophilized, resuspended in 180 µL of sterile water in order to
maintain appropriate salt concentration, and stored at 4°C.
Acrylation Reaction
Analysis of the amino acid sequence of the 140 kDa cloned fragment of L1 based
on GenBank accession no. NM_000425 (Appendix E) revealed that L1 contains 71
lysines per mol. Standard reaction conditions for NHS-containing crosslinkers call for
0.1-10 mM concentrations. The L1 fragment cloned as described in Chapter V is a 140
kDa protein, and a 1 mg/mL solution is equivalent to 0.0071 mmol/L concentration of
protein. Typically, 2 to 50-fold molar excesses of crosslinker are used for reactions, and
a 50 molar excess of crosslinker to L1 was used, resulting in a 0.36M concentration of
acrylate-PEG-NHS used for this reaction. A 10X solution of 12.4 mg/mL acrylate-PEGNHS in anhydrous DMSO was made fresh for each reaction, and 10µL of this solution
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was added to 100 µL of 1mg/mL L1 for an organic solvent carryover of 10% final
volume in the aqueous reaction, and reacted for 2 hours at room temperature with
shaking. At the completion of the reaction, a buffer exchange into 50mM PBS pH 7.4
was performed using 0.5 mL Zeba desalt columns (Pierce), according to the
manufacturer’s instructions, to remove unreacted crosslinker and solvent contamination.
The acrylated protein was stored at 4°C protected from light.
Electrophoresis of Acrylated L1
Samples of acrylated and non-acrylated L1 were immediately collected for SDSPAGE (sodium dodecyl polyacrylamide gel electrophoresis) analysis (3 µL protein
diluted in 6 µL PBS + 3 µL 4X reducing buffer) and immediately frozen at -80°C.
Protein samples were separated by SDS-PAGE on a 6% polyacrylamide gel using Trisglycine buffer under reducing conditions at 100V for 150 minutes. The gel was silver
stained (SilverSNAP® Stain Kit II, Pierce) and imaged using a Kodak Electrophoresis
Documentation and Analysis System 120.

RESULTS AND DISCUSSION
Neuronal Differentiation of HT22 and B35 Cells
Figure 7.1 shows the phase contrast images of HT22 cells on different adsorbed
proteins under varying media conditions.
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L1

Blank Well

Figure 7.1 Phase contrast images of HT22 mouse hippocampal cells attached to
protein-adsorbed wells under varying media conditions. Scalebar = 100 µm.

HT22 cells proliferated extensively on adsorbed laminin and fibronectin under all
media conditions tested, and on blank wells under 10% and 2% serum conditions.
Slightly less proliferation was observed on adsorbed L1 under 10% and 2% serum
conditions. The cells exhibited limited attachment to adsorbed L1 and blank wells when
plated directly in serum-free media (data now shown); however, plating in 2% serum
media for 2 hours followed by replacement with serum-free media supplemented with
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20ng/mL NGF enhanced differentiation into a neuronal phenotype on both adsorbed L1
and blank wells, as evidenced by the arrest of proliferation and the development of
pyramidal neuron morphology with neurite outgrowth. Although L1 has been described
as a potential survival factor for primary rat embryonic hippocampal neurons in serumfree media [239], its survival role for the HT22 cell line is unknown, and in this
experiment, HT22 cells did not attach when cells were plated directly in serum-free
media. The similar appearance of the L1 and blank wells for the 2% serum media for 2
hours followed by replacement with serum-free media supplemented with 20ng/mL NGF
condition may be attributed to adsorption of media proteins to the hydrophobic bacterial
polystyrene surface during the 2 hour incubation in serum media. Because T904-acrylate
hydrogels limit protein adsorption, immobilization of L1 to these hydrogels may enable
better evaluation of the role of L1 in HT22 attachment and neuronal differentiation.

Figure 7.2 shows the phase contrast images of B35 cells on different adsorbed
proteins under varying media conditions.
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Figure 7.2 Phase contrast images of B35 rat neuroblastoma cells attached to
protein-adsorbed wells under varying media conditions. Scalebar = 100 µm.

B35 cells survived and proliferated extensively on adsorbed laminin and
fibronectin under serum conditions with slightly less proliferation observed on the 2%
serum followed by serum-free media condition. Less proliferation was observed on L1
and blank wells under serum conditions and limited attachment occurred when plated
directly in serum-free media (data not shown). When cells were plated in 2% serum for 2
hours followed by serum-free media, arrestment of proliferation occurred on adsorbed L1
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and blank wells, but because B35 cells appear to extend neurites even while proliferating,
it is difficult to distinguish changes in morphology. No differences were observed with
the addition of NGF to serum-free media (data now shown).

Although distinct

morphological differences are not evident, limited attachment of cells to blank wells in
2% serum for 2 hours followed by serum-free media as compared to L1 indicates that L1
does support attachment of B35 cells. Because T904-acrylate hydrogels limit protein
adsorption, immobilization of L1 to these hydrogels may enable better evaluation of the
role of L1 in B35 attachment.

Primary Mammalian Neuron Dissection
Primary neurons are sensitive to media osmolalilty; embryonic chick brain has
measured approximately 272 mOsm [Bray, 1991 #729] and adult rat brain has measured
approximately 307 mOsm. [Bandaranayake, 1978 #730] The measured osmolalities of
three of our media formulations are Basal Medium Eagle (BME, 291 mOsm),
DMEM/F12 with L-glutamine (322 mOsm), and Neurobasal (224 mOsm). Although
both BME and DMEM/F12 are close to the measured osmolality of rat brain, BME was
chosen for CNS-derived chick and rat neurons because it does not contain L-glutamine,
allowing supplementation at the time of use. L-glutamine is unstable and is rapidly
decomposed into ammonia, which is toxic to CNS-derived neurons in concentrations of
less than 600µM. [354] [355, 356]
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Figure 7.3 shows extensive neurite outgrowth from rat postnatal day 7 cerebellar
neurons cultured on laminin. Rat cerebellar neurons also responded favorably to L1 (data
not shown).

Figure 7.3 Rat postnatal day 7 cerebellar neurons cultured on adsorbed 10 µg/mL
laminin. Neurons were cultured 24 hours and then stained for actin (red). Scalebar
= 100µm.

Figure 7.4 shows extensive neurite outgrowth and neural networks from rat
postnatal day 7 dorsal root ganglia cultured on laminin.
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Figure 7.4 Rat postnatal day 7 dorsal root ganglia cultured on adsorbed 10µg/mL
laminin. Neurons were cultured 24 hours and then stained for actin (red). Scalebar
= 100µm.

Although DRG are a commonly used model to assess neural regeneration, these
cells did not attach to adsorbed L1, but did attach to adsorbed fibronectin, on which CNSderived chick forebrain and rat cerebellar neurons did not attach (data not shown). All
primary cells (chick forebrain, rat cerebellar, rat DRG) responded favorably to adsorbed
laminin, as expected. In addition, DRG cell bodies are surrounded by satellite Schwann
cells that form a discrete anatomical unit. [25] Efforts to remove these contaminating
Schwann cells by plating them out on bacterial polystyrene plates prior to DRG cell
seeding resulted in incomplete removal of contaminating cells, with resultant Schwann
cell proliferation and an inability to ascertain if neurite outgrowth was the result of glial
cell support or the cell adhesion molecule. Another approach taken to eliminate glial cell
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contamination was to use cytosine arabinoside, a mitotic inhibitor, to prevent the
proliferation of Schwann cells; however, the DRG did not survive under these conditions,
possibly due to cytotoxicity resulting from noncompetitive antagonism of nerve growth
factor (NGF) that is essential for DRG survival. [357, 358] In conclusion, rat postnatal
day 7 cerebellar neurons were determined to be the ideal mammalian primary cell model
for future work with L1 immobilized to T904-acrylate hydrogels.

Cytocompatibility of T904-Acrylate Hydrogels with Primary Neurons
Figure 7.5 is a phase contrast image of chick forebrain neurons cultured on 0.1%
PLL (positive control, 7.5A) and on 0.1% PLL in the presence of a hydrogel (7.5B).

A

B
HYDROGEL

Figure 7.5 Documentation of cytocompatibility. Phase contrast images of chick
embryonic day 8 forebrain neurons cultured on (A) 0.1% PLL and (B) 0.1% PLL in
the presence of a T904-acrylate hydrogel. Scalebar = 100µm.
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The bright, round cell bodies indicate healthy cells with no discernable difference
between the positive control and cells exposed to the hydrogel with no rinsing prior to
cell seeding.

Neuronal Response to T904-Acrylate Hydrogels with Encapsulated L1
B35 and primary chick forebrain neurons showed little evidence of attachment to
hydrogels with encapsulated L1 70µg/mL, comparable to hydrogels with no protein.
Positive controls of 96-well bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL
reduced L1 adsorbed overnight demonstrated significant attachment and proliferation of
B35 cells, and significant attachment and neurite outgrowth of primary chick forebrain
neurons at 24 hours. This is in stark contrast to the favorable spreading response of NIH
3T3 fibroblasts on encapsulated fibronectin hydrogels of 50, 75, and 100 µg/mL
concentrations. NIH 3T3 cell attachment to fibronectin is primarily mediated through
RGD, an integrin binding tripeptide in the FN-III repeat; however, Ig domains 1-6
reproduce the full biological activity of the entire L1 extracellular region, while Ig
domains 1-4 are the minimum regions necessary for homophilic binding. [274]

Ig

domains 1-6 are linked by disulfide bonds and these bonds are reduced with DTT prior to
encapsulation within the T904-acrylate hydrogels. We therefore hypothesize that the L1
protein loses bioactivity upon encapsulation into T904-acrylate hydrogels via Michael
addition because of a change in conformation that occurs when the reduced disulfide
bonds of Ig domains 1-6 bind with acrylate groups within the hydrogel. As a result, no
further experiments were conducted utilizing encapsulated L1.
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Neuronal Response to T904-Acrylate Hydrogels with
Surface-Immobilized Reduced L1
B35 and primary chick forebrain neurons showed little evidence of attachment to
hydrogels with reduced L1, comparable to hydrogels with no protein. Positive controls
of 96-well bacterial polystyrene wells with 10 µg/mL L1 and 10 µg/mL reduced L1
adsorbed overnight demonstrated significant attachment and proliferation of B35 cells,
and significant attachment and neurite outgrowth of primary chick forebrain neurons at
24 hours.

Acrylate groups are inherently hydrophobic because their CH=CH2

carbonaceous side groups are non-polar and thus do not attract water strongly. We
hypothesize

that

this

immobilization

technique

failed

because

the

inherent

hydrophobicity of the acrylate groups contributes to their retreat within the hydrogel upon
application of the hydrophilic reduced L1 solution, thus hindering the Michael addition
protein conjugation reaction. An alternative explanation is that the filtration method used
may not be sufficient to remove all excess DTT, possibly resulting in a reformation of L1
disulfide bonds prior to adding the solution to the hydrogels. As a result, no further
experiments were conducted utilizing reduced L1.

Acrylation of L1 For Surface-Immobilization To
T904-Acrylate Hydrogels
Analysis of the amino acid sequence of the 140 kDa cloned fragment of L1 based
on GenBank accession no. NM_000425 (Appendix E) revealed that L1 contains 71
lysines per mol, and the acrylate-PEG-NHS used to acrylate fibronectin has a molecular
weight of 3450 Da. Conjugation of 1-4 lysines per mol of L1 with acrylate-PEG-NHS
should result in an estimated 3-13kDa increase in molecular weight.
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Figure 7.6

demonstrates an approximate 8-10 kDa increase in molecular weight of the acrylated
protein as evidenced by lane 3. This data demonstrates successful acrylation of the L1
protein.

1

2

3

250 kDa
150 kDa

100 kDa
75 kDa
Figure 7.6 Documentation of L1 acrylation. Proteins were separated utilizing SDSPAGE and stained with Silver Stain (Pierce). Lane 1, molecular weight marker;
lane 2, L1; lane 3, acrylated L1. Gels were loaded with equal quantities of total
protein (3 µg/lane).

Previous efforts to acrylate lower concentrations of L1 were unsuccessful, likely due to
hydrolysis of the NHS-esters.
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CONCLUSION
In conclusion, these studies demonstrate that both HT22 and B35 cells may be
used to model neuronal cell response to immobilized L1 on a hydrogel surface when
cultured in 2% serum for 2 hours followed by serum-free media with and without NGF,
respectively. B35 cells display clearer evidence of attachment to L1 and do not require
the addition of NGF; however, B35 are loosely adherent and care must be taken when
changing media to avoid cell detachment. Mammalian neuron dissection methods for rat
postnatal day 7 cerebellar neurons and dorsal root ganglia were developed, but cerebellar
neurons were determined to be the ideal primary mammalian neuronal model for future
L1 studies. T904-acrylate hydrogels with no rinsing prior to cell seeding were not toxic
to primary chick embryonic day 8 forebrain neurons cultured on PLL at 24 hours. These
studies also indicate that hydrogels with encapsulated and reduced L1 are not suitable for
neural regeneration strategies, possibly due to a conformational change of the protein and
hydrophobicity of acrylate groups, respectively.

SDS-PAGE analysis demonstrated

successful acrylation of the L1 protein, but only when a 1 mg/mL concentration was
used; lower concentrations were probably not sufficient to prevent hydrolysis of the
NHS-ester during the acrylation reaction. Future work should include further analysis of
immobilized acrylated L1 to T904-acrylate hydrogels to study neural regeneration at
early timepoints with the conditions described for HT22 or B35 neuronal cell lines and
with chick embryonic day 8 and rat postnatal day 7 primary neurons.
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CHAPTER EIGHT
CONCLUSION AND RECOMMENDATIONS

CONCLUSION
The first objective of this research was to clone and express a bioactive 140kDa
fragment of L1 neural cell adhesion molecule, chosen for its critical role in proper
nervous system development and because it has demonstrated selectivity of neuron
adhesion in the presence of astrocytes, which play a major role in nervous system
inflammation.

These studies described the expression of a 140 kDa extracellular

fragment of L1 in the baculovirus/insect cell expression system with an average yield of
8

approximately 250-300 µg per 1x10 High Five cells and comparable neurite outgrowth
as compared to commercially available mammalian L1-Fc (R&D Systems).
The second objective of this research was to synthesize acrylated Tetronic
macromers and develop Michael addition methods for hydrogel crosslinking and protein
immobilization, and to evaluate hydrogel cytocompatibility, immobilized protein
bioactivity, and immobilization efficiency in terms of cell spreading and proliferation
using NIH 3T3 fibroblasts and fibronectin. Using a model cell line with a well known
RGD-dependent interaction allowed the demonstration of the feasibility of this system for
neural repair. Acrylated Tetronic macromers were synthesized as previously described
and typically demonstrated approximately 83% acrylation efficiency.

Methods

developed for hydrogel crosslinking included using a 1:1 acrylate:thiol ratio for
encapsulated protein, a 1.1:1 acrylate:thiol ratio for surface-immobilized reduced protein,
and a 1:1.1 acrylate:thiol ratio for surface-immobilized acrylated protein.

166

Heggli et al. demonstrated functionalization of poly(styrene)-gr-PEG beads with
acrylic groups using Michael addition conjugation of cysteine and a 13 amino acid
peptide in aqueous solution [359]; however, the studies described in this dissertation
demonstrated failure of fibroblast spreading on hydrogels with pendant acrylate groups
incubated in reduced fibronectin solution. The failure of cell spreading may be the result
of (1) inaccurate acrylate:thiol ratio calculations, (2) limited protein conjugation to the
surface, (3) a lack of conjugated protein bioactivity as a result of conformation change
due to disulfide bond reduction, or (4) disulfide bond reformation prior to conjugation.
The 10% excess acrylate may not be sufficient to leave pendant unreacted acrylate groups
on the hydrogel surface because the acrylate:thiol ratio was calculated based on the
estimated molecular weight of T904-acrylate.

Because our T904-acrylate products

typically displayed approximately 83% acrylation efficiency, less acrylate groups may be
present than what was assumed for the calculation, resulting in no unreacted pendant
acrylate groups within the hydrogels. The acrylate:thiol calculation should be refined to
incorporate the acrylation efficiency for a more accurate ratio estimation, and studies
using varying percentages of excess acrylate should be conducted to optimize conditions
for hydrogel crosslinking and for surface-conjugation of reduced protein.

Another

potential problem is that acrylate groups are inherently hydrophobic because the
CH=CH2 carbonaceous side group is non-polar and thus does not attract water strongly,
and incubation of hydrogels with pendant acrylate groups in aqueous fibronectin solution
may not favor Michael addition surface-conjugation of reduced protein. An alternative
method to coax hydrophobic acrylate groups to the surface by crosslinking hydrogels
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between glass slides with a hydrophobic coating, such as Rain-X, may be employed to
test this theory; however, polymerization between glass is not translatable to the longterm objective of crosslinking hydrogels within the fiber grooves.
As discussed in Chapter 6, control wells with adsorbed reduced fibronectin on
bacterial polystyrene plates did demonstrate fibroblast spreading and proliferation, which
could either indicate that disulfide bond reduction did not impact bioactivity of adsorbed
fibronectin or that disulfide bonds reformed. Reduced fibronectin was diluted to 100
µg/mL in 50mM PBS pH 7.4, which does not contain divalent cations and is the
appropriate buffer for Michael addition conjugation.

It is possible that the column

filtration performed following fibronectin reduction was not sufficient to remove excess
DTT resulting in a reformation of disulfide bonds and possibly conjugation of DTT thiols
to hydrogel pendant acrylate groups; an alternative approach to using soluble reducing
agents for protein reduction that would eliminate the need for column filtration and
reduce the time prior to adding protein solution to the hydrogels is to use an immobilized
reducing agent, such as Pierce Immobilized TCEP Disulfide Reducing Gel (Product
#77712). An indirect Enzyme-Linked Immunosorbent Assay (ELISA) using an HRPconjugated anti-fibronectin antibody and a fluorogenic substrate (Pierce QuantaBlu) may
be used to test if fibronectin is conjugated to the suface of the hydrogels but will not
assay the bioactivity of the immobilized protein. Conjugation of fibronectin thiols to
acrylate groups on the hydrogel surface may induce a different protein conformation than
adsorption that may interfere with bioactivity even if conjugation is successful; however,
the success of encapsulated reduced fibronectin in promoting fibroblast spreading and
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proliferation implies that covalent immobilization of reduced fibronectin is not
detrimental to bioactivity.

There is also evidence that disulfide bond reduction is

important to fibronectin’s bioactivity in vivo. Fibronectin multimer formation occurs in
vitro via the C-terminal free thiols upon exposure to a thiol reagent [343, 344] and in vivo
depending upon exposure to metal ions [345], and homocysteine binding to plasma
fibronectin in vivo is mediated through thiol-disulfide exchange at the C-terminal
disulfide bonds.[346]

In addition, fibronectin’s bioactivity is linked with the RGD

tripeptide in the FN-III repeat, which does not contain disulfide bonds. [324, 325]
For both encapsulated and acrylated fibronectin, concentrations of 50, 75, and 100
µg/mL promoted maximum fibroblast spreading, and both methods displayed a
maximum cell spread area of approximately 3400 µm2 with 100 µg/mL of fibronectin.
Prior studies using 100 µg/mL of thiolated fibronectin immobilized to polystyrene
surfaces through Pluronic-pyridyl disulfide (F108-PDS) modification demonstrated cell
surface areas >8000 µm2 [339]; therefore, future work may include higher concentrations
of fibronectin to determine if increased fibroblast spreading areas are attainable on
encapsulated and surface-immobilized acrylated fibronectin hydrogels.

Encapsulated

fibronectin supported fibroblast spreading at lower concentrations than acrylated
fibronectin; cell spread area of approximately 2000 µm2 was observed on hydrogels with
2.5 µg/mL of encapsulated fibronectin and 25 µg/mL of acrylated fibronectin.
Only encapsulated 100 µg/mL fibronectin hydrogels supported fibroblast
proliferation at 5 days, indicating that hydrolytic degradation of the hydrogel rapidly
erodes the surface layer of conjugated fibronectin, within 48 hours. An alternative
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approach for enhanced control of hydrolytic degradation may be activation of the T904
terminal hydroxyl groups with various chloroalkyl chloride chemical intermediaries to
generate an acrylamide-terminated Tetronic macromer (Figure 8.1).

Figure 8.1 Acrylamide-Terminated Tetronic Macromer

The final objective of this research was to assess HT22 and B35 response to L1 in
order to establish a model neuronal cell line, to establish methods for primary mammalian
neuron culture, to evaluate the cytocompatibility of T904-acrylate hydrogels with
primary neurons, and to develop immobilization methods for L1.

These studies

demonstrated that B35 cells displayed clearer evidence of attachment to L1, but only
when cultured in 2% serum for 2 hours followed by serum-free media; however, bacterial
polystyrene plates do adsorb protein which may account for the cell attachment observed
with both serum media conditions. B35 cells demonstrated a lack of attachment to T904acrylate hydrogels with no protein when used as negative controls, and immobilization of
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L1 to these hydrogels may better enable the elucidation of L1 as a requirement for cell
attachment. Dissection protocols were established for both rat postnatal day 7 cerebellar
neurons and DRG; however, only cerebellar neurons attached and extended neurites on
L1, thus demonstrating their suitability for future studies with mammalian neurons out of
the cell types tested. T904-acrylate hydrogels with no rinsing prior to cell seeding were
not toxic to primary chick embryonic day 8 forebrain neurons cultured in the presence of
the hydrogel with no rinsing on PLL at 24 hours.
These studies demonstrated failure of B35 cell and chick embryonic day 8
forebrain neuron attachment to hydrogels with encapsulated and reduced L1.

The

proposed mechanisms of failure as discussed for surface-immobilization of reduced
fibronectin also apply to surface-immobilization of reduced L1; however, the additional
failure of encapsulated L1 indicates a loss of protein bioactivity not demonstrated with
encapsulated fibronectin. All six immunoglobulin domains of L1 have been shown to be
required for full bioactivity [274], and their quaternary horseshoe structure depicted in
Figure 8.2 is important for homophilic binding interactions that are critical for neural
applications. Reduction of the L1 protein with DTT breaks the disulfide bonds
responsible for this quaternary structure. Although positive controls of adsorbed reduced
L1 on bacterial polystyrene demonstrated B35 attachment and proliferation and chick
embryonic day 8 neuron attachment and neurite outgrowth, covalent immobilization of
reduced L1 appears to effect a loss in bioactivity.
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Figure 8.2 Quaternary Structure of L1 Ig Domains
(Reprinted from Haspel and Grumet, 2003 [241])

In addition, these studies demonstrated that a 1mg/mL concentration of L1 was
necessary for acrylation of the protein to prevent hydrolysis of the NHS-esters during the
acrylation reaction; however, surface conjugation and confirmation of bioactivity is yet
unproven. Surface-conjugated acrylated L1 may not be bioactive if the quaternary
horseshoe structure is disrupted or if the primary amine at the N-terminus is bound,
effectively reversing the orientation of the protein as it appears on the cell surface.
It was stated previously that selection of an appropriate immobilization chemistry
is likely to be critical for full retention of L1 bioactivity based on the increased number
and distribution of bioactive regions in L1. An alternative approach to test the bioactivity
of immobilized L1 in physiologically relevant orientation is encapsulation or surface-
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immobilization of NTA-PEG-acrylate previously synthesized in the lab for conjugation to
the 6X Histidine tag added to the C-terminus of the insect cell-derived 140 kDa L1
fragment (Figure 8.3).

I) NTA-PEG-Acrylate
L1

6X His

II) NHS-PEG-Acrylate

III) PDEA-PEG-Acrylate

NiSO4
H2N

L1

HS

L1

L1
6X-His

Ni
-OOC

COOCOONTA

L1

L1

NH
C O

S
S

Gel

Gel

PEG

Gel

Figure 2. Proposed mechanisms of L1 immobilizationLusing various
di-functional cross-linkers

Figure 8.3 Immobilization of L1 through 6X His Tag
(Reprinted from Lee et al., 2007 [360])

Although this method will not overcome the instability of immobilized ligands
within or on the surface of T904-acrylate hydrogels, resulting from hydrolytic
degradation of the hydrogels and the potential for in vivo enzymatic degradation due
to the presence of reducing enzymes such as thioredoxins [361], it may be useful for
demonstrating the importance of maintaining physiologic protein orientation for
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bioactivity. The insect cell-derived 140 kDa L1 fragment also contains a 14 amino
acid V5 epitope (-Gly-Lys-Pro-Ile-Pro-Asn-Pro-Leu-Leu-Gly-Leu-Asp-Ser-Thr-)
prior to the 6X His tag recognizable by Invitrogen anti-V5 antibody (IgG2a). Another
possible immobilization method to maintain physiologic orientation of L1, although
with limited clinical applicability, is encapsulation or surface-immobilization of
acrylated anti-V5 antibody generated using acrylate-PEG-NHS, to bind to the Cterminus of the L1 protein.

RECOMMENDATIONS
A major limitation of using adherent cultures for protein production is that
relatively small amounts of protein may be produced at any given time due to the
requirement for large amounts of incubator space. In addition, insect cells require a
separate incubator from mammalian cells because they are cultured at 27°C with no CO2.
The insect cell culture system described in Chapter 5 typically yielded 1.8mL of 160
µg/mL concentration of L1 from 4- 175cm2 T-flasks. These studies have demonstrated
the necessity for a 1mg/mL concentration of L1 in order to successfully acrylate the
protein. In order to obtain sufficient quantities of protein to continue this research, largescale transfections will be required. For example, 1mL of 1mg/mL concentration L1 is
enough protein to test 100 conditions in 96-well plates using 100µg/mL concentration.
To produce 1mL of 1mg/mL will require 6.25mL of 160 µg/mL, or 14 flasks. An
alternative approach that may be considered is perfusion bioreators for higher protein
production. [362, 363]
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Additional considerations for long-term studies include analysis of the appropriate
mechanical properties for hydrogels to optimize neurite outgrowth, and the effect of loss
of mechanical properties due to hydrogel degradation on neurite outgrowth. Growth cone
advance is mediated by a minimum “threshold” value of tension [364], and Gunn et al.
demonstrated greatest neurite extension from PC12 cells seeded on PEG-diacrylate
hydrogels with an elastic modulus in the range of approximately 50-200 kPa. [215] In
this work, only 23% T904-acrylate hydrogels were tested in order to evaluate protein
conjugation strategies; however, future studies should be conducted to evaluate the
hydrogel mechanical properties over a varying T904-acrylate concentration range in an
effort to optimize conditions to provide a synergistic benefit to neurite outgrowth.
Analysis of the appropriate mechanical properties for fibers based on spinal cord
mechanics is also warranted. Several studies have examined the viscoelastic behavior of
the spinal cord. [201-204] In addition, as discussed in Chapter 4, discrepancies exist in
the reported values of elastic modulus for the spinal cord and no consensus has been
reached regarding the appropriate elastic modulus for neural scaffolds. [203, 206, 208]
A final future consideration is analysis of clearance of acrylate- and acrylamideterminated Tetronics and PLA breakdown products in the CNS. Total volume of pH 7.33
cerebrospinal fluid is 125-150ml with a turnover rate of 3-4 times per day, or 0.35 ml/min
(500 ml/day). [365] Radiolabeled PEG clearance following brain injection has been
examined [366], and the potential neurotoxicity of acrylic acid and acrylamide must be
assessed. [367] PLA has demonstrated biocompatibility for spinal cord applications
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[289], and studies have demonstrated that cerebral spinal fluid (CSF) is capable of
buffering and eliminating 3 mM/L increases in lactic acid. [368, 369]
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APPENDIX A
SYNTHESIS OF T904-ACRYLATE WITH TEA, 30g REACTION
Materials/Chemicals
Material/Chemical
Tetronic 904
Toluene HPLC
Dichloromethane
HPLC
Ethyl ether anhydrous,
BHT stabilized
Hexanes HPLC
Triethylamine (TEA)
Acryloyl chloride 96%
Calcium hydride 93%
0-20mm grain
Molecular sieves
(Grade 514, Type 4A,
8-12 mesh)
Celite fine 500
Sodium sulfate
anhydrous
4-Methoxyphenol 99%

Vendor
BASF
Fisher
Acros
(Fisher)
Fisher

Part Number
30085638
T290-4
61005-0040

Fisher
Acros
(Fisher)
Sigma
Acros
(Fisher)
Fisher

H302-4
157911000

Flammable cabinet
Chemical cabinet

A24109-500
196791000

Flammable refrigerator in 505
Flammable cabinet

BP2631-500

Chemical cabinet

E318-20

Storage
Chemical cabinet
Flammable cabinet
Flammable cabinet
Flammable refrigerator in 505

Fluka
(Sigma)
Fisher

22145

Chemical cabinet

S421-3

Chemical cabinet

Aldrich

M18655

Chemical cabinet

Table A.1: Materials/Chemicals used for Synthesis of T904-Acrylate

Safety
•

•
•

Wear nitrile gloves when handling organic solvents and triple glove so that total
glove thickness is at least 15mil (our gloves are 5mil). If solvent spills on gloves,
immediately remove outer glove and replace (solvents - particularly ether,
dichloromethane, toluene, hexane - can penetrate nitrile gloves in under 4 minutes).
Latex gloves should not be worn to handle solvents as the permeation rate is much
quicker (in seconds for dichloromethane).
Wear lab coat, safety goggles, and nitrile gloves when handling organic solvents and
always handle under the chemical fume hood.
Calcium hydride is extremely reactive and must be handled with care (see page 2).
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General Notes
•
•
•

Parafilm all chemical bottles to prevent moisture penetration.
Clean rotavap with acetone before and after each use.
Clean and dry glassware as it is used or there will not be enough for all steps, but
allow solvent volatilization under the chemical fume hood first.

Preparation for Synthesis
Make sure all glassware has been cleaned with sodium hydroxide, rinsed at least six
times with DI water followed by one acetone rinse, and completely dried in 60°C oven
overnight:
• Condenser
• Connector
• Round bottom reaction flasks
• Evaporator trap with inner vapor tube at bottom
• Addition funnel
• Separation funnel
• Buchner funnels
• Filter flasks
• Erlenmeyer flasks
• Glass stopper
• Teflon valves with washers
Glassware used for the reaction and final filter/rotavap/precipitation steps after sodium
sulfate wash must be extremely dry and should be dried under vacuum at 100°C for 3
hours and then left to cool under vacuum overnight until use (use vacuum oven).
Make Dehydrated Dichloromethane In Advance
•
•

•
•
•

Typically prepare at least 500mL for each 30g reaction.
Prepare bottle for dehydrated dichloromethane storage and activated molecular sieves
by drying under vacuum at 110°C for 3 hours and then leave to cool under vacuum
overnight until use. Activated molecular sieves may be stored under vacuum for one
month.
Cover the bottom of a 1L glass bottle with calcium hydride, add 1L of
dichloromethane and mix overnight with stirring. The cap should be closed.
Filter dehydrated dichloromethane on ice bath using a vacuum-heated and dried
Buchner funnel with filter paper and Celite fine 500 into a vacuum-heated and dried
1L filter flask.
Repeat the previous step using only filter paper to remove any Celite.
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•
•

•

Transfer filtered dehydrated dichloromethane into vacuum-heated and dried 1L amber
glass bottle with activated molecular sieves for storage. Dehydrated dichloromethane
may be stored for one month.
SAFETY NOTE: Calcium hydride reacts violently with water, acids, lower alcohols,
and heat to produce hydrogen gas and caustic calcium hydroxide. The hydrogen gas
may be ignited by the heat of the reaction. In the event of fire, use dry chemical, lime
or dry sand. DO NOT use water, foam, carbon dioxide, or halon.
PROPER DISPOSAL OF CALCIUM HYDRIDE: Allow solvent to volatilize off
the calcium hydride overnight under the chemical fume hood. Dispose of dried
calcium hydride in the labeled plastic container that is stored in the flammables
cabinet under the hood. Ensure the lid is tightly sealed.

Procedure
ALL STEPS MUST BE PERFORMED UNDER CHEMICAL FUME HOOD!
Day 1 - Azeotropic Distillation and Reaction:
•
•
•
•

T904: 30g (MW6700)
Dehydrated dichloromethane: 300 mL
30
× 90.51
8 × 6700
≈ 2.910ml
8X Acryloyl chloride:
1.114
30
× 101.19
4 × 6700
4X Triethylamine (TEA):
≈ 2.496ml
0.726
1. Refer to figure A.1 at the end of this protocol for the azeotropic distillation set-up.
2. Start this early in the morning so the reaction is begun early afternoon in order to
allow time for Day 2 steps during the day (reaction needs 24 hours).
3. Use oven dried glassware (condenser, connector, round bottom reaction flask).
4. Weigh T904 with a beaker and dissolve it in 100ml toluene (tare a 150 mL beaker
on the balance to measure T904). Allow to dissolve for several minutes while
stirring vigorously with spatula.
5. Decant dissolved T904 of step 2 into the reaction flask. Add an additional
100mL, stir vigorously, and decant into reaction flask. Repeat for a total volume
of 300mL.
6. Set up the azeotropic distillation system with magnetic bar inside the flask
(parafilm all connections, wrap with glass fibers and foil to insulate, connect
water line and drain to condenser and clamp in place using binder clips). Refer to
the last page of this protocol for an explanation and diagram of azeotropic
distillation.
7. Allow T904 solution to stir for about 10 minutes prior to heating up the oil bath.
8. Heat the reaction flask (hot oil bath) up to 130°C.
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9. Boil the flask. As water is removed, it will appear to be cloudy and white in the
connector column.
10. The connector column volume is approximately 30mL. Boil off a total of
approximately half of the solution volume (150mL). Boil off 120mL, allow the
column to fill and reflux for one hour, then stop the distillation and cool down the
reaction and remove the final 30mL (approximately 2 hours).
11. Vacuum-evaporate at 90°C to remove the toluene using the evaporator trap with
inner vapor tube at bottom.
a. Use the lower power vacuum pump, 90°C water bath, and maximum
rotation (should take approximately 30mins - 1 hr). Add ice on the
cooling trap.
12. Dissolve purified T904 in 240ml dehydrated dichloromethane.
13. Set up the reaction batch with stirring system.
14. Pipette TEA to the reaction flask and allow to mix for several minutes with
stirring on an ice bath.
15. Cool down the reaction flask for several minutes.
16. Attach the addition funnel to the top of the reaction (parafilm the connection) and
add the acryloyl chloride solution in 60ml dehydrated dichloromethane into the
addition funnel.
17. Dropwise-add step 12 solution into the reaction slowly (within 2hrs) using a
steady continuous drip. Add ice to ice bath as needed.
18. When all the acryloyl chloride solution has been added, move the reaction system
to cold room on 5th floor (put aluminum foil around the reaction flask to protect it
from light, grease the fitting, parafilm the closure).
19. Run the reaction with stirring in the cold room for 24 hours.
Day 2 – Filtration, Ether/Hexane Precipitation:
1. Stop the reaction and filter with filter paper and Celite fine 500 using a Buchner
funnel once to remove TEA-HCl. Filter one more time with filter paper without
Celite using a Buchner funnel to remove the remaining Celite in the product.
Make sure to use dry funnels and filter flasks and use a new funnel/flask for each
filtration step. Add solution slowly as it is very viscous and will clog the filter if
too much is added too quickly.
2. Add 2 chips of 4-methoxyphenol and allow to dissolve for 5 minutes.
3. Vacuum-evaporate at 30°C to remove the dichloromethane using the evaporator
trap with inner vapor tube at bottom.
a. Use the lower power vacuum pump, 30°C water bath, and maximum
rotation (should take approximately 1 hour). Add ice on the cooling trap.
4. Using an Erlenmeyer flask, precipitate in 50/50 ether/hexane. Total volume
should be 500mL. Add 250mL of ether to reaction flask and swirl and transfer to
Erlenmeyer flask. Then add 250mL of hexanes to reaction flask (to try and
remove as much product as possible from the reaction flask) and swirl and
transfer to Erlenmeyer flask. Mix with stirring for at least 5 minutes.
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5. Remove stir bar, seal Erlenmeyer flask with rubber stopper and wrap with
parafilm, cover entire flask in foil and label, and place flask in flammable freezer
in 505 at -20°C and allow precipitated product to settle overnight.
Day 3 – pH Neutralizations and Final Precipitations (4 precipitations total):
1. Quickly decant the waste solvent without disturbing the settled product at the
bottom.
2. Redissolve the product in 300 mL dichloromethane (does not have to be
dehydrated as water will be added during washing steps). Check pH (typically it
will be pH 4.0 before starting the wash steps).
3. Transfer the product to the separation funnel. Make sure the Teflon valve has a
gasket or it will leak.
4. Wash it with 30ml 10% NaHCO3 once and shake the funnel gently, opening the
valve periodically to release the gas. If using different reaction sizes, use 10% of
the total volume for washes. Place the funnel back in the ring holder, remove the
top, and allow the bicarbonate solution to separate out (water will rise to the top
and appear opaque white). Use a piece of rubber hose to “whip” the funnel to
encourage separation if needed. Open the valve to pour off the product into a
clean, dry beaker, stopping when reaching the separated waste. Remove the
waste to a separate beaker.
5. Check the pH of the product and repeat step 9 until the pH is neutralized (pH 7.0)
by pouring the product back into the separation funnel (typically 2 washes).
6. Once product pH is neutralized, add 30ml double-deionized (Millipore) water
instead of 10% NaHCO3 and follow the method in step 9, to remove sodium
bicarbonate. Ensure the pH of the product AND the water waste are neutral, and
then do 2 water washes beyond what is required for neutral pH (typically 4-6 total
water washes).
7. Add sodium sulfate to the product beaker to dehydrate (approximately 4-6 times)
until the solution becomes clear. Add approximately one small weigh boat of
sodium sulfate (just enough to cover the bottom of beaker), mix using a spatula
for approximately 5 minutes, allow to settle, then pour into another beaker and
repeat. Add a very small amount of dichloromethane (not dehydrated) to the
waste sodium sulfate to remove any remaining product and add this back to the
product. When all the water is removed, the sodium sulfate will become salt-like
with individual particles moving instead of slushy and the product will be very
clear. The final wash should be in an Erlenmeyer flask so it can be sealed
overnight. Dump waste sodium sulfate onto aluminum foil for disposal (allow
solvent to evaporate first).
8. Once the solution becomes clear (typically after 4 washes), allow sodium sulfate
to settle and filter the product with filter paper using a Buchner funnel to remove
sodium sulfate.
9. Decant solution to a new dry round bottom flask.
10. Add 2 chips of 4-methoxyphenol and allow to dissolve for 5 minutes.
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11. Vacuum-evaporate at 30°C to remove the dichloromethane using the evaporator
trap with inner vapor tube at bottom.
a. Use the lower power vacuum pump, 30°C water bath, and maximum
rotation (should take approximately 1 hour). Add ice on the cooling trap.
12. Using an Erlenmeyer flask, precipitate in 50/50 ether/hexane. Total volume
should be 500mL. Add 250mL of ether to reaction flask and swirl and transfer to
Erlenmeyer flask. Then add 250mL of hexanes to reaction flask (to try and
remove as much product as possible from the reaction flask) and swirl and
transfer to Erlenmeyer flask. Mix with stirring for 5 minutes.
13. Remove stir bar, seal Erlenmeyer flask with rubber stopper and wrap with
parafilm, cover entire flask in foil and label, and place flask in flammable freezer
in 505 at -20°C and allow precipitated product to settle overnight.
14. Quickly decant the waste solvent without disturbing the settled product at the
bottom. Dispose of waste solvent in the appropriate waste container.
15. Using an Erlenmeyer flask, precipitate in 100% ether. Total volume should be
500mL. Mix with stirring for 5 minutes.
16. Remove stir bar, seal Erlenmeyer flask with rubber stopper and wrap with
parafilm, cover entire flask in foil and label, and place flask in flammable freezer
in 505 at -20°C and allow precipitated product to settle overnight. If possible, try
to do two precipitations per day (early morning and late evening), but if the
product is not settled, leave overnight.
17. Repeat 100% ether precipitations two more times for a total of three (3) 100%
ether precipitations.
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Final Day – Dry Product and NMR:
1. Set-up a small dessicator with dessicant and place it in a large Styrofoam cooler
on ice. Vent the dessicator into the chemical fume hood. Ensure the ice level is
below the top of the dessicator to prevent moisture infiltration when opening and
closing the dessicator.
2. Allow the dessicator to cool down for at least 30 minutes under vacuum prior to
drying any product in it. Ensure vacuum pressure is > 20psi.
3. Tare the balance and weigh a dry large Petri dish and take note of the weight (in
order to determine final yield of product).
4. Quickly decant the waste solvent without disturbing the settled product at the
bottom. Dispose of waste solvent in the appropriate waste container.
5. Pour the remaining product/solvent mix into the Petri dish for drying. Do not fill
Petri dish beyond half full or the product will be forced out of the Petri dish when
under vacuum. Dry in multiple steps if necessary, but keep product cold and
protected from light (in -20C freezer). Ensure vacuum pressure is > 20psi.
6. Place the Petri dish into the vacuum chamber and dry under vacuum on ice for at
least 4 hours (6-8 hours if possible). Replace ice as needed.
7. Once the product is dried and all the ether is removed, weigh the Petri dish and
determine the final yield of product.
8. Check NMR of product in chloroform and determine reaction efficiency (25mg
product in 1mL chloroform).
9. Store the final dried product in a labeled closed container at -20°C (or cover the
Petri dish with foil and label).
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Azeotropic Distillation
An azeotropic mixture has a boiling point that does not change when vapor is removed by
evaporation. The boiling point may be higher or lower than any of the components of the
mixture, e.g. a toluene / water mixture has bp 85.0°C, but bp toluene is 110.6°C and bp
water is 100.0°C. Steam distillation is used to separate volatile from non-volatile
components and the reduction in boiling point reduces thermal decomposition. For the
toluene-water system, below 85°C the two liquid phases coexist. At 85°C the sum of the
vapor pressures of water and toluene = one atmosphere, and boiling starts.
In a mixture of toluene and water, boiling occurs at 85°C and both water and toluene are
in the vapor that condenses to form two layers. The bottom layer of water has 0.06%
toluene dissolved in it. The top layer of toluene has 0.05% water dissolved in it. The
relative volumes are 18% water and 82% toluene. The excess toluene flows back into the
flask and distils back over with more water. At 85°C, vapor pressure of water = 57.7 kPa
and vapor pressure of toluene = 50.6 kPa.
Weight of water =

molar mass water (g/mol) Vapor pressure water
18 57.7
×
=
×
= 0.250... = 25%
molar mass toluene (g/mol) Vapor pressure toluene 82 50.6

[The most common unit for vapor pressure is the torr. 1 torr = 1 mm Hg (one millimeter
of mercury). The international unit for pressure is: 1 pascal = a force of 1 newton per
square meter = 10 dyn/cm² = 0.01 mbar= 0.0075 mmHg = 0.00000969 atm= 0.00014
psi.] Be careful! Do experiment in a fume hood because toluene vapor is harmful.

Condenser

Connector

Figure A.1 Azeotropic Distillation Set-Up
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NOTE: Designed specifically for azeotropic distillation using solvents lighter than water.
The set-up depicted in Figure A.1 uses a Dean-Stark trap that comes standard with a 4mm
bore PTFE stopcock. The 12mL and 25mL traps use a 2mm bore stopcocks. We don’t
use this set-up with the thermometer in a reaction flask. We simply connect the top of a
round-bottom reaction flask directly to the connector end and wrap this part with glass
fibers and aluminum foil.
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APPENDIX B
GENBANK AMINO ACID SEQUENCE FOR BOVINE SERUM FIBRONECTIN
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&id=462100
LOCUS
P07589
2265 aa
linear MAM 10-JUN-2008
DEFINITION Fibronectin (FN).
ACCESSION P07589
VERSION P07589.3 GI:462100
DBSOURCE swissprot: locus FINC_BOVIN, accession P07589;
class: standard.
created: Apr 1, 1988.
sequence updated: Feb 1, 1994.
annotation updated: Jun 10, 2008.
xrefs: K00800.1, AAA30521.2,

L = LYSINE, 122 total
C = CYSTEINE, 64 total
1 qaqqivqpqs pLtvsqskpg Cydngkhyqi nqqwertyLg saLvCtCygg srgfnCeskp
61 epeetCfdky tgntyrvgdt yerpkdsmiw dCtCigagrg risCtianrC heggqsykig
121 dtwrrphetg gymLeCvCLg ngkgewtCkp iaekCfdqaa gtsyvvgetw ekpyqgwmmv
181 dCtCLgegsg ritCtsrnrC ndqdtrtsyr igdtwskkdn rgnLLqCiCt gngrgewkCe
241 rhtsLqttsa gsgsftdvrt aiyqpqphpq pppyghCvtd sgvvysvgmq wLktqgnkqm
301 LCtCLgngvs Cqetavtqty ggnsngepCv Lpftyngktf ysCttegrqd ghLwCsttsn
361 yeqdqkysfC tdhtvLvqtr ggnsngaLCh fpfLynnhny tdCtsegrrd nmkwCgttqn
421 ydadqkfgfC pmaaheeiCt tnegvmyrig dqwdkqhdmg hmmrCtCvgn grgewtCvay
481 sqLrdqCivd gitynvndtf hkrheeghmL nCtCfgqgrg rwkCdpvdqC qdsetrtfyq
541 igdswekyLq gvryqCyCyg rgigewaCqp Lqtypdtsgp vqviitetps qpnshpiqws
601 apesshisky iLrwkpknsp drwkeatipg hLnsytikgL rpgvvyegqL isvqhygqre
661 vtrfdfttts tspavtsntv tgettpLspv vatsesvtei tassfvvswv sasdtvsgfr
721 veyeLseegd epqyLdLpst atsvnipdLL pgrkytvnvy eiseegeqnL iLstsqttap
781 dappdptvdq vddtsivvrw srprapitgy rivyspsveg ssteLnLpet ansvtLsdLq
841 pgvqynitiy aveenqestp vfiqqettgv prsdkvpppr dLqfvevtdv kitimwtppe
901 spvtgyrvdv ipvnLpgehg qrLpvsrntf aevtgLspgv tyhfkvfavn qgreskpLta
961 qqatkLdapt nLqfinetdt tvivtwtppr arivgyrLtv gLtrggqpkq ynvgpaasqy
1021 pLrnLqpgse yavsLvavkg nqqsprvtgv fttLqpLgsi phyntevtet tivitwtpap
1081 rigfkLgvrp sqggeaprev tsesgsivvs gLtpgveyvy tisvLrdgqe rdapivkkvv
1141 tpLspptnLh LeanpdtgvL tvswersttp ditgyrittt ptngqqgysL eevvhadqss
1201 CtfenLspgL eynvsvytvk ddkesvpisd tiipavpppt dLrftnvgpd tmrvtwapps
1261 sieLtnLLvr yspvkneedv aeLsispsdn avvLtnLLpg teyLvsvssv yeqhesipLr
1321 grqktaLdsp sgidfsdita nsftvhwiap ratitgyrir hhpenmggrp redrvppsrn
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1381 sitLtnLnpg teyvvsivaL nskeesLpLv gqqstvsdvp rdLeviaatp tsLLiswdap
1441 avtvryyrit ygetggsspv qeftvpgsks tatisgLkpg vdytitvyav tgrgdspass
1501 kpvsinyrte idkpsqmqvt dvqdnsisvr wLpssspvtg yrvttapkng pgpsktktvg
1561 pdqtemtieg Lqptveyvvs vyaqnqnges qpLvqtavtt ipaptnLkft qvtptsLtaq
1621 wtapnvqLtg yrvrvtpkek tgpmkeinLa pdsssvvvsg Lmvatkyevs vyaLkdtLts
1681 rpaqgvvttL envspprrar vtdatettit iswrtkteti tgfqvdaipa ngqtpiqrti
1741 rpdvrsytit gLqpgtdyki hLytLndnar sspvvidast aidapsnLrf LattpnsLLv
1801 swqpprarit gyiikyekpg spprevvprp rpgvteatit gLepgteyti qviaLknnqk
1861 sepLigrkkt deLpqLvtLp hpnLhgpeiL dvpstvqktp fitnpgydtg ngiqLpgtsg
1921 qqpsLgqqmi feehgfrrtt ppttatpvrh rprpyppnvn eeiqighvpr gdvdhhLyph
1981 vvgLnpnast gqeaLsqtti swtpfqesse yiisChpvgi deepLqfrvp gtsasatLtg
2041 Ltrgatynii veavkdqqrq kvreevvtvg nsvdqgLsqp tddsCfdpyt vshyaigeew
2101 erLsdsgfkL sCqCLgfgsg hfrCdsskwC hdngvnykig ekwdrqgeng qmmsCtCLgn
2161 gkgefkCdph eatCyddgkt yhvgeqwqke yLgaiCsCtC fggqrgwrCd nCrrpgaepg
2221 negstahsyn qysqryhqrt ntnvnCpieC fmpLdvqadr edsre

188

APPENDIX C
RAT POSTNATAL DAY 7 CEREBELLAR NEURON DISSECTION PROTOCOL
Supplies:
• 25mm, 0.2 µm syringe filter (Nalgene 190-2520)
• Sterile 35mm petri dishes (Falcon 353801)
• Sterile 100mm petri dishes (Fisher 08-757-13)
• Sterile 15mL centrifuge tubes (Fisher 05-539-12)
• Sterile 50mL centrifuge tubes (Fisher 05-539-8)
• 3mL syringe with 22G1½ needle (BD309574)
• 96-well plates (Corning 3596)
• Autoclave biohazard bags (Fisher 01-814A)
Dissection Tools:
• Large scissors
• Fine scissors (Fine Science Tools 91500-09)
• Dumont #5 fine forceps Inox – two pair (Fine Science Tools 91150-20)
• Coarse straight forceps
• Styrofoam base covered in foil and sterile needles (any size)
NOTE: Autoclave all dissection tools prior to use.
Materials:
Materials
Gibco Basal Medium Eagle (BME) without
L-glutamine
Fisher Potassium Chloride (KCl)
Acros D(+)-Glucose
Gibco Fetal Bovine Serum OR
Hyclone Fetal Bovine Serum
Gibco L-glutamine 200 mM OR
Hyclone L-glutamine 200mM
(Protect from light)
Gibco 100X Antibiotic-Antimycotic
10,000 IU/ml penicillin
10,000 µg/mL streptomycin
25 µg/mL amphotericin B
Gibco L15 Medium
Fisher DNase

Part No.
21010-046

Storage
+4°C

P217-500
41095-5000
16140-063
SH30070.02
25030-149
SH30034.02

Room Temp.
Room Temp.
-20°C

15240-096

-20°C

-20°C

+4°C
-20°C

Table C.1: Materials used for Rat Cerebellar Neuron Dissection
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Preparation of Sterile HBSS with 1% Glucose:
HEPES is added to 1X HBSS to replace the buffering action of the missing
bicarbonate in order to maintain physiological pH 7.4 in air, so it can be used outside
the CO2 incubator (HBSS is used in this protocol for the dissection and trypsin steps,
both of which are done in air).
1L:
• Make 1L of 1X HBSS: add 100mL of 10X HBSS without Ca, Mg, bicarbonate, or
phenol red to 900mL of Millipore water with stirring.
• Add 5 mM HEPES (1.3g/L, MW=260.3) to 900mL of 1X HBSS and wait until
dissolved.
• Add 10g of glucose and wait until dissolved.
• Add 10 mL (1%) antibiotic/antimycotic.
• Adjust pH to 7.4 with NaOH.
• Bring liquid level up to 1L with 1X HBSS. Verify pH is 7.4.
• Filter-sterilize and store at +4°C.
Preparation of 1.0% Trypsin:
• Dilute 10mL of 2.5% trypsin without Ca, Mg, phenol red in 15mL of sterile HBSS
with 1% glucose to make 1.0% trypsin.
• Freeze in 5mL aliquots at -20°C. Store ≤1 year.
OR
Preparation of 1.0% Trypsin/ 0.2% EDTA solution:
• Dissolve 200mg EDTA in 10mL Millipore water (2% w/v) and sterilize with 0.2um
syringe filter.
• Add 10mL of 2.5% trypsin without Ca, Mg, phenol red and 2.5mL sterile EDTA
solution to 12.5mL of sterile HBSS with 1% glucose to make 1% trypsin-0.2%
EDTA.
• Freeze in 5mL aliquots at -20°C. Store ≤1 year.
Preparation of 1.0% Dnase:
• Dilute 40 mg DNase in 4 mL of L15 media for a 10 mg/mL concentration.
• Syringe-filter with 0.2µm syringe filter.
• Freeze in 500µL aliquots at -20°C. Store ≤1 year.
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Preparation of Serum Medium:
Base Medium: BME without L-glutamine
• 20 mM potassium chloride (KCl)
• 33 mM glucose
• 10% fetal bovine serum (FBS)
• 50 U/ml penicillin, 50 µg/mL streptomycin, 125 ng/mL antibiotic/antimycotic
solution (1:200 dilution)
• 2mM L-glutamine (1:100 dilution)
Instructions:
1. Add media components in the order listed above.
2. Sterile-filter media after adding KCl and glucose using a 25mm, 0.2 µm
syringe filter (Nalgene 190-2520).
3. Make stock solution of media without L-glutamine and store at +4°C.
4. Add L-glutamine (2 mM final concentration) immediately prior to use. Use
media within 1 week of adding L-glutamine.
To make 10 mL:
BME
9 mL
KCl
15 mg
Glucose
59 mg
FBS
1 mL
AB/AM
50 µL
L-glutamine 100 µL

To make 50 mL:
BME
45 mL
KCl
75 mg
Glucose
295 mg
FBS
5 mL
AB/AM
250 µL
L-glutamine 500 µL

Preparation for Dissection:
1. Prepare and sterilize media.
2. Ensure dissection tools are autoclaved. If autoclaving is not possible, sterilize tools
with 70% ethanol for 30 minutes.
3. UV sterilize the dissection hood for at least 30 minutes prior to dissection.
Dissection:
1. Wipe the styrofoam base covered in foil with 70% ethanol and allow to dry.
2. Carefully pin the rat head to the styrofoam base with two sterile needles through the
nose to stabilize the head.
3. Use the large scissors to carefully remove the skin covering the brain.
4. Use the fine scissors to carefully remove the top portion of the brain and expose the
cerebellum. Refer to Protocols for Neural Cell Culture (Federoff and Richardson, 3rd
edition) Chapter 4, Figure 1. The cerebellum is sausage-shaped and sits directly
below the pair of optic lobes.
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5. Dissect the cerebellum and carefully remove the meninges and all blood vessels in a
35mm petri dish in ice cold HBSS with glucose.
Dissociation and Plating:
1. Warm L15 and serum media in 37°C incubator with 7% CO2 for 30 minutes to bring
temperature and pH up to physiological levels.
2. Transfer the cleaned cerebellum to a clean 35mm petri dish, add 1 mL of 1% trypsin
in HBSS, and mince the cerebellum into small pieces with the fine scissors.
3. Under a sterile cell culture hood, add 100uL 1% DNase and mix gently.
4. Incubate for 15 min in 37ºC water bath.
5. Transfer minced tissue into a sterile 15mL tube, add 3 mL of serum media to
deactivate the trypsin, and centrifuge at 1,000 rpm for 5 min.
6. Carefully remove supernatant and add 1 ml fresh media to the cell pellet. Gently
resuspend the cells by pipetting up and down a few times, avoiding air bubbles.
7. Gently triturate cells at least 20 times using a 3mL syringe with 22G1½ needle
(BD309574). A sterile fire-polished glass pipet may also be used. Avoid air bubbles.
8. Dilute the cell suspension 10-fold in serum media and count the cells using a
hemacytometer (typically 7-12 million cells per cerebellum).
9. Plate cells using the serum media. REMINDER: L-glutamine (Gibco or Hyclone,
200 mM) must be added to the media immediately before use: 10 µL L-glutamine to
1 mL media (2mM final concentration)
10. Plating densities of 20,000 cells per 96-well typically provide good results. Corning
3596 96-well plates have a well diameter of 6.4mm and growth area of 0.32 cm2, so
this plating density is equivalent to 62,500 cells/ cm2.
Conclusion of Dissection:
1. Gently clean all dissection tools immediately with detergent to prevent drying of
blood.
2. Wipe the dissection hood with 70% ethanol and UV sterilize for at least 30 minutes.
3. Dispose of all waste in an autoclave biohazard bag, tie the bag shut, and dispose of in
the designated freezer.
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APPENDIX D
RAT POSTNATAL DAY 7 DORSAL ROOT GANGLIA
DISSECTION PROTOCOL
Supplies:
• 25mm, 0.2 µm syringe filter (Nalgene 190-2520)
• Sterile 35mm petri dishes (Falcon 353801)
• Sterile 100mm petri dishes (Fisher 08-757-13)
• Sterile 15mL centrifuge tubes (Fisher 05-539-12)
• Sterile 50mL centrifuge tubes (Fisher 05-539-8)
• 3mL syringe with 22G1½ needle (BD309574)
• 96-well plates (Corning 3596)
• Autoclave biohazard bags (Fisher 01-814A)
Dissection Tools:
• Large scissors
• Fine scissors (Fine Science Tools 91500-09)
• Dumont #5 fine forceps Inox – two pair (Fine Science Tools 91150-20)
• Coarse straight forceps
• Styrofoam base covered in foil and sterile needles (any size)
NOTE: Autoclave all dissection tools prior to use.
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Materials:
MATERIAL
DMEM-F12 with L-glut
L15 Medium
BSA (bovine serum albumin)
FBS (fetal bovine serum)
100X Antibiotic/Antimycotic
-10,000 U/mL penicillin G
-10,000 ug/mL streptomycin
sulfate
-25 ug/mL amphotericin
NGF-7S
2.5% Trypsin w/o Ca, Mg*,
phenol red**
EDTA***
10X HBSS w/o Ca, Mg*,
bicarb, phenol red**
Glucose
HEPES
Collagenase
DNAse

VENDOR
Mediatech
Gibco
Sigma
Hyclone
Gibco

PART NUMBER
10-090-CV
A3059-10G
SH30070.02HI
15240-096

STORAGE
+4°C
+4°C
+4°C
-20°C
-20°C

Invitrogen
Invitrogen

13290-010
15090-046

-20°C
-20°C

Acros
Gibco

32721-1000
14185-052

Room Temp.
Room Temp.

Sigma
Fisher
Worthington
Fisher

G-7528
BP410-500

Room Temp.
Room Temp.
-20°C
-20°C

Table D.1: Materials used for Rat Dorsal Root Ganglia Dissection

NOTES:
*Ca2+ and Mg2+ in the trypsin and the salt solution can cause cells to adhere to each
together.
**Phenol red may damage neurons in alkaline pH during the dissection and dissociation
steps.
***EDTA (disodium ethylenediamine tetraacetic acid) may be added to trypsin as a
chelating agent to bind Ca2+ and Mg2+ ions that can interfere with the action of trypsin.
Preparation of NGF:
20 µg/mL, 0.1% BSA
• Make 1% BSA solution (10mg in 1mL Millipore water) and sterile filter through
0.2µm syringe filter.
• In laminar flow hood, dissolve 100ug NGF 7S in 4.5 mL DMEM-F12.
• Add 500µL of sterile 1% BSA solution (to make 0.1% final concentration).
• Aliquot into 50µL aliquots (20 µg/mL concentration) and freeze at -20°C. Store ≤1
year.
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Preparation of Sterile HBSS with 1% Glucose:
HEPES is added to 1X HBSS to replace the buffering action of the missing
bicarbonate in order to maintain physiological pH 7.4 in air, so it can be used outside
the CO2 incubator (HBSS is used in this protocol for the dissection and trypsin steps,
both of which are done in air).
1L:
• Make 1L of 1X HBSS: add 100mL of 10X HBSS without Ca, Mg, bicarbonate, or
phenol red to 900mL of Millipore water with stirring.
• Add 5 mM HEPES (1.3g/L, MW=260.3) to 900mL of 1X HBSS and wait until
dissolved.
• Add 10g of glucose and wait until dissolved.
• Add 10 mL (1%) antibiotic/antimycotic.
• Adjust pH to 7.4 with NaOH.
• Bring liquid level up to 1L with 1X HBSS. Verify pH is 7.4.
• Filter-sterilize and store at +4°C.
Preparation of 1% Trypsin:
• Dilute 10mL of 2.5% trypsin without Ca, Mg, phenol red in 15mL of sterile HBSS
with 1% glucose to make 1.0% trypsin.
• Freeze in 5mL aliquots at -20°C. Store ≤1 year.
OR
Preparation of 1% Trypsin/ 0.2% EDTA solution:
• Dissolve 200mg EDTA in 10mL Millipore water (2% w/v) and sterilize with 0.2um
syringe filter.
• Add 10mL of 2.5% trypsin without Ca, Mg, phenol red and 2.5mL sterile EDTA
solution to 12.5mL of sterile HBSS with 1% glucose to make 1% trypsin-0.2%
EDTA.
• Freeze in 5mL aliquots at -20°C. Store ≤1 year.
Preparation of 1.33% Collagenase:
• Dilute 53.2 mg collagenase in 4 mL of L15 media for a 13.3 mg/mL concentration.
• Syringe-filter with 0.2µm syringe filter.
• Freeze in 500µL aliquots at -20°C. Store ≤1 year.
Preparation of 1.0% Dnase:
• Dilute 40 mg DNase in 4 mL of L15 media for a 10 mg/mL concentration.
• Syringe-filter with 0.2µm syringe filter.
• Freeze in 500µL aliquots at -20°C. Store ≤1 year.
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Preparation of Serum Medium:

•
•
•
•

Base Medium: DMEM-F12 with L-glutamine
10% FBS (100 µL per mL media)
1% antibiotic/antimycotic (10 µL per mL media)
Add 1µL of NGF (20 µg/mL stock solution) per mL media for 20ng/mL
concentration of NGF. Add NGF immediately prior to use.
Complete culture medium with NGF can be stored at +4°C for up to 5 days.
25mL:
22.5 mL DMEM-F12
2.5 mL FBS
250 µL antibiotic/antimycotic
25 µL NGF (20 µg/mL stock solution)

Preparation for Dissection:
1. Prepare and sterilize media.
2. Ensure dissection tools are autoclaved. If autoclaving is not possible, sterilize tools
with 70% ethanol for 30 minutes.
3. UV sterilize the dissection hood for at least 30 minutes prior to dissection.
Dissection Method:
1. Thaw out one 4mL aliquot of trypsin and warm to 37°C in water bath. Use ice-cold
sterile HBSS with glucose.
2. Perform dissection in the open dissection hood with microscope.
3. Set-up an autoclave bag for all waste products.
4. Prior to the dissection, pour ice-cold HBSS with glucose into:
a. 4mL in 100mm petri dish for postnatal rat
b. 2mL in 35mm petri dish for storage of DRG during dissection
c. 2mL in 15mL tube (for transfer of DRG from 35mm petri dish)
5. Use the dissection microscope with the under-sided lamp to illuminate the rat.
6. Turn the rat on its side and gently cut along the vertebral column with the large
scissors to separate the spinal column.
7. Use the small scissors to cut through the bone on each side of the spinal column and
gently separate the two halves to expose the spinal cord.
8. Carefully separate the spinal cord from the bone to expose the DRG.
9. Pluck the DRG from spinal column using fine forceps, and cut the spinal nerves close
to the DRG to minimize contamination by nonneuronal cells from nerve sheaths.
Transfer the DRG to the separate 35mm petri dish containing cold HBSS with
glucose.
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10. Transfer DRG from 35mm petri dish to 15mL centrifuge tube with 1mL pipet. The
cells may adhere to the plastic tip and petri dish so rinse thoroughly to make sure all
tissue is transferred.
11. It should take approximately 15 minutes per rat. Do not take longer than 1 hour to do
the dissection (limit time to 1-1/2 hours from start of dissection to plating to minimize
cell damage, this includes 30 min dissociation in trypsin).
Dissociation and Plating:
1. Warm L15 and serum media in 37°C incubator with 7% CO2 for 30 minutes to bring
temperature and pH up to physiological levels.
2. In a cell culture hood, allow tissue to settle, remove HBSS, and add 2mL L15 media
and 0.5mL of 1.33% collagenase and incubate in 37°C water bath for 30 minutes.
3. Centrifuge cells at 1000 rpm for 5 minutes and discard supernatant.
4. Add 4 mL of DMEM/F12 (no serum), 1mL 1% trypsin in HBSS, and 50µL of 1%
DNase, and incubate in 37ºC with 7% CO2 incubator for 30 minutes.
5. Centrifuge cells at 1000 rpm for 5 minutes and discard supernatant.
6. Add 4 mL of serum medium to deactivate the trypsin, centrifuge again, and discard
supernatant.
7. Add 2 mL of warm serum medium and triturate at least 20 times with 3mL syringe
with 22G needle (needle diameter is 0.7mm), avoiding air bubbles as this will damage
cells. Ensure all tissue is broken up.
8. Add 4mL media and mix gently. Add the 6mL cell suspension to 100mm petri dish
and incubate for 2-4 hours in humidified 37°C, 7% CO2 incubator. Non-neuronal
cells should adhere to petri dish and neurons should remain floating or weakly
attached.
9. After 2-4 hours, tilt petri dish at 45 degrees and gently wash bottom twice to remove
weakly attached neurons, then transfer to 15mL tube.
10. Centrifuge at 1000 rpm for 5 minutes. Ensure there is a pellet, remove media, and
resuspend in 200µL warm serum media by triturating 3-4 times gently with 200µL
pipet tip.
11. Count cells using hemacytometer (1:2 dilution). Neurons appear rounded and phasebright whereas non-neuronal cells are darker and irregularly shaped. DRG neuron
diameters may be 7µm to 18 µm.
12. Seed approximately twice as many neurons as you think you will need in each 96well as approximately 30-40% of cells will not attach in the first day of culture and up
to 50% are lost after 3 days of culture.
13. Plate cells using the serum media. REMINDER: NGF must be added to the media
immediately before use.
14. Plate cells in 100µL media per well. Change media after allowing 2 hours for
attachment and add 200µL media per well. OR Plate cells in 200µL media and
change media the next morning.
15. Incubate in a humidified 37°C, 7% CO2 incubator.
16. Change media every 2 days.
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17. Corning 3596 96-well plates (Fisher 07-200-90) have well diameter of 6.4mm and
growth area of 0.32 cm2, currently seeding 2,000 DRG’s per 96-well.
Conclusion of Dissection:
1. Gently clean all dissection tools immediately with detergent to prevent drying of
blood.
2. Wipe the dissection hood with 70% ethanol and UV sterilize for at least 30 minutes.
3. Dispose of all waste in an autoclave biohazard bag, tie the bag shut, and dispose of in
the designated freezer.
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APPENDIX E
PREDICTED AMINO ACID SEQUENCE FOR 140 kDA L1 FRAGMENT
GenBank accession no. NM_000425
L = LYSINE, 71 total
C = CYSTEINE, 14 total

MVVALRYVWPLLLCSPCLLIQIPEEYEGHHVMEPPVITEQSPRRLVVFPT
DDISLKCEASGKPEVQFRWTRDGVHFKPKEELGVTVYQSPHSGSFTITGN
NSNFAQRFQGIYRCFASNKLGTAMSHEIRLMAEGAPKWPKETVKPVEVEE
GESVVLPCNPPPSAEPLRIYWMNSKILHIKQDERVTMGQNGNLYFANVLT
SDNHSDYICHAHFPGTRTIIQKEPIDLRVKATNSMIDRKPRLLFPTNSSS
HLVALQGQPLVLECIAEGFPTPTIKWLRPSGPMPADRVTYQNHNKTLQLL
KVGEEDDGEYRCLAENSLGSARHAYYVTVEAAPYWLHKPQSHLYGPGETA
RLDCQVQGRPQPEVTWRINGIPVEELAKDQKYRIQRGALILSNVQPSDTM
VTQCEARNRHGLLLANAYIYVVQLPAKILTADNQTYMAVQGSTAYLLCKA
FGAPVPSVQWLDEDGTTVLQDERFFPYANGTLGIRDLQANDTGRYFCLAA
NDQNNVTIMANLKVKDATQITQGPRSTIEKKGSRVTFTCQASFDPSLQPS
ITWRGDGRDLQELGDSDKYFIEDGRLVIHSLDYSDQGNYSCVASTELDVV
ESRAQLLVVGSPGPVPRLVLSDLHLLTQSQVRVSWSPAEDHNAPIEKYDI
EFEDKEMAPEKWYSLGKVPGNQTSTTLKLSPYVHYTFRVTAINKYGPGEP
SPVSETVVTPEAAPEKNPVDVKGEGNETTNMVITWKPLRWMDWNAPQVQY
RVQWRPQGTRGPWQEQIVSDPFLVVSNTSTFVPYEIKVQAVNSQGKGPEP
QVTIGYSGEDYPQAIPELEGIEILNSSAVLVKWRPVDLAQVKGHLRGYNV
TYWREGSQRK
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